{"@type": "small molecule", "@created": "2022-12-02", "@updated": "2022-12-03", "drugbank-id": [{"@primary": true, "$": "DB17297"}], "name": "Enitociclib", "description": null, "cas-number": "1610408-97-3", "unii": "1255AT22ZJ", "average-mass": 404.44, "monoisotopic-mass": 404.111853336, "groups": {"group": ["investigational"]}, "general-references": {"articles": null, "textbooks": null, "links": null, "attachments": null}, "synthesis-reference": null, "indication": null, "pharmacodynamics": null, "mechanism-of-action": null, "toxicity": null, "metabolism": null, "absorption": null, "half-life": null, "protein-binding": null, "route-of-elimination": null, "volume-of-distribution": null, "clearance": null, "salts": null, "synonyms": {"synonym": [{"@language": "english", "@coder": "", "$": "2-pyridinamine, 5-fluoro-4-(4-fluoro-2-methoxyphenyl)-n-(4-(((s(s))-s-methylsulfonimidoyl)methyl)-2-pyridinyl)-"}]}, "products": null, "international-brands": null, "mixtures": null, "packagers": null, "manufacturers": null, "prices": null, "categories": null, "affected-organisms": null, "dosages": null, "atc-codes": null, "ahfs-codes": null, "pdb-entries": null, "patents": null, "food-interactions": null, "drug-interactions": null, "calculated-properties": {"property": [{"kind": "logP", "value": "3.71", "source": "ALOGPS"}, {"kind": "logS", "value": "-4.7", "source": "ALOGPS"}, {"kind": "Water Solubility", "value": "7.76e-03 g/l", "source": "ALOGPS"}, {"kind": "logP", "value": "2.56", "source": "ChemAxon"}, {"kind": "IUPAC Name", "value": "(S)-[(2-{[5-fluoro-4-(4-fluoro-2-methoxyphenyl)pyridin-2-yl]amino}pyridin-4-yl)methyl](imino)methyl-lambda6-sulfanone", "source": "ChemAxon"}, {"kind": "Traditional IUPAC Name", "value": "(S)-[(2-{[5-fluoro-4-(4-fluoro-2-methoxyphenyl)pyridin-2-yl]amino}pyridin-4-yl)methyl](imino)methyl-lambda6-sulfanone", "source": "ChemAxon"}, {"kind": "Molecular Weight", "value": "404.44", "source": "ChemAxon"}, {"kind": "Monoisotopic Weight", "value": "404.111853336", "source": "ChemAxon"}, {"kind": "SMILES", "value": "COC1=C(C=CC(F)=C1)C1=CC(NC2=NC=CC(C[S@@](C)(=N)=O)=C2)=NC=C1F", "source": "ChemAxon"}, {"kind": "Molecular Formula", "value": "C19H18F2N4O2S", "source": "ChemAxon"}, {"kind": "InChI", "value": "InChI=1S/C19H18F2N4O2S/c1-27-17-8-13(20)3-4-14(17)15-9-19(24-10-16(15)21)25-18-7-12(5-6-23-18)11-28(2,22)26/h3-10,22H,11H2,1-2H3,(H,23,24,25)/t28-/m0/s1", "source": "ChemAxon"}, {"kind": "InChIKey", "value": "YZCUMZWULWOUMD-NDEPHWFRSA-N", "source": "ChemAxon"}, {"kind": "Polar Surface Area (PSA)", "value": "87.96", "source": "ChemAxon"}, {"kind": "Refractivity", "value": "103.02", "source": "ChemAxon"}, {"kind": "Polarizability", "value": "39.71", "source": "ChemAxon"}, {"kind": "Rotatable Bond Count", "value": "6", "source": "ChemAxon"}, {"kind": "H Bond Acceptor Count", "value": "6", "source": "ChemAxon"}, {"kind": "H Bond Donor Count", "value": "2", "source": "ChemAxon"}, {"kind": "pKa (strongest acidic)", "value": "13.52", "source": "ChemAxon"}, {"kind": "pKa (strongest basic)", "value": "4.46", "source": "ChemAxon"}, {"kind": "Physiological Charge", "value": "0", "source": "ChemAxon"}, {"kind": "Number of Rings", "value": "3", "source": "ChemAxon"}, {"kind": "Bioavailability", "value": "1", "source": "ChemAxon"}, {"kind": "Rule of Five", "value": "1", "source": "ChemAxon"}, {"kind": "Ghose Filter", "value": "1", "source": "ChemAxon"}, {"kind": "MDDR-Like Rule", "value": "1", "source": "ChemAxon"}]}, "experimental-properties": null, "external-identifiers": {"external-identifier": [{"resource": "ChemSpider", "identifier": "81367557"}, {"resource": "ChEMBL", "identifier": "CHEMBL4762845"}]}, "external-links": null, "pathways": null, "reactions": null, "snp-effects": null, "snp-adverse-drug-reactions": null, "targets": null, "enzymes": null, "carriers": null, "transporters": null}, {"@type": "small molecule", "@created": "2022-12-02", "@updated": "2022-12-13", "drugbank-id": [{"@primary": true, "$": "DB17298"}], "name": "Disufenton", "description": null, "cas-number": "168021-77-0", "unii": "797K01YF1M", "average-mass": 337.36, "monoisotopic-mass": 337.028994175, "groups": {"group": ["investigational"]}, "general-references": {"articles": null, "textbooks": null, "links": null, "attachments": null}, "synthesis-reference": null, "indication": null, "pharmacodynamics": null, "mechanism-of-action": null, "toxicity": null, "metabolism": null, "absorption": null, "half-life": null, "protein-binding": null, "route-of-elimination": null, "volume-of-distribution": null, "clearance": null, "salts": {"salt": [{"drugbank-id": [{"@primary": true, "$": "DBSALT003322"}], "name": "Disufenton sodium", "unii": "7M1J3HN9VO", "cas-number": "168021-79-2", "inchikey": "XLZOVRYBVCMCGL-UHFFFAOYSA-L", "average-mass": 404.31, "monoisotopic-mass": 403.98210337}]}, "synonyms": {"synonym": [{"@language": "english", "@coder": "", "$": "1,3-benzenedisulfonic acid, 4-(((1,1-dimethylethyl)oxidoimino)methyl)-"}, {"@language": "english", "@coder": "", "$": "2,4-disulfonyl-.alpha.-phenyl-tert-butylnitrone"}, {"@language": "english", "@coder": "", "$": "4-(((1,1-dimethylethyl)imino)methyl)benzene-1,3-disulfonate n-oxide"}, {"@language": "english", "@coder": "", "$": "4-(((1,1-dimethylethyl)imino)methyl)benzene-1,3-disulphonate n-oxide"}, {"@language": "english", "@coder": "", "$": "4-(((1,1-dimethylethyl)oxidoimino)methyl)-1,3-benzenedisulfonic acid"}, {"@language": "english", "@coder": "", "$": "4-tert-butyliminomethyl)benzene-,3-disulfonate n-oxide"}, {"@language": "english", "@coder": "", "$": "4-tert-butyliminomethyl)benzene-,3-disulphonate n-oxide"}]}, "products": null, "international-brands": null, "mixtures": null, "packagers": null, "manufacturers": null, "prices": null, "categories": {"category": [{"category": "Antioxidants", "mesh-id": "D000975"}, {"category": "Arylsulfonates", "mesh-id": "D001190"}, {"category": "Arylsulfonic Acids", "mesh-id": "D017739"}, {"category": "Benzene Derivatives", "mesh-id": "D001555"}, {"category": "Biological Factors", "mesh-id": "D001685"}, {"category": "Cardiovascular Agents", "mesh-id": "D002317"}, {"category": "Compounds used in a research, industrial, or household setting", "mesh-id": "D020313"}, {"category": "Protective Agents", "mesh-id": "D020011"}, {"category": "Stroke", "mesh-id": "D020521"}, {"category": "Sulfonic Acids", "mesh-id": "D013451"}, {"category": "Sulfur Acids", "mesh-id": "D013456"}, {"category": "Sulfur Compounds", "mesh-id": "D013457"}]}, "affected-organisms": null, "dosages": null, "atc-codes": null, "ahfs-codes": null, "pdb-entries": null, "patents": null, "food-interactions": null, "drug-interactions": null, "calculated-properties": {"property": [{"kind": "logP", "value": "-2.1", "source": "ALOGPS"}, {"kind": "logS", "value": "-2.9", "source": "ALOGPS"}, {"kind": "Water Solubility", "value": "3.98e-01 g/l", "source": "ALOGPS"}, {"kind": "logP", "value": "-2.1", "source": "ChemAxon"}, {"kind": "IUPAC Name", "value": "(Z)-tert-butyl[(2,4-disulfophenyl)methylidene]oxidoazanium", "source": "ChemAxon"}, {"kind": "Traditional IUPAC Name", "value": "(Z)-tert-butyl[(2,4-disulfophenyl)methylidene]oxidoazanium", "source": "ChemAxon"}, {"kind": "Molecular Weight", "value": "337.36", "source": "ChemAxon"}, {"kind": "Monoisotopic Weight", "value": "337.028994175", "source": "ChemAxon"}, {"kind": "SMILES", "value": "CC(C)(C)[N+](\\[O-])=C\\C1=C(C=C(C=C1)S(O)(=O)=O)S(O)(=O)=O", "source": "ChemAxon"}, {"kind": "Molecular Formula", "value": "C11H15NO7S2", "source": "ChemAxon"}, {"kind": "InChI", "value": "InChI=1S/C11H15NO7S2/c1-11(2,3)12(13)7-8-4-5-9(20(14,15)16)6-10(8)21(17,18)19/h4-7H,1-3H3,(H,14,15,16)(H,17,18,19)/b12-7-", "source": "ChemAxon"}, {"kind": "InChIKey", "value": "OVTCHWSLKGENKP-GHXNOFRVSA-N", "source": "ChemAxon"}, {"kind": "Polar Surface Area (PSA)", "value": "134.81", "source": "ChemAxon"}, {"kind": "Refractivity", "value": "78.1", "source": "ChemAxon"}, {"kind": "Polarizability", "value": "31.55", "source": "ChemAxon"}, {"kind": "Rotatable Bond Count", "value": "4", "source": "ChemAxon"}, {"kind": "H Bond Acceptor Count", "value": "7", "source": "ChemAxon"}, {"kind": "H Bond Donor Count", "value": "2", "source": "ChemAxon"}, {"kind": "pKa (strongest acidic)", "value": "-2.9", "source": "ChemAxon"}, {"kind": "Physiological Charge", "value": "-2", "source": "ChemAxon"}, {"kind": "Number of Rings", "value": "1", "source": "ChemAxon"}, {"kind": "Bioavailability", "value": "1", "source": "ChemAxon"}, {"kind": "Rule of Five", "value": "1", "source": "ChemAxon"}, {"kind": "Ghose Filter", "value": "0", "source": "ChemAxon"}, {"kind": "MDDR-Like Rule", "value": "0", "source": "ChemAxon"}]}, "experimental-properties": null, "external-identifiers": {"external-identifier": [{"resource": "ChemSpider", "identifier": "5289390"}, {"resource": "Wikipedia", "identifier": "Disufenton_sodium"}, {"resource": "ChEMBL", "identifier": "CHEMBL1206050"}, {"resource": "ZINC", "identifier": "ZINC000002022427"}]}, "external-links": null, "pathways": null, "reactions": null, "snp-effects": null, "snp-adverse-drug-reactions": null, "targets": null, "enzymes": null, "carriers": null, "transporters": null}, {"@type": "small molecule", "@created": "2022-12-02", "@updated": "2022-12-03", "drugbank-id": [{"@primary": true, "$": "DB17299"}], "name": "p-Toluenesulfonamide", "description": null, "cas-number": "70-55-3", "unii": "I8266RI90M", "average-mass": 171.21, "monoisotopic-mass": 171.035399708, "groups": {"group": ["investigational"]}, "general-references": {"articles": null, "textbooks": null, "links": null, "attachments": null}, "synthesis-reference": null, "indication": null, "pharmacodynamics": null, "mechanism-of-action": null, "toxicity": null, "metabolism": null, "absorption": null, "half-life": null, "protein-binding": null, "route-of-elimination": null, "volume-of-distribution": null, "clearance": null, "salts": null, "synonyms": {"synonym": [{"@language": "english", "@coder": "", "$": "4-methylbenzenesulfonamide"}, {"@language": "english", "@coder": "", "$": "4-toluenesulfonamide"}, {"@language": "english", "@coder": "", "$": "Benzenesulfonamide, 4-methyl-"}, {"@language": "english", "@coder": "", "$": "P-methylbenzenesulfonamide"}, {"@language": "english", "@coder": "", "$": "P-toluenesulfonylamide"}, {"@language": "english", "@coder": "", "$": "P-tosylamide"}, {"@language": "english", "@coder": "", "$": "Para-toluenesulfonamide"}, {"@language": "english", "@coder": "", "$": "Tolbutamide impurity a"}, {"@language": "english", "@coder": "", "$": "Toluene-4-sulphonamide"}, {"@language": "english", "@coder": "", "$": "Toluenesulfonamide, p-"}]}, "products": null, "international-brands": null, "mixtures": null, "packagers": null, "manufacturers": null, "prices": null, "categories": {"category": [{"category": "Amides", "mesh-id": "D000577"}, {"category": "Benzene Derivatives", "mesh-id": "D001555"}, {"category": "Sulfones", "mesh-id": "D013450"}, {"category": "Sulfur Compounds", "mesh-id": "D013457"}]}, "affected-organisms": null, "dosages": null, "atc-codes": null, "ahfs-codes": null, "pdb-entries": {"pdb-entry": ["4yxi", "5rtl", "6gm9"]}, "patents": null, "food-interactions": null, "drug-interactions": null, "calculated-properties": {"property": [{"kind": "logP", "value": "0.72", "source": "ALOGPS"}, {"kind": "logS", "value": "-1.9", "source": "ALOGPS"}, {"kind": "Water Solubility", "value": "2.27e+00 g/l", "source": "ALOGPS"}, {"kind": "logP", "value": "1.09", "source": "ChemAxon"}, {"kind": "IUPAC Name", "value": "4-methylbenzene-1-sulfonamide", "source": "ChemAxon"}, {"kind": "Traditional IUPAC Name", "value": "p-toluenesulfonamide", "source": "ChemAxon"}, {"kind": "Molecular Weight", "value": "171.21", "source": "ChemAxon"}, {"kind": "Monoisotopic Weight", "value": "171.035399708", "source": "ChemAxon"}, {"kind": "SMILES", "value": "CC1=CC=C(C=C1)S(N)(=O)=O", "source": "ChemAxon"}, {"kind": "Molecular Formula", "value": "C7H9NO2S", "source": "ChemAxon"}, {"kind": "InChI", "value": "InChI=1S/C7H9NO2S/c1-6-2-4-7(5-3-6)11(8,9)10/h2-5H,1H3,(H2,8,9,10)", "source": "ChemAxon"}, {"kind": "InChIKey", "value": "LMYRWZFENFIFIT-UHFFFAOYSA-N", "source": "ChemAxon"}, {"kind": "Polar Surface Area (PSA)", "value": "60.16", "source": "ChemAxon"}, {"kind": "Refractivity", "value": "43.26", "source": "ChemAxon"}, {"kind": "Polarizability", "value": "16.97", "source": "ChemAxon"}, {"kind": "Rotatable Bond Count", "value": "1", "source": "ChemAxon"}, {"kind": "H Bond Acceptor Count", "value": "2", "source": "ChemAxon"}, {"kind": "H Bond Donor Count", "value": "1", "source": "ChemAxon"}, {"kind": "pKa (strongest acidic)", "value": "10.46", "source": "ChemAxon"}, {"kind": "Physiological Charge", "value": "0", "source": "ChemAxon"}, {"kind": "Number of Rings", "value": "1", "source": "ChemAxon"}, {"kind": "Bioavailability", "value": "1", "source": "ChemAxon"}, {"kind": "Rule of Five", "value": "1", "source": "ChemAxon"}, {"kind": "Ghose Filter", "value": "1", "source": "ChemAxon"}, {"kind": "MDDR-Like Rule", "value": "0", "source": "ChemAxon"}]}, "experimental-properties": null, "external-identifiers": {"external-identifier": [{"resource": "ChEBI", "identifier": "34435"}, {"resource": "KEGG Compound", "identifier": "C14412"}, {"resource": "ChemSpider", "identifier": "6033"}, {"resource": "BindingDB", "identifier": "10859"}, {"resource": "PDB", "identifier": "4J8"}, {"resource": "ChEMBL", "identifier": "CHEMBL574"}, {"resource": "ZINC", "identifier": "ZINC000000388056"}]}, "external-links": null, "pathways": null, "reactions": null, "snp-effects": null, "snp-adverse-drug-reactions": null, "targets": null, "enzymes": null, "carriers": null, "transporters": null}, {"@type": "small molecule", "@created": "2022-12-02", "@updated": "2022-12-03", "drugbank-id": [{"@primary": true, "$": "DB17300"}], "name": "Tyroserleutide", "description": null, "cas-number": "138168-48-6", "unii": "L9TIM50J8N", "average-mass": 381.429, "monoisotopic-mass": 381.189985601, "groups": {"group": ["investigational"]}, "general-references": {"articles": null, "textbooks": null, "links": null, "attachments": null}, "synthesis-reference": null, "indication": null, "pharmacodynamics": null, "mechanism-of-action": null, "toxicity": null, "metabolism": null, "absorption": null, "half-life": null, "protein-binding": null, "route-of-elimination": null, "volume-of-distribution": null, "clearance": null, "salts": null, "synonyms": {"synonym": [{"@language": "english", "@coder": "", "$": "L-leucine, l-tyrosyl-l-seryl-"}, {"@language": "english", "@coder": "", "$": "L-tyrosine-l-serine-l-leucine"}]}, "products": null, "international-brands": null, "mixtures": null, "packagers": null, "manufacturers": null, "prices": null, "categories": {"category": [{"category": "Amino Acids, Peptides, and Proteins", "mesh-id": "D000602"}, {"category": "Peptides", "mesh-id": "D010455"}]}, "affected-organisms": null, "dosages": null, "atc-codes": null, "ahfs-codes": null, "pdb-entries": null, "patents": null, "food-interactions": null, "drug-interactions": null, "calculated-properties": {"property": [{"kind": "logP", "value": "-1.7", "source": "ALOGPS"}, {"kind": "logS", "value": "-2.6", "source": "ALOGPS"}, {"kind": "Water Solubility", "value": "9.29e-01 g/l", "source": "ALOGPS"}, {"kind": "logP", "value": "-2.4", "source": "ChemAxon"}, {"kind": "IUPAC Name", "value": "(2S)-2-[(2S)-2-[(2S)-2-amino-3-(4-hydroxyphenyl)propanamido]-3-hydroxypropanamido]-4-methylpentanoic acid", "source": "ChemAxon"}, {"kind": "Traditional IUPAC Name", "value": "(2S)-2-[(2S)-2-[(2S)-2-amino-3-(4-hydroxyphenyl)propanamido]-3-hydroxypropanamido]-4-methylpentanoic acid", "source": "ChemAxon"}, {"kind": "Molecular Weight", "value": "381.429", "source": "ChemAxon"}, {"kind": "Monoisotopic Weight", "value": "381.189985601", "source": "ChemAxon"}, {"kind": "SMILES", "value": "CC(C)C[C@H](NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1)C(O)=O", "source": "ChemAxon"}, {"kind": "Molecular Formula", "value": "C18H27N3O6", "source": "ChemAxon"}, {"kind": "InChI", "value": "InChI=1S/C18H27N3O6/c1-10(2)7-14(18(26)27)20-17(25)15(9-22)21-16(24)13(19)8-11-3-5-12(23)6-4-11/h3-6,10,13-15,22-23H,7-9,19H2,1-2H3,(H,20,25)(H,21,24)(H,26,27)/t13-,14-,15-/m0/s1", "source": "ChemAxon"}, {"kind": "InChIKey", "value": "MQGGXGKQSVEQHR-KKUMJFAQSA-N", "source": "ChemAxon"}, {"kind": "Polar Surface Area (PSA)", "value": "161.98", "source": "ChemAxon"}, {"kind": "Refractivity", "value": "96.91", "source": "ChemAxon"}, {"kind": "Polarizability", "value": "39.41", "source": "ChemAxon"}, {"kind": "Rotatable Bond Count", "value": "10", "source": "ChemAxon"}, {"kind": "H Bond Acceptor Count", "value": "7", "source": "ChemAxon"}, {"kind": "H Bond Donor Count", "value": "6", "source": "ChemAxon"}, {"kind": "pKa (strongest acidic)", "value": "3.63", "source": "ChemAxon"}, {"kind": "pKa (strongest basic)", "value": "7.73", "source": "ChemAxon"}, {"kind": "Physiological Charge", "value": "0", "source": "ChemAxon"}, {"kind": "Number of Rings", "value": "1", "source": "ChemAxon"}, {"kind": "Bioavailability", "value": "1", "source": "ChemAxon"}, {"kind": "Rule of Five", "value": "0", "source": "ChemAxon"}, {"kind": "Ghose Filter", "value": "0", "source": "ChemAxon"}, {"kind": "MDDR-Like Rule", "value": "0", "source": "ChemAxon"}]}, "experimental-properties": null, "external-identifiers": {"external-identifier": [{"resource": "ChEBI", "identifier": "165965"}, {"resource": "ChemSpider", "identifier": "8220951"}]}, "external-links": null, "pathways": null, "reactions": null, "snp-effects": null, "snp-adverse-drug-reactions": null, "targets": null, "enzymes": null, "carriers": null, "transporters": null}, {"@type": "biotech", "@created": "2022-12-02", "@updated": "2022-12-03", "drugbank-id": [{"@primary": true, "$": "DB17301"}], "name": "Tavokinogene telseplasmid", "description": "Tavokinogene telseplasmid consists of a DNA Plasmid Vector Encoding IL-12.", "cas-number": "1971880-37-1", "unii": "MF4P7VQ2K8", "groups": {"group": ["investigational"]}, "general-references": {"articles": null, "textbooks": null, "links": null, "attachments": null}, "synthesis-reference": null, "indication": null, "pharmacodynamics": null, "mechanism-of-action": null, "toxicity": null, "metabolism": null, "absorption": null, "half-life": null, "protein-binding": null, "route-of-elimination": null, "volume-of-distribution": null, "clearance": null, "salts": null, "synonyms": {"synonym": [{"@language": "english", "@coder": "", "$": "Dna plasmid containing genes coding for the human interleukin 12 (il-12) p35 and p40 subunits that are separated by an internal ribosomal entry site (ires) and under the control of a single cytomegalovirus (cmv) promoter"}, {"@language": "english", "@coder": "", "$": "Dna plasmid encoding interleukin-12 ino-9012"}, {"@language": "english", "@coder": "", "$": "Pumvc3-hil"}, {"@language": "english", "@coder": "", "$": "pUMVC3-hIL-12-NGVL331"}]}, "products": null, "international-brands": null, "mixtures": null, "packagers": null, "manufacturers": null, "prices": null, "categories": null, "affected-organisms": null, "dosages": null, "atc-codes": null, "ahfs-codes": null, "pdb-entries": null, "patents": null, "food-interactions": null, "drug-interactions": null, "sequences": null, "experimental-properties": null, "external-identifiers": null, "external-links": null, "pathways": null, "reactions": null, "snp-effects": null, "snp-adverse-drug-reactions": null, "targets": null, "enzymes": null, "carriers": null, "transporters": null}, {"@type": "biotech", "@created": "2022-12-02", "@updated": "2022-12-03", "drugbank-id": [{"@primary": true, "$": "DB17302"}], "name": "SNS01-T", "description": "SNS01-T is a gene therapy nanoparticle. It is composed of three components: a B cell-specific plasmid expressing eIF5AK50R; an siRNA that targets the native eIF5A that promotes growth/anti-apoptosis of cancer cells; and polyethylenimine.[A254706]", "cas-number": null, "unii": null, "groups": {"group": ["investigational"]}, "general-references": {"articles": {"article": [{"ref-id": "A254706", "pubmed-id": "21638795", "citation": "Authors unspecified: Abstracts of the American Society of Gene & Cell Therapy 14th Annual Meeting. May 18-May 21, 2011. Seattle, Washington, USA. Mol Ther. 2011 May;19 Suppl 1:S1-361."}]}, "textbooks": null, "links": null, "attachments": null}, "synthesis-reference": null, "indication": null, "pharmacodynamics": null, "mechanism-of-action": null, "toxicity": null, "metabolism": null, "absorption": null, "half-life": null, "protein-binding": null, "route-of-elimination": null, "volume-of-distribution": null, "clearance": null, "salts": null, "synonyms": null, "products": null, "international-brands": null, "mixtures": null, "packagers": null, "manufacturers": null, "prices": null, "categories": null, "affected-organisms": null, "dosages": null, "atc-codes": null, "ahfs-codes": null, "pdb-entries": null, "patents": null, "food-interactions": null, "drug-interactions": null, "sequences": null, "experimental-properties": null, "external-identifiers": null, "external-links": null, "pathways": null, "reactions": null, "snp-effects": null, "snp-adverse-drug-reactions": null, "targets": null, "enzymes": null, "carriers": null, "transporters": null}, {"@type": "biotech", "@created": "2022-12-02", "@updated": "2022-12-03", "drugbank-id": [{"@primary": true, "$": "DB17303"}], "name": "Leuvectin", "description": "Leuvectin (formerly known as VCL-1102) is a gene therapy. It consists of a plasmid encoding human interleukin (IL)-2 formulated with the cationic lipid 1,2-dimyristyloxypropyl-3-dimethyl-hydroxyethyl ammonium bromide/dioleyl-phosphatidyl-ethanolamine (DMRIE/DOPE).[A254711]", "cas-number": null, "unii": null, "groups": {"group": ["investigational"]}, "general-references": {"articles": {"article": [{"ref-id": "A254711", "pubmed-id": "10506635", "citation": "Galanis E, Hersh EM, Stopeck AT, Gonzalez R, Burch P, Spier C, Akporiaye ET, Rinehart JJ, Edmonson J, Sobol RE, Forscher C, Sondak VK, Lewis BD, Unger EC, O'Driscoll M, Selk L, Rubin J: Immunotherapy of advanced malignancy by direct gene transfer of an interleukin-2 DNA/DMRIE/DOPE lipid complex: phase I/II experience. J Clin Oncol. 1999 Oct;17(10):3313-23. doi: 10.1200/JCO.1999.17.10.3313."}]}, "textbooks": null, "links": null, "attachments": null}, "synthesis-reference": null, "indication": null, "pharmacodynamics": null, "mechanism-of-action": null, "toxicity": null, "metabolism": null, "absorption": null, "half-life": null, "protein-binding": null, "route-of-elimination": null, "volume-of-distribution": null, "clearance": null, "salts": null, "synonyms": {"synonym": [{"@language": "english", "@coder": "", "$": "DNA-lipid complex (DMRIE/DOPE)/plasmid vector (VCL-1102, Vical) expressing human interleukin-2"}]}, "products": null, "international-brands": null, "mixtures": null, "packagers": null, "manufacturers": null, "prices": null, "categories": {"category": [{"category": "Biological Products", "mesh-id": "D001688"}, {"category": "Complex Mixtures", "mesh-id": "D045424"}, {"category": "Gene Transfer Techniques", "mesh-id": "D018014"}, {"category": "Vaccines", "mesh-id": "D014612"}]}, "affected-organisms": null, "dosages": null, "atc-codes": null, "ahfs-codes": null, "pdb-entries": null, "patents": null, "food-interactions": null, "drug-interactions": null, "sequences": null, "experimental-properties": null, "external-identifiers": null, "external-links": null, "pathways": null, "reactions": null, "snp-effects": null, "snp-adverse-drug-reactions": null, "targets": null, "enzymes": null, "carriers": null, "transporters": null}, {"@type": "small molecule", "@created": "2022-12-02", "@updated": "2022-12-03", "drugbank-id": [{"@primary": true, "$": "DB17304"}], "name": "Doranidazole", "description": null, "cas-number": "149838-23-3", "unii": "911XR034RX", "average-mass": 247.207, "monoisotopic-mass": 247.080435151, "groups": {"group": ["investigational"]}, "general-references": {"articles": null, "textbooks": null, "links": null, "attachments": null}, "synthesis-reference": null, "indication": null, "pharmacodynamics": null, "mechanism-of-action": null, "toxicity": null, "metabolism": null, "absorption": null, "half-life": null, "protein-binding": null, "route-of-elimination": null, "volume-of-distribution": null, "clearance": null, "salts": null, "synonyms": {"synonym": [{"@language": "english", "@coder": "", "$": "(2rs,3sr)-3-((2-nitroimidazol-1-yl)methoxy)butane-1,2,4-triol"}, {"@language": "english", "@coder": "", "$": "1,2,4-butanetriol, 3-((2-nitro-1h-imidazol-1-yl)methoxy)-, (2r,3s)-rel-"}]}, "products": null, "international-brands": null, "mixtures": null, "packagers": null, "manufacturers": null, "prices": null, "categories": {"category": [{"category": "Carbohydrates", "mesh-id": "D002241"}, {"category": "Glycosides", "mesh-id": "D006027"}, {"category": "Imidazoles", "mesh-id": "D007093"}, {"category": "Nitro Compounds", "mesh-id": "D009574"}, {"category": "Nucleic Acids, Nucleotides, and Nucleosides", "mesh-id": "D009706"}]}, "affected-organisms": null, "dosages": null, "atc-codes": null, "ahfs-codes": null, "pdb-entries": null, "patents": null, "food-interactions": null, "drug-interactions": null, "calculated-properties": {"property": [{"kind": "logP", "value": "-1.5", "source": "ALOGPS"}, {"kind": "logS", "value": "-1.2", "source": "ALOGPS"}, {"kind": "Water Solubility", "value": "1.55e+01 g/l", "source": "ALOGPS"}, {"kind": "logP", "value": "-1.2", "source": "ChemAxon"}, {"kind": "IUPAC Name", "value": "(2R,3S)-3-[(2-nitro-1H-imidazol-1-yl)methoxy]butane-1,2,4-triol", "source": "ChemAxon"}, {"kind": "Traditional IUPAC Name", "value": "(2R,3S)-3-[(2-nitroimidazol-1-yl)methoxy]butane-1,2,4-triol", "source": "ChemAxon"}, {"kind": "Molecular Weight", "value": "247.207", "source": "ChemAxon"}, {"kind": "Monoisotopic Weight", "value": "247.080435151", "source": "ChemAxon"}, {"kind": "SMILES", "value": "OC[C@@H](O)[C@H](CO)OCN1C=CN=C1[N+]([O-])=O", "source": "ChemAxon"}, {"kind": "Molecular Formula", "value": "C8H13N3O6", "source": "ChemAxon"}, {"kind": "InChI", "value": "InChI=1S/C8H13N3O6/c12-3-6(14)7(4-13)17-5-10-2-1-9-8(10)11(15)16/h1-2,6-7,12-14H,3-5H2/t6-,7+/m1/s1", "source": "ChemAxon"}, {"kind": "InChIKey", "value": "FIITXXIVUIXYMI-RQJHMYQMSA-N", "source": "ChemAxon"}, {"kind": "Polar Surface Area (PSA)", "value": "130.88", "source": "ChemAxon"}, {"kind": "Refractivity", "value": "53.77", "source": "ChemAxon"}, {"kind": "Polarizability", "value": "22.49", "source": "ChemAxon"}, {"kind": "Rotatable Bond Count", "value": "7", "source": "ChemAxon"}, {"kind": "H Bond Acceptor Count", "value": "7", "source": "ChemAxon"}, {"kind": "H Bond Donor Count", "value": "3", "source": "ChemAxon"}, {"kind": "pKa (strongest acidic)", "value": "13.31", "source": "ChemAxon"}, {"kind": "pKa (strongest basic)", "value": "0.038", "source": "ChemAxon"}, {"kind": "Physiological Charge", "value": "0", "source": "ChemAxon"}, {"kind": "Number of Rings", "value": "1", "source": "ChemAxon"}, {"kind": "Bioavailability", "value": "1", "source": "ChemAxon"}, {"kind": "Rule of Five", "value": "1", "source": "ChemAxon"}, {"kind": "Ghose Filter", "value": "0", "source": "ChemAxon"}, {"kind": "MDDR-Like Rule", "value": "0", "source": "ChemAxon"}]}, "experimental-properties": null, "external-identifiers": {"external-identifier": [{"resource": "ChemSpider", "identifier": "144199"}, {"resource": "ChEMBL", "identifier": "CHEMBL2107741"}]}, "external-links": null, "pathways": null, "reactions": null, "snp-effects": null, "snp-adverse-drug-reactions": null, "targets": null, "enzymes": null, "carriers": null, "transporters": null}, {"@type": "biotech", "@created": "2022-12-05", "@updated": "2022-12-06", "drugbank-id": [{"@primary": true, "$": "DB17305"}], "name": "MV-NB-02", "description": null, "cas-number": null, "unii": null, "groups": {"group": ["investigational"]}, "general-references": {"articles": null, "textbooks": null, "links": null, "attachments": null}, "synthesis-reference": null, "indication": null, "pharmacodynamics": null, "mechanism-of-action": null, "toxicity": null, "metabolism": null, "absorption": null, "half-life": null, "protein-binding": null, "route-of-elimination": null, "volume-of-distribution": null, "clearance": null, "salts": null, "synonyms": null, "products": null, "international-brands": null, "mixtures": null, "packagers": null, "manufacturers": null, "prices": null, "categories": null, "affected-organisms": null, "dosages": null, "atc-codes": null, "ahfs-codes": null, "pdb-entries": null, "patents": null, "food-interactions": null, "drug-interactions": null, "sequences": null, "experimental-properties": null, "external-identifiers": null, "external-links": null, "pathways": null, "reactions": null, "snp-effects": null, "snp-adverse-drug-reactions": null, "targets": null, "enzymes": null, "carriers": null, "transporters": null}, {"@type": "small molecule", "@created": "2022-12-05", "@updated": "2022-12-06", "drugbank-id": [{"@primary": true, "$": "DB17306"}], "name": "Metavert", "description": null, "cas-number": "1841125-91-4", "unii": "IZB8PZ86FH", "average-mass": 326.312, "monoisotopic-mass": 326.101504947, "groups": {"group": ["investigational"]}, "general-references": {"articles": null, "textbooks": null, "links": null, "attachments": null}, "synthesis-reference": null, "indication": null, "pharmacodynamics": null, "mechanism-of-action": null, "toxicity": null, "metabolism": null, "absorption": null, "half-life": null, "protein-binding": null, "route-of-elimination": null, "volume-of-distribution": null, "clearance": null, "salts": null, "synonyms": {"synonym": [{"@language": "english", "@coder": "", "$": "Benzamide, n-hydroxy-4-(5-((4-methoxyphenyl)amino)-1,3,4-oxadiazol-2-yl)-"}, {"@language": "english", "@coder": "", "$": "N-hydroxy-4-(5-((4-methoxyphenyl)amino)-1,3,4-oxadiazol-2-yl)benzamide"}]}, "products": null, "international-brands": null, "mixtures": null, "packagers": null, "manufacturers": null, "prices": null, "categories": null, "affected-organisms": null, "dosages": null, "atc-codes": null, "ahfs-codes": null, "pdb-entries": null, "patents": null, "food-interactions": null, "drug-interactions": null, "calculated-properties": {"property": [{"kind": "logP", "value": "2.4", "source": "ALOGPS"}, {"kind": "logS", "value": "-3.4", "source": "ALOGPS"}, {"kind": "Water Solubility", "value": "1.46e-01 g/l", "source": "ALOGPS"}, {"kind": "logP", "value": "1.79", "source": "ChemAxon"}, {"kind": "IUPAC Name", "value": "N-hydroxy-4-{5-[(4-methoxyphenyl)amino]-1,3,4-oxadiazol-2-yl}benzamide", "source": "ChemAxon"}, {"kind": "Traditional IUPAC Name", "value": "N-hydroxy-4-{5-[(4-methoxyphenyl)amino]-1,3,4-oxadiazol-2-yl}benzamide", "source": "ChemAxon"}, {"kind": "Molecular Weight", "value": "326.312", "source": "ChemAxon"}, {"kind": "Monoisotopic Weight", "value": "326.101504947", "source": "ChemAxon"}, {"kind": "SMILES", "value": "COC1=CC=C(NC2=NN=C(O2)C2=CC=C(C=C2)C(=O)NO)C=C1", "source": "ChemAxon"}, {"kind": "Molecular Formula", "value": "C16H14N4O4", "source": "ChemAxon"}, {"kind": "InChI", "value": "InChI=1S/C16H14N4O4/c1-23-13-8-6-12(7-9-13)17-16-19-18-15(24-16)11-4-2-10(3-5-11)14(21)20-22/h2-9,22H,1H3,(H,17,19)(H,20,21)", "source": "ChemAxon"}, {"kind": "InChIKey", "value": "TWABKXHHSQCZPI-UHFFFAOYSA-N", "source": "ChemAxon"}, {"kind": "Polar Surface Area (PSA)", "value": "109.51", "source": "ChemAxon"}, {"kind": "Refractivity", "value": "97.35", "source": "ChemAxon"}, {"kind": "Polarizability", "value": "32.98", "source": "ChemAxon"}, {"kind": "Rotatable Bond Count", "value": "5", "source": "ChemAxon"}, {"kind": "H Bond Acceptor Count", "value": "6", "source": "ChemAxon"}, {"kind": "H Bond Donor Count", "value": "3", "source": "ChemAxon"}, {"kind": "pKa (strongest acidic)", "value": "8.95", "source": "ChemAxon"}, {"kind": "pKa (strongest basic)", "value": "-1.4", "source": "ChemAxon"}, {"kind": "Physiological Charge", "value": "0", "source": "ChemAxon"}, {"kind": "Number of Rings", "value": "3", "source": "ChemAxon"}, {"kind": "Bioavailability", "value": "1", "source": "ChemAxon"}, {"kind": "Rule of Five", "value": "1", "source": "ChemAxon"}, {"kind": "Ghose Filter", "value": "1", "source": "ChemAxon"}, {"kind": "MDDR-Like Rule", "value": "0", "source": "ChemAxon"}]}, "experimental-properties": null, "external-identifiers": {"external-identifier": [{"resource": "ChemSpider", "identifier": "64853731"}]}, "external-links": null, "pathways": null, "reactions": null, "snp-effects": null, "snp-adverse-drug-reactions": null, "targets": null, "enzymes": null, "carriers": null, "transporters": null}, {"@type": "small molecule", "@created": "2022-12-05", "@updated": "2022-12-13", "drugbank-id": [{"@primary": true, "$": "DB17307"}], "name": "IKT-001Pro", "description": null, "cas-number": null, "unii": "WQJ8L8YJ7U", "groups": {"group": ["investigational"]}, "general-references": {"articles": null, "textbooks": null, "links": null, "attachments": null}, "synthesis-reference": null, "indication": null, "pharmacodynamics": null, "mechanism-of-action": null, "toxicity": null, "metabolism": null, "absorption": null, "half-life": null, "protein-binding": null, "route-of-elimination": null, "volume-of-distribution": null, "clearance": null, "salts": {"salt": [{"drugbank-id": [{"@primary": true, "$": "DBSALT003324"}], "name": "IKT-001 Mesylate", "unii": null, "cas-number": null, "inchikey": null}]}, "synonyms": null, "products": null, "international-brands": null, "mixtures": null, "packagers": null, "manufacturers": null, "prices": null, "categories": {"category": [{"category": "Kinase Inhibitor", "mesh-id": null}]}, "affected-organisms": null, "dosages": null, "atc-codes": null, "ahfs-codes": null, "pdb-entries": null, "patents": null, "food-interactions": null, "drug-interactions": null, "calculated-properties": null, "experimental-properties": null, "external-identifiers": null, "external-links": null, "pathways": null, "reactions": null, "snp-effects": null, "snp-adverse-drug-reactions": null, "targets": null, "enzymes": null, "carriers": null, "transporters": null}, {"@type": "small molecule", "@created": "2022-12-05", "@updated": "2022-12-06", "drugbank-id": [{"@primary": true, "$": "DB17308"}], "name": "Laurocapram", "description": null, "cas-number": "59227-89-3", "unii": "1F3X9DRV9X", "average-mass": 281.484, "monoisotopic-mass": 281.271864751, "groups": {"group": ["approved"]}, "general-references": {"articles": null, "textbooks": null, "links": null, "attachments": null}, "synthesis-reference": null, "indication": null, "pharmacodynamics": null, "mechanism-of-action": null, "toxicity": null, "metabolism": null, "absorption": null, "half-life": null, "protein-binding": null, "route-of-elimination": null, "volume-of-distribution": null, "clearance": null, "salts": null, "synonyms": {"synonym": [{"@language": "english", "@coder": "", "$": "1-dodecylazacycloheptan-2-one"}, {"@language": "english", "@coder": "", "$": "1-dodecylhexahydro-2h-azepin-2-one"}, {"@language": "english", "@coder": "", "$": "1-n-dodecylazacycloheptan-2-one"}, {"@language": "english", "@coder": "", "$": "2h-azepin-2-one, 1-dodecylhexahydro-"}, {"@language": "english", "@coder": "", "$": "Azone"}, {"@language": "english", "@coder": "", "$": "N-dodecyl-.epsilon.-caprolactam"}]}, "products": null, "international-brands": null, "mixtures": null, "packagers": null, "manufacturers": null, "prices": null, "categories": null, "affected-organisms": null, "dosages": null, "atc-codes": null, "ahfs-codes": null, "pdb-entries": null, "patents": null, "food-interactions": null, "drug-interactions": null, "calculated-properties": {"property": [{"kind": "logP", "value": "5.32", "source": "ALOGPS"}, {"kind": "logS", "value": "-5.7", "source": "ALOGPS"}, {"kind": "Water Solubility", "value": "5.26e-04 g/l", "source": "ALOGPS"}, {"kind": "logP", "value": "5.41", "source": "ChemAxon"}, {"kind": "IUPAC Name", "value": "1-dodecylazepan-2-one", "source": "ChemAxon"}, {"kind": "Traditional IUPAC Name", "value": "laurocapram", "source": "ChemAxon"}, {"kind": "Molecular Weight", "value": "281.484", "source": "ChemAxon"}, {"kind": "Monoisotopic Weight", "value": "281.271864751", "source": "ChemAxon"}, {"kind": "SMILES", "value": "CCCCCCCCCCCCN1CCCCCC1=O", "source": "ChemAxon"}, {"kind": "Molecular Formula", "value": "C18H35NO", "source": "ChemAxon"}, {"kind": "InChI", "value": "InChI=1S/C18H35NO/c1-2-3-4-5-6-7-8-9-10-13-16-19-17-14-11-12-15-18(19)20/h2-17H2,1H3", "source": "ChemAxon"}, {"kind": "InChIKey", "value": "AXTGDCSMTYGJND-UHFFFAOYSA-N", "source": "ChemAxon"}, {"kind": "Polar Surface Area (PSA)", "value": "20.31", "source": "ChemAxon"}, {"kind": "Refractivity", "value": "87.04", "source": "ChemAxon"}, {"kind": "Polarizability", "value": "37.26", "source": "ChemAxon"}, {"kind": "Rotatable Bond Count", "value": "11", "source": "ChemAxon"}, {"kind": "H Bond Acceptor Count", "value": "1", "source": "ChemAxon"}, {"kind": "H Bond Donor Count", "value": "0", "source": "ChemAxon"}, {"kind": "pKa (strongest basic)", "value": "-0.89", "source": "ChemAxon"}, {"kind": "Physiological Charge", "value": "0", "source": "ChemAxon"}, {"kind": "Number of Rings", "value": "1", "source": "ChemAxon"}, {"kind": "Bioavailability", "value": "0", "source": "ChemAxon"}, {"kind": "Rule of Five", "value": "0", "source": "ChemAxon"}, {"kind": "Ghose Filter", "value": "1", "source": "ChemAxon"}, {"kind": "MDDR-Like Rule", "value": "0", "source": "ChemAxon"}]}, "experimental-properties": null, "external-identifiers": {"external-identifier": [{"resource": "ChemSpider", "identifier": "39176"}, {"resource": "ChEMBL", "identifier": "CHEMBL76591"}, {"resource": "ZINC", "identifier": "ZINC000008214596"}, {"resource": "RxCUI", "identifier": "1603852"}]}, "external-links": null, "pathways": null, "reactions": null, "snp-effects": null, "snp-adverse-drug-reactions": null, "targets": null, "enzymes": null, "carriers": null, "transporters": null}, {"@type": "small molecule", "@created": "2022-12-05", "@updated": "2022-12-06", "drugbank-id": [{"@primary": true, "$": "DB17309"}], "name": "Minnelide", "description": null, "cas-number": "1254702-87-8", "unii": "1CIV2UMO40", "average-mass": 514.374, "monoisotopic-mass": 514.09807256, "groups": {"group": ["investigational"]}, "general-references": {"articles": null, "textbooks": null, "links": null, "attachments": null}, "synthesis-reference": null, "indication": null, "pharmacodynamics": null, "mechanism-of-action": null, "toxicity": null, "metabolism": null, "absorption": null, "half-life": null, "protein-binding": null, "route-of-elimination": null, "volume-of-distribution": null, "clearance": null, "salts": null, "synonyms": {"synonym": [{"@language": "english", "@coder": "", "$": "14-o-phosphonooxymethyltriptolide disodium salt"}, {"@language": "english", "@coder": "", "$": "Trisoxireno(4b,5:6,7:8a,9)phenanthro(1,2-c)furan-1(3h)-one, 3b,4,4a,6,6a,7a,7b,8b,9,10-decahydro-8b-methyl-6a-(1-methylethyl)-6-((phosphonooxy)methoxy)-, sodium salt (1:2), (3bs,4as,5ar,6r,6as,7as,7bs,8as,8bs)-"}]}, "products": null, "international-brands": null, "mixtures": null, "packagers": null, "manufacturers": null, "prices": null, "categories": {"category": [{"category": "Alkylating Drugs", "mesh-id": "D000477"}, {"category": "Antineoplastic Agents", "mesh-id": "D000970"}, {"category": "Antineoplastic Agents, Alkylating", "mesh-id": "D018906"}, {"category": "Ethers", "mesh-id": "D004987"}, {"category": "Ethers, Cyclic", "mesh-id": "D004988"}, {"category": "Noxae", "mesh-id": "D009676"}, {"category": "Organophosphorus Compounds", "mesh-id": "D009943"}, {"category": "Terpenes", "mesh-id": "D013729"}, {"category": "Toxic Actions", "mesh-id": "D004786"}]}, "affected-organisms": null, "dosages": null, "atc-codes": null, "ahfs-codes": null, "pdb-entries": null, "patents": null, "food-interactions": null, "drug-interactions": null, "calculated-properties": {"property": [{"kind": "logP", "value": "1.78", "source": "ALOGPS"}, {"kind": "logS", "value": "-1.8", "source": "ALOGPS"}, {"kind": "Water Solubility", "value": "8.18e+00 g/l", "source": "ALOGPS"}, {"kind": "logP", "value": "1.27", "source": "ChemAxon"}, {"kind": "IUPAC Name", "value": "disodium {[(1S,2S,4S,5S,7S,8R,9R,11S,13S)-1-methyl-17-oxo-7-(propan-2-yl)-3,6,10,16-tetraoxaheptacyclo[11.7.0.0^{2,4}.0^{2,9}.0^{5,7}.0^{9,11}.0^{14,18}]icos-14(18)-en-8-yl]oxy}methyl phosphate", "source": "ChemAxon"}, {"kind": "Traditional IUPAC Name", "value": "disodium {[(1S,2S,4S,5S,7S,8R,9R,11S,13S)-7-isopropyl-1-methyl-17-oxo-3,6,10,16-tetraoxaheptacyclo[11.7.0.0^{2,4}.0^{2,9}.0^{5,7}.0^{9,11}.0^{14,18}]icos-14(18)-en-8-yl]oxy}methyl phosphate", "source": "ChemAxon"}, {"kind": "Molecular Weight", "value": "514.374", "source": "ChemAxon"}, {"kind": "Monoisotopic Weight", "value": "514.09807256", "source": "ChemAxon"}, {"kind": "SMILES", "value": "[Na+].[Na+].[H][C@@]12C[C@@H]3O[C@@]33[C@H](OCOP([O-])([O-])=O)[C@]4(O[C@H]4[C@@H]4O[C@]34[C@@]1(C)CCC1=C2COC1=O)C(C)C", "source": "ChemAxon"}, {"kind": "Molecular Formula", "value": "C21H25Na2O10P", "source": "ChemAxon"}, {"kind": "InChI", "value": "InChI=1S/C21H27O10P.2Na/c1-9(2)19-14(30-19)15-21(31-15)18(3)5-4-10-11(7-26-16(10)22)12(18)6-13-20(21,29-13)17(19)27-8-28-32(23,24)25;;/h9,12-15,17H,4-8H2,1-3H3,(H2,23,24,25);;/q;2*+1/p-2/t12-,13-,14-,15-,17+,18-,19-,20+,21+;;/m0../s1", "source": "ChemAxon"}, {"kind": "InChIKey", "value": "ZHBJMVNZRZUQEP-KIKMAQITSA-L", "source": "ChemAxon"}, {"kind": "Polar Surface Area (PSA)", "value": "145.54", "source": "ChemAxon"}, {"kind": "Refractivity", "value": "101.74", "source": "ChemAxon"}, {"kind": "Polarizability", "value": "43.85", "source": "ChemAxon"}, {"kind": "Rotatable Bond Count", "value": "5", "source": "ChemAxon"}, {"kind": "H Bond Acceptor Count", "value": "8", "source": "ChemAxon"}, {"kind": "H Bond Donor Count", "value": "0", "source": "ChemAxon"}, {"kind": "pKa (strongest acidic)", "value": "1.46", "source": "ChemAxon"}, {"kind": "pKa (strongest basic)", "value": "-3.7", "source": "ChemAxon"}, {"kind": "Physiological Charge", "value": "-2", "source": "ChemAxon"}, {"kind": "Number of Rings", "value": "7", "source": "ChemAxon"}, {"kind": "Bioavailability", "value": "1", "source": "ChemAxon"}, {"kind": "Rule of Five", "value": "0", "source": "ChemAxon"}, {"kind": "Ghose Filter", "value": "0", "source": "ChemAxon"}, {"kind": "MDDR-Like Rule", "value": "0", "source": "ChemAxon"}]}, "experimental-properties": null, "external-identifiers": {"external-identifier": [{"resource": "ChemSpider", "identifier": "52083318"}, {"resource": "Wikipedia", "identifier": "Triptolide"}, {"resource": "ChEMBL", "identifier": "CHEMBL3740500"}]}, "external-links": null, "pathways": null, "reactions": null, "snp-effects": null, "snp-adverse-drug-reactions": null, "targets": null, "enzymes": null, "carriers": null, "transporters": null}, {"@type": "biotech", "@created": "2022-12-05", "@updated": "2022-12-06", "drugbank-id": [{"@primary": true, "$": "DB17310"}], "name": "Heme arginate", "description": null, "cas-number": "100438-92-4", "unii": "R1B526117P", "groups": {"group": ["investigational"]}, "general-references": {"articles": null, "textbooks": null, "links": null, "attachments": null}, "synthesis-reference": null, "indication": null, "pharmacodynamics": null, "mechanism-of-action": null, "toxicity": null, "metabolism": null, "absorption": null, "half-life": null, "protein-binding": null, "route-of-elimination": null, "volume-of-distribution": null, "clearance": null, "salts": null, "synonyms": {"synonym": [{"@language": "english", "@coder": "", "$": "Haem arginate"}]}, "products": null, "international-brands": null, "mixtures": null, "packagers": null, "manufacturers": null, "prices": null, "categories": {"category": [{"category": "Amino Acids", "mesh-id": "D000596"}, {"category": "Amino Acids, Basic", "mesh-id": "D024361"}, {"category": "Amino Acids, Diamino", "mesh-id": "D000599"}, {"category": "Amino Acids, Essential", "mesh-id": "D000601"}, {"category": "Amino Acids, Peptides, and Proteins", "mesh-id": "D000602"}, {"category": "Biological Factors", "mesh-id": "D001685"}, {"category": "Heterocyclic Compounds, Fused-Ring", "mesh-id": "D000072471"}, {"category": "Metalloporphyrins", "mesh-id": "D008665"}, {"category": "Pigments, Biological", "mesh-id": "D010860"}, {"category": "Porphyrias", "mesh-id": "D011164"}, {"category": "Porphyrins", "mesh-id": "D011166"}]}, "affected-organisms": null, "dosages": null, "atc-codes": null, "ahfs-codes": null, "pdb-entries": null, "patents": null, "food-interactions": null, "drug-interactions": null, "sequences": null, "experimental-properties": null, "external-identifiers": {"external-identifier": [{"resource": "ChemSpider", "identifier": "21249455"}, {"resource": "Wikipedia", "identifier": "Heme_arginate"}, {"resource": "RxCUI", "identifier": "26506"}]}, "external-links": null, "pathways": null, "reactions": null, "snp-effects": null, "snp-adverse-drug-reactions": null, "targets": null, "enzymes": null, "carriers": null, "transporters": null}, {"@type": "biotech", "@created": "2022-12-05", "@updated": "2022-12-06", "drugbank-id": [{"@primary": true, "$": "DB17311"}], "name": "Hepcortespenlisimut-L", "description": null, "cas-number": null, "unii": null, "groups": {"group": ["investigational"]}, "general-references": {"articles": null, "textbooks": null, "links": null, "attachments": null}, "synthesis-reference": null, "indication": null, "pharmacodynamics": null, "mechanism-of-action": null, "toxicity": null, "metabolism": null, "absorption": null, "half-life": null, "protein-binding": null, "route-of-elimination": null, "volume-of-distribution": null, "clearance": null, "salts": null, "synonyms": {"synonym": [{"@language": "english", "@coder": "", "$": "Hepko-V5"}]}, "products": null, "international-brands": null, "mixtures": null, "packagers": null, "manufacturers": null, "prices": null, "categories": null, "affected-organisms": null, "dosages": null, "atc-codes": null, "ahfs-codes": null, "pdb-entries": null, "patents": null, "food-interactions": null, "drug-interactions": null, "sequences": null, "experimental-properties": null, "external-identifiers": {"external-identifier": [{"resource": "Wikipedia", "identifier": "Cancer_vaccine"}]}, "external-links": null, "pathways": null, "reactions": null, "snp-effects": null, "snp-adverse-drug-reactions": null, "targets": null, "enzymes": null, "carriers": null, "transporters": null}, {"@type": "small molecule", "@created": "2022-12-05", "@updated": "2022-12-06", "drugbank-id": [{"@primary": true, "$": "DB17312"}], "name": "Dotamtate Pb-212", "description": null, "cas-number": null, "unii": "E9N7QV53AK", "average-mass": 1642.66, "monoisotopic-mass": 1641.618999761, "groups": {"group": ["investigational"]}, "general-references": {"articles": null, "textbooks": null, "links": null, "attachments": null}, "synthesis-reference": null, "indication": null, "pharmacodynamics": null, "mechanism-of-action": null, "toxicity": null, "metabolism": null, "absorption": null, "half-life": null, "protein-binding": null, "route-of-elimination": null, "volume-of-distribution": null, "clearance": null, "salts": null, "synonyms": {"synonym": [{"@language": "english", "@coder": "", "$": "212Pb-dotamtate"}, {"@language": "english", "@coder": "", "$": "Alphamedix"}, {"@language": "english", "@coder": "", "$": "Dotamtate lead Pb-212"}, {"@language": "english", "@coder": "", "$": "Lead-212 dotamtate"}]}, "products": null, "international-brands": null, "mixtures": null, "packagers": null, "manufacturers": null, "prices": null, "categories": null, "affected-organisms": null, "dosages": null, "atc-codes": null, "ahfs-codes": null, "pdb-entries": null, "patents": null, "food-interactions": null, "drug-interactions": null, "calculated-properties": {"property": [{"kind": "logP", "value": "0.94", "source": "ALOGPS"}, {"kind": "logS", "value": "-4", "source": "ALOGPS"}, {"kind": "Water Solubility", "value": "1.52e-01 g/l", "source": "ALOGPS"}, {"kind": "logP", "value": "3.45", "source": "ChemAxon"}, {"kind": "IUPAC Name", "value": "lambda2-(212Pb)lead(2+) 2-[7-({[(1R)-1-{[(4R,7S,10S,13R,16S,19R)-10-(4-aminobutyl)-4-{[(1S,2R)-1-carboxy-2-hydroxypropyl]-C-hydroxycarbonimidoyl}-6,9,12,15,18-pentahydroxy-7-[(1R)-1-hydroxyethyl]-13-[(1H-indol-3-yl)methyl]-16-[(4-oxidophenyl)methyl]-1,2-dithia-5,8,11,14,17-pentaazacycloicosa-5,8,11,14,17-pentaen-19-yl]-C-hydroxycarbonimidoyl}-2-phenylethyl]-C-hydroxycarbonimidoyl}methyl)-4,10-bis[(C-hydroxycarbonimidoyl)methyl]-1,4,7,10-tetraazacyclododecan-1-yl]ethanimidate", "source": "ChemAxon"}, {"kind": "Traditional IUPAC Name", "value": "lambda2-(212Pb)lead(2+) 2-[7-({[(1R)-1-{[(4R,7S,10S,13R,16S,19R)-10-(4-aminobutyl)-4-{[(1S,2R)-1-carboxy-2-hydroxypropyl]-C-hydroxycarbonimidoyl}-6,9,12,15,18-pentahydroxy-7-[(1R)-1-hydroxyethyl]-13-(1H-indol-3-ylmethyl)-16-[(4-oxidophenyl)methyl]-1,2-dithia-5,8,11,14,17-pentaazacycloicosa-5,8,11,14,17-pentaen-19-yl]-C-hydroxycarbonimidoyl}-2-phenylethyl]-C-hydroxycarbonimidoyl}methyl)-4,10-bis(C-hydroxycarbonimidoylmethyl)-1,4,7,10-tetraazacyclododecan-1-yl]ethanimidate", "source": "ChemAxon"}, {"kind": "Molecular Weight", "value": "1642.66", "source": "ChemAxon"}, {"kind": "Monoisotopic Weight", "value": "1641.618999761", "source": "ChemAxon"}, {"kind": "SMILES", "value": "[212Pb++].[H][C@](C)(O)[C@]([H])(N=C(O)[C@]1([H])CSSC[C@]([H])(N=C(O)[C@@]([H])(CC2=CC=CC=C2)N=C(O)CN2CCN(CC(O)=N)CCN(CC([O-])=N)CCN(CC(O)=N)CC2)C(O)=N[C@@]([H])(CC2=CC=C([O-])C=C2)C(O)=N[C@]([H])(CC2=CNC3=CC=CC=C23)C(O)=N[C@@]([H])(CCCCN)C(O)=N[C@]([H])(C(O)=N1)[C@@]([H])(C)O)C(O)=O", "source": "ChemAxon"}, {"kind": "Molecular Formula", "value": "C65H91N17O16PbS2", "source": "ChemAxon"}, {"kind": "InChI", "value": "InChI=1S/C65H93N17O16S2.Pb/c1-38(83)56-64(96)76-51(63(95)78-57(39(2)84)65(97)98)37-100-99-36-50(75-59(91)47(28-40-10-4-3-5-11-40)71-55(89)35-82-26-24-80(33-53(68)87)22-20-79(32-52(67)86)21-23-81(25-27-82)34-54(69)88)62(94)73-48(29-41-15-17-43(85)18-16-41)60(92)74-49(30-42-31-70-45-13-7-6-12-44(42)45)61(93)72-46(58(90)77-56)14-8-9-19-66;/h3-7,10-13,15-18,31,38-39,46-51,56-57,70,83-85H,8-9,14,19-30,32-37,66H2,1-2H3,(H2,67,86)(H2,68,87)(H2,69,88)(H,71,89)(H,72,93)(H,73,94)(H,74,92)(H,75,91)(H,76,96)(H,77,90)(H,78,95)(H,97,98);/q;+2/p-2/t38-,39-,46+,47-,48+,49-,50+,51+,56+,57+;/m1./s1/i;1+5", "source": "ChemAxon"}, {"kind": "InChIKey", "value": "XWRQOPLCTVHUPG-DGSPUKEMSA-L", "source": "ChemAxon"}, {"kind": "Polar Surface Area (PSA)", "value": "551.38", "source": "ChemAxon"}, {"kind": "Refractivity", "value": "428.38", "source": "ChemAxon"}, {"kind": "Polarizability", "value": "147.53", "source": "ChemAxon"}, {"kind": "Rotatable Bond Count", "value": "26", "source": "ChemAxon"}, {"kind": "H Bond Acceptor Count", "value": "32", "source": "ChemAxon"}, {"kind": "H Bond Donor Count", "value": "18", "source": "ChemAxon"}, {"kind": "pKa (strongest acidic)", "value": "2.48", "source": "ChemAxon"}, {"kind": "Physiological Charge", "value": "0", "source": "ChemAxon"}, {"kind": "Number of Rings", "value": "6", "source": "ChemAxon"}, {"kind": "Bioavailability", "value": "0", "source": "ChemAxon"}, {"kind": "Rule of Five", "value": "0", "source": "ChemAxon"}, {"kind": "Ghose Filter", "value": "0", "source": "ChemAxon"}, {"kind": "MDDR-Like Rule", "value": "1", "source": "ChemAxon"}]}, "experimental-properties": null, "external-identifiers": null, "external-links": null, "pathways": null, "reactions": null, "snp-effects": null, "snp-adverse-drug-reactions": null, "targets": null, "enzymes": null, "carriers": null, "transporters": null}, {"@type": "biotech", "@created": "2022-12-05", "@updated": "2022-12-06", "drugbank-id": [{"@primary": true, "$": "DB17313"}], "name": "CAR BCMA-CS1", "description": "CAR BCMA-CS1 is a lentiviral transfected chimeric antigen receptor (CAR) T-cell therapy modified to target B-cell maturation antigen and CS1.", "cas-number": null, "unii": null, "groups": {"group": ["investigational"]}, "general-references": {"articles": null, "textbooks": null, "links": null, "attachments": null}, "synthesis-reference": null, "indication": null, "pharmacodynamics": null, "mechanism-of-action": null, "toxicity": null, "metabolism": null, "absorption": null, "half-life": null, "protein-binding": null, "route-of-elimination": null, "volume-of-distribution": null, "clearance": null, "salts": null, "synonyms": {"synonym": [{"@language": "english", "@coder": "", "$": "BCMA-CS1 cCAR T cell therapy"}]}, "products": null, "international-brands": null, "mixtures": null, "packagers": null, "manufacturers": null, "prices": null, "categories": null, "affected-organisms": null, "dosages": null, "atc-codes": null, "ahfs-codes": null, "pdb-entries": null, "patents": null, "food-interactions": null, "drug-interactions": null, "sequences": null, "experimental-properties": null, "external-identifiers": null, "external-links": null, "pathways": null, "reactions": null, "snp-effects": null, "snp-adverse-drug-reactions": null, "targets": null, "enzymes": null, "carriers": null, "transporters": null}, {"@type": "biotech", "@created": "2022-12-05", "@updated": "2022-12-06", "drugbank-id": [{"@primary": true, "$": "DB17314"}], "name": "KTH-222", "description": null, "cas-number": null, "unii": null, "groups": {"group": ["investigational"]}, "general-references": {"articles": null, "textbooks": null, "links": null, "attachments": null}, "synthesis-reference": null, "indication": null, "pharmacodynamics": null, "mechanism-of-action": null, "toxicity": null, "metabolism": null, "absorption": null, "half-life": null, "protein-binding": null, "route-of-elimination": null, "volume-of-distribution": null, "clearance": null, "classification": {"description": null, "direct-parent": "Peptides", "kingdom": "Organic Compounds", "superclass": "Organic Acids", "class": "Carboxylic Acids and Derivatives", "subclass": "Amino Acids, Peptides, and Analogues"}, "salts": null, "synonyms": {"synonym": [{"@language": "english", "@coder": "", "$": "Leu-Lys-Gly-Gln-Leu-Arg-Cys-Ile"}, {"@language": "english", "@coder": "", "$": "NH2-LKGQLRCI-C02H"}]}, "products": null, "international-brands": null, "mixtures": null, "packagers": null, "manufacturers": null, "prices": null, "categories": null, "affected-organisms": null, "dosages": null, "atc-codes": null, "ahfs-codes": null, "pdb-entries": null, "patents": null, "food-interactions": null, "drug-interactions": null, "sequences": null, "experimental-properties": null, "external-identifiers": null, "external-links": null, "pathways": null, "reactions": null, "snp-effects": null, "snp-adverse-drug-reactions": null, "targets": null, "enzymes": null, "carriers": null, "transporters": null}, {"@type": "biotech", "@created": "2022-12-05", "@updated": "2022-12-06", "drugbank-id": [{"@primary": true, "$": "DB17315"}], "name": "Leukocyte interleukin", "description": null, "cas-number": null, "unii": null, "groups": {"group": ["investigational"]}, "general-references": {"articles": null, "textbooks": null, "links": null, "attachments": null}, "synthesis-reference": null, "indication": null, "pharmacodynamics": null, "mechanism-of-action": null, "toxicity": null, "metabolism": null, "absorption": null, "half-life": null, "protein-binding": null, "route-of-elimination": null, "volume-of-distribution": null, "clearance": null, "salts": null, "synonyms": {"synonym": [{"@language": "english", "@coder": "", "$": "BC-IL"}]}, "products": null, "international-brands": {"international-brand": [{"name": "Multikine", "company": "CEL-SCI"}]}, "mixtures": null, "packagers": null, "manufacturers": null, "prices": null, "categories": null, "affected-organisms": null, "dosages": null, "atc-codes": null, "ahfs-codes": null, "pdb-entries": null, "patents": null, "food-interactions": null, "drug-interactions": null, "sequences": null, "experimental-properties": null, "external-identifiers": null, "external-links": null, "pathways": null, "reactions": null, "snp-effects": null, "snp-adverse-drug-reactions": null, "targets": null, "enzymes": null, "carriers": null, "transporters": null}, {"@type": "biotech", "@created": "2022-12-05", "@updated": "2022-12-06", "drugbank-id": [{"@primary": true, "$": "DB17316"}], "name": "Liposomal N-acetylglucosminyl-N-acetylmuramly-L-Ala-D-isoGln-L-Ala-gylceroldipalmitoyl", "description": null, "cas-number": null, "unii": null, "groups": {"group": ["investigational"]}, "general-references": {"articles": null, "textbooks": null, "links": null, "attachments": null}, "synthesis-reference": null, "indication": null, "pharmacodynamics": null, "mechanism-of-action": null, "toxicity": null, "metabolism": null, "absorption": null, "half-life": null, "protein-binding": null, "route-of-elimination": null, "volume-of-distribution": null, "clearance": null, "salts": null, "synonyms": {"synonym": [{"@language": "english", "@coder": "", "$": "Liposome-incorporated DTP-GDP"}]}, "products": null, "international-brands": {"international-brand": [{"name": "ImmTher", "company": "Endorex Corp"}]}, "mixtures": null, "packagers": null, "manufacturers": null, "prices": null, "categories": null, "affected-organisms": null, "dosages": null, "atc-codes": null, "ahfs-codes": null, "pdb-entries": null, "patents": null, "food-interactions": null, "drug-interactions": null, "sequences": null, "experimental-properties": null, "external-identifiers": null, "external-links": null, "pathways": null, "reactions": null, "snp-effects": null, "snp-adverse-drug-reactions": null, "targets": null, "enzymes": null, "carriers": null, "transporters": null}, {"@type": "biotech", "@created": "2022-12-05", "@updated": "2022-12-06", "drugbank-id": [{"@primary": true, "$": "DB17317"}], "name": "Belzupacap Sarotalocan", "description": null, "cas-number": "2390462-37-8", "unii": "DK0ZGA5Y2R", "groups": {"group": ["investigational"]}, "general-references": {"articles": null, "textbooks": null, "links": null, "attachments": null}, "synthesis-reference": null, "indication": null, "pharmacodynamics": null, "mechanism-of-action": null, "toxicity": null, "metabolism": null, "absorption": null, "half-life": null, "protein-binding": null, "route-of-elimination": null, "volume-of-distribution": null, "clearance": null, "classification": {"description": null, "direct-parent": "Peptides", "kingdom": "Organic Compounds", "superclass": "Organic Acids", "class": "Carboxylic Acids and Derivatives", "subclass": "Amino Acids, Peptides, and Analogues"}, "salts": null, "synonyms": {"synonym": [{"@language": "english", "@coder": "", "$": "Belzupacap serotalocan"}, {"@language": "english", "@coder": "", "$": "Human papillomavirus virus-like particles conjugated with ir700 dye au-011"}, {"@language": "english", "@coder": "", "$": "Light-activated au-011"}, {"@language": "english", "@coder": "", "$": "Viral nanoparticle conjugates au-011"}]}, "products": null, "international-brands": null, "mixtures": null, "packagers": null, "manufacturers": null, "prices": null, "categories": null, "affected-organisms": null, "dosages": null, "atc-codes": null, "ahfs-codes": null, "pdb-entries": null, "patents": null, "food-interactions": null, "drug-interactions": null, "sequences": null, "experimental-properties": null, "external-identifiers": null, "external-links": null, "pathways": null, "reactions": null, "snp-effects": null, "snp-adverse-drug-reactions": null, "targets": null, "enzymes": null, "carriers": null, "transporters": null}, {"@type": "biotech", "@created": "2022-12-05", "@updated": "2022-12-08", "drugbank-id": [{"@primary": true, "$": "DB17318"}], "name": "TPIV 200", "description": null, "cas-number": null, "unii": null, "groups": {"group": ["investigational"]}, "general-references": {"articles": null, "textbooks": null, "links": null, "attachments": null}, "synthesis-reference": null, "indication": null, "pharmacodynamics": null, "mechanism-of-action": null, "toxicity": null, "metabolism": null, "absorption": null, "half-life": null, "protein-binding": null, "route-of-elimination": null, "volume-of-distribution": null, "clearance": null, "salts": null, "synonyms": null, "products": null, "international-brands": null, "mixtures": null, "packagers": null, "manufacturers": null, "prices": null, "categories": null, "affected-organisms": null, "dosages": null, "atc-codes": null, "ahfs-codes": null, "pdb-entries": null, "patents": null, "food-interactions": null, "drug-interactions": null, "sequences": null, "experimental-properties": null, "external-identifiers": null, "external-links": null, "pathways": null, "reactions": null, "snp-effects": null, "snp-adverse-drug-reactions": null, "targets": null, "enzymes": null, "carriers": null, "transporters": null}, {"@type": "small molecule", "@created": "2022-12-05", "@updated": "2022-12-06", "drugbank-id": [{"@primary": true, "$": "DB17319"}], "name": "Aroplatin", "description": null, "cas-number": "114488-24-3", "unii": "J7M4Z2D183", "groups": {"group": ["investigational"]}, "general-references": {"articles": null, "textbooks": null, "links": null, "attachments": null}, "synthesis-reference": null, "indication": null, "pharmacodynamics": null, "mechanism-of-action": null, "toxicity": null, "metabolism": null, "absorption": null, "half-life": null, "protein-binding": null, "route-of-elimination": null, "volume-of-distribution": null, "clearance": null, "salts": null, "synonyms": {"synonym": [{"@language": "english", "@coder": "", "$": "cis-bis-neodecanoato-trans-R,R-1,2-diaminocyclohexane-Pt (II)"}, {"@language": "english", "@coder": "", "$": "L-NDDP"}]}, "products": null, "international-brands": null, "mixtures": null, "packagers": null, "manufacturers": null, "prices": null, "categories": {"category": [{"category": "Antineoplastic Agents", "mesh-id": "D000970"}, {"category": "Organometallic Compounds", "mesh-id": "D009942"}]}, "affected-organisms": null, "dosages": null, "atc-codes": null, "ahfs-codes": null, "pdb-entries": null, "patents": null, "food-interactions": null, "drug-interactions": null, "calculated-properties": null, "experimental-properties": null, "external-identifiers": null, "external-links": null, "pathways": null, "reactions": null, "snp-effects": null, "snp-adverse-drug-reactions": null, "targets": null, "enzymes": null, "carriers": null, "transporters": null}, {"@type": "biotech", "@created": "2022-12-05", "@updated": "2022-12-06", "drugbank-id": [{"@primary": true, "$": "DB17320"}], "name": "Prexigebersen", "description": null, "cas-number": "202484-91-1", "unii": "8W1O4Y961B", "groups": {"group": ["investigational"]}, "general-references": {"articles": null, "textbooks": null, "links": null, "attachments": null}, "synthesis-reference": null, "indication": null, "pharmacodynamics": null, "mechanism-of-action": null, "toxicity": null, "metabolism": null, "absorption": null, "half-life": null, "protein-binding": null, "route-of-elimination": null, "volume-of-distribution": null, "clearance": null, "salts": null, "synonyms": {"synonym": [{"@language": "english", "@coder": "", "$": "Dna, d(a-t-a-t-t-t-g-g-c-g-a-t-g-g-c-t-t-c)"}, {"@language": "english", "@coder": "", "$": "L-grb-2 antisense"}, {"@language": "english", "@coder": "", "$": "Liposomal grb2 antisense oligonucleotide"}, {"@language": "english", "@coder": "", "$": "Liposome-incorporated grb2 antisense oligodeoxynucleotide"}]}, "products": null, "international-brands": null, "mixtures": null, "packagers": null, "manufacturers": null, "prices": null, "categories": null, "affected-organisms": null, "dosages": null, "atc-codes": null, "ahfs-codes": null, "pdb-entries": null, "patents": null, "food-interactions": null, "drug-interactions": null, "sequences": null, "experimental-properties": null, "external-identifiers": null, "external-links": null, "pathways": null, "reactions": null, "snp-effects": null, "snp-adverse-drug-reactions": null, "targets": null, "enzymes": null, "carriers": null, "transporters": null}, {"@type": "biotech", "@created": "2022-12-05", "@updated": "2022-12-06", "drugbank-id": [{"@primary": true, "$": "DB17321"}], "name": "MEM136", "description": null, "cas-number": null, "unii": null, "groups": {"group": ["investigational"]}, "general-references": {"articles": null, "textbooks": null, "links": null, "attachments": null}, "synthesis-reference": null, "indication": null, "pharmacodynamics": null, "mechanism-of-action": null, "toxicity": null, "metabolism": null, "absorption": null, "half-life": null, "protein-binding": null, "route-of-elimination": null, "volume-of-distribution": null, "clearance": null, "classification": {"description": null, "direct-parent": "Peptides", "kingdom": "Organic Compounds", "superclass": "Organic Acids", "class": "Carboxylic Acids and Derivatives", "subclass": "Amino Acids, Peptides, and Analogues"}, "salts": null, "synonyms": null, "products": null, "international-brands": null, "mixtures": null, "packagers": null, "manufacturers": null, "prices": null, "categories": null, "affected-organisms": null, "dosages": null, "atc-codes": null, "ahfs-codes": null, "pdb-entries": null, "patents": null, "food-interactions": null, "drug-interactions": null, "sequences": null, "experimental-properties": null, "external-identifiers": null, "external-links": null, "pathways": null, "reactions": null, "snp-effects": null, "snp-adverse-drug-reactions": null, "targets": null, "enzymes": null, "carriers": null, "transporters": null}, {"@type": "biotech", "@created": "2022-12-05", "@updated": "2022-12-06", "drugbank-id": [{"@primary": true, "$": "DB17322"}], "name": "BI 836826", "description": null, "cas-number": null, "unii": "LB090AB8DB", "groups": {"group": ["investigational"]}, "general-references": {"articles": null, "textbooks": null, "links": null, "attachments": null}, "synthesis-reference": null, "indication": null, "pharmacodynamics": null, "mechanism-of-action": null, "toxicity": null, "metabolism": null, "absorption": null, "half-life": null, "protein-binding": null, "route-of-elimination": null, "volume-of-distribution": null, "clearance": null, "classification": {"description": null, "direct-parent": "Peptides", "kingdom": "Organic Compounds", "superclass": "Organic Acids", "class": "Carboxylic Acids and Derivatives", "subclass": "Amino Acids, Peptides, and Analogues"}, "salts": null, "synonyms": null, "products": null, "international-brands": null, "mixtures": null, "packagers": null, "manufacturers": null, "prices": null, "categories": {"category": [{"category": "Amino Acids, Peptides, and Proteins", "mesh-id": "D000602"}, {"category": "Antibodies", "mesh-id": "D000906"}, {"category": "Antibodies, Monoclonal", "mesh-id": "D000911"}, {"category": "Antineoplastic Agents", "mesh-id": "D000970"}, {"category": "Antineoplastic Agents, Immunological", "mesh-id": "D000074322"}, {"category": "Blood Proteins", "mesh-id": "D001798"}, {"category": "Globulins", "mesh-id": "D005916"}, {"category": "Immunoglobulins", "mesh-id": "D007136"}, {"category": "Immunoproteins", "mesh-id": "D007162"}, {"category": "Proteins", "mesh-id": "D011506"}, {"category": "Serum Globulins", "mesh-id": "D012712"}]}, "affected-organisms": null, "dosages": null, "atc-codes": null, "ahfs-codes": null, "pdb-entries": null, "patents": null, "food-interactions": null, "drug-interactions": null, "sequences": null, "experimental-properties": null, "external-identifiers": null, "external-links": null, "pathways": null, "reactions": null, "snp-effects": null, "snp-adverse-drug-reactions": null, "targets": null, "enzymes": null, "carriers": null, "transporters": null}, {"@type": "biotech", "@created": "2022-12-05", "@updated": "2022-12-06", "drugbank-id": [{"@primary": true, "$": "DB17323"}], "name": "CRS-207", "description": null, "cas-number": null, "unii": "JJX4JHS4PO", "groups": {"group": ["investigational"]}, "general-references": {"articles": null, "textbooks": null, "links": null, "attachments": null}, "synthesis-reference": null, "indication": null, "pharmacodynamics": null, "mechanism-of-action": null, "toxicity": null, "metabolism": null, "absorption": null, "half-life": null, "protein-binding": null, "route-of-elimination": null, "volume-of-distribution": null, "clearance": null, "salts": null, "synonyms": {"synonym": [{"@language": "english", "@coder": "", "$": "Listeria monocytogenes strain attenuated strain CRS-207"}, {"@language": "english", "@coder": "", "$": "Live-attenuated Listeria monocytogenes actA/inlB/human mesothelin (hMeso) Strain hMeso38"}]}, "products": null, "international-brands": null, "mixtures": null, "packagers": null, "manufacturers": null, "prices": null, "categories": null, "affected-organisms": null, "dosages": null, "atc-codes": null, "ahfs-codes": null, "pdb-entries": null, "patents": null, "food-interactions": null, "drug-interactions": null, "sequences": null, "experimental-properties": null, "external-identifiers": null, "external-links": null, "pathways": null, "reactions": null, "snp-effects": null, "snp-adverse-drug-reactions": null, "targets": null, "enzymes": null, "carriers": null, "transporters": null}, {"@type": "biotech", "@created": "2022-12-05", "@updated": "2022-12-06", "drugbank-id": [{"@primary": true, "$": "DB17324"}], "name": "Listeria monocytogenes", "description": null, "cas-number": null, "unii": "3O44K14A86", "groups": {"group": ["investigational"]}, "general-references": {"articles": null, "textbooks": null, "links": null, "attachments": null}, "synthesis-reference": null, "indication": null, "pharmacodynamics": null, "mechanism-of-action": null, "toxicity": null, "metabolism": null, "absorption": null, "half-life": null, "protein-binding": null, "route-of-elimination": null, "volume-of-distribution": null, "clearance": null, "salts": null, "synonyms": {"synonym": [{"@language": "english", "@coder": "", "$": "Bacterium monocytogenes hominis whole"}, {"@language": "english", "@coder": "", "$": "Bacterium monocytogenes whole"}, {"@language": "english", "@coder": "", "$": "Listeria monocytogenes whole"}]}, "products": null, "international-brands": null, "mixtures": null, "packagers": null, "manufacturers": null, "prices": null, "categories": null, "affected-organisms": null, "dosages": null, "atc-codes": null, "ahfs-codes": null, "pdb-entries": null, "patents": null, "food-interactions": null, "drug-interactions": null, "sequences": null, "experimental-properties": null, "external-identifiers": {"external-identifier": [{"resource": "Wikipedia", "identifier": "Listeria_monocytogenes"}, {"resource": "RxCUI", "identifier": "1491871"}]}, "external-links": null, "pathways": null, "reactions": null, "snp-effects": null, "snp-adverse-drug-reactions": null, "targets": null, "enzymes": null, "carriers": null, "transporters": null}, {"@type": "biotech", "@created": "2022-12-05", "@updated": "2022-12-06", "drugbank-id": [{"@primary": true, "$": "DB17325"}], "name": "ADXS 31164", "description": null, "cas-number": null, "unii": null, "groups": {"group": ["investigational"]}, "general-references": {"articles": null, "textbooks": null, "links": null, "attachments": null}, "synthesis-reference": null, "indication": null, "pharmacodynamics": null, "mechanism-of-action": null, "toxicity": null, "metabolism": null, "absorption": null, "half-life": null, "protein-binding": null, "route-of-elimination": null, "volume-of-distribution": null, "clearance": null, "salts": null, "synonyms": {"synonym": [{"@language": "english", "@coder": "", "$": "ADXS-HER2 construct vaccine"}]}, "products": null, "international-brands": null, "mixtures": null, "packagers": null, "manufacturers": null, "prices": null, "categories": null, "affected-organisms": null, "dosages": null, "atc-codes": null, "ahfs-codes": null, "pdb-entries": null, "patents": null, "food-interactions": null, "drug-interactions": null, "sequences": null, "experimental-properties": null, "external-identifiers": null, "external-links": null, "pathways": null, "reactions": null, "snp-effects": null, "snp-adverse-drug-reactions": null, "targets": null, "enzymes": null, "carriers": null, "transporters": null}, {"@type": "biotech", "@created": "2022-12-05", "@updated": "2022-12-06", "drugbank-id": [{"@primary": true, "$": "DB17326"}], "name": "Delolimogene mupadenorepvec", "description": null, "cas-number": "2061938-98-3", "unii": "3ZQ57V6YWZ", "groups": {"group": ["investigational"]}, "general-references": {"articles": null, "textbooks": null, "links": null, "attachments": null}, "synthesis-reference": null, "indication": null, "pharmacodynamics": null, "mechanism-of-action": null, "toxicity": null, "metabolism": null, "absorption": null, "half-life": null, "protein-binding": null, "route-of-elimination": null, "volume-of-distribution": null, "clearance": null, "salts": null, "synonyms": {"synonym": [{"@language": "english", "@coder": "", "$": "Dna (synthetic human adenovirus 5/35 vector load703 human cd137 ligand and trimerized membrane-bound isoleucine zipper-containing human cd40 ligand-specifying)"}]}, "products": null, "international-brands": null, "mixtures": null, "packagers": null, "manufacturers": null, "prices": null, "categories": null, "affected-organisms": null, "dosages": null, "atc-codes": null, "ahfs-codes": null, "pdb-entries": null, "patents": null, "food-interactions": null, "drug-interactions": null, "sequences": null, "experimental-properties": null, "external-identifiers": null, "external-links": null, "pathways": null, "reactions": null, "snp-effects": null, "snp-adverse-drug-reactions": null, "targets": null, "enzymes": null, "carriers": null, "transporters": null}, {"@type": "biotech", "@created": "2022-12-05", "@updated": "2022-12-06", "drugbank-id": [{"@primary": true, "$": "DB17327"}], "name": "Zalsenertant tetraxetan lutetium Lu-177", "description": null, "cas-number": null, "unii": "WH9EXQ390Z", "groups": {"group": ["investigational"]}, "general-references": {"articles": null, "textbooks": null, "links": null, "attachments": null}, "synthesis-reference": null, "indication": null, "pharmacodynamics": null, "mechanism-of-action": null, "toxicity": null, "metabolism": null, "absorption": null, "half-life": null, "protein-binding": null, "route-of-elimination": null, "volume-of-distribution": null, "clearance": null, "salts": null, "synonyms": null, "products": null, "international-brands": null, "mixtures": null, "packagers": null, "manufacturers": null, "prices": null, "categories": null, "affected-organisms": null, "dosages": null, "atc-codes": null, "ahfs-codes": null, "pdb-entries": null, "patents": null, "food-interactions": null, "drug-interactions": null, "sequences": null, "experimental-properties": null, "external-identifiers": null, "external-links": null, "pathways": null, "reactions": null, "snp-effects": null, "snp-adverse-drug-reactions": null, "targets": null, "enzymes": null, "carriers": null, "transporters": null}, {"@type": "biotech", "@created": "2022-12-05", "@updated": "2022-12-06", "drugbank-id": [{"@primary": true, "$": "DB17328"}], "name": "RAD 502", "description": null, "cas-number": null, "unii": null, "groups": {"group": ["investigational"]}, "general-references": {"articles": null, "textbooks": null, "links": null, "attachments": null}, "synthesis-reference": null, "indication": null, "pharmacodynamics": null, "mechanism-of-action": null, "toxicity": null, "metabolism": null, "absorption": null, "half-life": null, "protein-binding": null, "route-of-elimination": null, "volume-of-distribution": null, "clearance": null, "classification": {"description": null, "direct-parent": "Peptides", "kingdom": "Organic Compounds", "superclass": "Organic Acids", "class": "Carboxylic Acids and Derivatives", "subclass": "Amino Acids, Peptides, and Analogues"}, "salts": null, "synonyms": {"synonym": [{"@language": "english", "@coder": "", "$": "Lutetium-177 labeled humanized monoclonal antibody targeting leucine rich repeat containing 15 (LRRC15)"}, {"@language": "english", "@coder": "", "$": "Radiolabelled DUNP19"}]}, "products": null, "international-brands": null, "mixtures": null, "packagers": null, "manufacturers": null, "prices": null, "categories": null, "affected-organisms": null, "dosages": null, "atc-codes": null, "ahfs-codes": null, "pdb-entries": null, "patents": null, "food-interactions": null, "drug-interactions": null, "sequences": null, "experimental-properties": null, "external-identifiers": null, "external-links": null, "pathways": null, "reactions": null, "snp-effects": null, "snp-adverse-drug-reactions": null, "targets": null, "enzymes": null, "carriers": null, "transporters": null}, {"@type": "biotech", "@created": "2022-12-06", "@updated": "2022-12-06", "drugbank-id": [{"@primary": true, "$": "DB17329"}], "name": "Eltrapuldencel-T", "description": null, "cas-number": null, "unii": "M2LBQ7RN2X", "groups": {"group": ["investigational"]}, "general-references": {"articles": null, "textbooks": null, "links": null, "attachments": null}, "synthesis-reference": null, "indication": null, "pharmacodynamics": null, "mechanism-of-action": null, "toxicity": null, "metabolism": null, "absorption": null, "half-life": null, "protein-binding": null, "route-of-elimination": null, "volume-of-distribution": null, "clearance": null, "salts": null, "synonyms": {"synonym": [{"@language": "english", "@coder": "", "$": "Autologous dendritic cells loaded with antigen from self-renewing, proliferating autologous irradiated tumour cells, in a solution of granulocyte-macrophage colony stimulating factor (GM-CSF)"}]}, "products": null, "international-brands": null, "mixtures": null, "packagers": null, "manufacturers": null, "prices": null, "categories": null, "affected-organisms": null, "dosages": null, "atc-codes": null, "ahfs-codes": null, "pdb-entries": null, "patents": null, "food-interactions": null, "drug-interactions": null, "sequences": null, "experimental-properties": null, "external-identifiers": null, "external-links": null, "pathways": null, "reactions": null, "snp-effects": null, "snp-adverse-drug-reactions": null, "targets": null, "enzymes": null, "carriers": null, "transporters": null}, {"@type": "biotech", "@created": "2022-12-06", "@updated": "2022-12-06", "drugbank-id": [{"@primary": true, "$": "DB17330"}], "name": "Onamelatucel-L", "description": null, "cas-number": null, "unii": null, "groups": {"group": ["investigational"]}, "general-references": {"articles": null, "textbooks": null, "links": null, "attachments": null}, "synthesis-reference": null, "indication": null, "pharmacodynamics": null, "mechanism-of-action": null, "toxicity": null, "metabolism": null, "absorption": null, "half-life": null, "protein-binding": null, "route-of-elimination": null, "volume-of-distribution": null, "clearance": null, "salts": null, "synonyms": {"synonym": [{"@language": "english", "@coder": "", "$": "Canvaxin"}]}, "products": null, "international-brands": null, "mixtures": null, "packagers": null, "manufacturers": null, "prices": null, "categories": {"category": [{"category": "Biological Products", "mesh-id": "D001688"}, {"category": "Complex Mixtures", "mesh-id": "D045424"}, {"category": "Melanoma", "mesh-id": "D008545"}, {"category": "Vaccines", "mesh-id": "D014612"}]}, "affected-organisms": null, "dosages": null, "atc-codes": null, "ahfs-codes": null, "pdb-entries": null, "patents": null, "food-interactions": null, "drug-interactions": null, "sequences": null, "experimental-properties": null, "external-identifiers": null, "external-links": null, "pathways": null, "reactions": null, "snp-effects": null, "snp-adverse-drug-reactions": null, "targets": null, "enzymes": null, "carriers": null, "transporters": null}, {"@type": "biotech", "@created": "2022-12-06", "@updated": "2022-12-08", "drugbank-id": [{"@primary": true, "$": "DB17331"}], "name": "Imvotamab", "description": null, "cas-number": null, "unii": null, "groups": {"group": ["investigational"]}, "general-references": {"articles": null, "textbooks": null, "links": null, "attachments": null}, "synthesis-reference": null, "indication": null, "pharmacodynamics": null, "mechanism-of-action": null, "toxicity": null, "metabolism": null, "absorption": null, "half-life": null, "protein-binding": null, "route-of-elimination": null, "volume-of-distribution": null, "clearance": null, "classification": {"description": null, "direct-parent": "Peptides", "kingdom": "Organic Compounds", "superclass": "Organic Acids", "class": "Carboxylic Acids and Derivatives", "subclass": "Amino Acids, Peptides, and Analogues"}, "salts": null, "synonyms": null, "products": null, "international-brands": null, "mixtures": null, "packagers": null, "manufacturers": null, "prices": null, "categories": null, "affected-organisms": null, "dosages": null, "atc-codes": null, "ahfs-codes": null, "pdb-entries": null, "patents": null, "food-interactions": null, "drug-interactions": null, "sequences": null, "experimental-properties": null, "external-identifiers": null, "external-links": null, "pathways": null, "reactions": null, "snp-effects": null, "snp-adverse-drug-reactions": null, "targets": null, "enzymes": null, "carriers": null, "transporters": null}, {"@type": "biotech", "@created": "2022-12-06", "@updated": "2022-12-08", "drugbank-id": [{"@primary": true, "$": "DB17332"}], "name": "Inalimarev", "description": null, "cas-number": "685563-13-7", "unii": null, "groups": {"group": ["investigational"]}, "general-references": {"articles": null, "textbooks": null, "links": null, "attachments": null}, "synthesis-reference": null, "indication": null, "pharmacodynamics": null, "mechanism-of-action": null, "toxicity": null, "metabolism": null, "absorption": null, "half-life": null, "protein-binding": null, "route-of-elimination": null, "volume-of-distribution": null, "clearance": null, "salts": null, "synonyms": null, "products": null, "international-brands": null, "mixtures": null, "packagers": null, "manufacturers": null, "prices": null, "categories": null, "affected-organisms": null, "dosages": null, "atc-codes": null, "ahfs-codes": null, "pdb-entries": null, "patents": null, "food-interactions": null, "drug-interactions": null, "sequences": null, "experimental-properties": null, "external-identifiers": null, "external-links": null, "pathways": null, "reactions": null, "snp-effects": null, "snp-adverse-drug-reactions": null, "targets": null, "enzymes": null, "carriers": null, "transporters": null}, {"@type": "biotech", "@created": "2022-12-06", "@updated": "2022-12-08", "drugbank-id": [{"@primary": true, "$": "DB17333"}], "name": "Falimarev", "description": null, "cas-number": "685563-14-8", "unii": null, "groups": {"group": ["investigational"]}, "general-references": {"articles": null, "textbooks": null, "links": null, "attachments": null}, "synthesis-reference": null, "indication": null, "pharmacodynamics": null, "mechanism-of-action": null, "toxicity": null, "metabolism": null, "absorption": null, "half-life": null, "protein-binding": null, "route-of-elimination": null, "volume-of-distribution": null, "clearance": null, "salts": null, "synonyms": null, "products": null, "international-brands": null, "mixtures": null, "packagers": null, "manufacturers": null, "prices": null, "categories": null, "affected-organisms": null, "dosages": null, "atc-codes": null, "ahfs-codes": null, "pdb-entries": null, "patents": null, "food-interactions": null, "drug-interactions": null, "sequences": null, "experimental-properties": null, "external-identifiers": null, "external-links": null, "pathways": null, "reactions": null, "snp-effects": null, "snp-adverse-drug-reactions": null, "targets": null, "enzymes": null, "carriers": null, "transporters": null}, {"@type": "biotech", "@created": "2022-12-06", "@updated": "2022-12-08", "drugbank-id": [{"@primary": true, "$": "DB17334"}], "name": "Indium In-111 altumomab pentetate", "description": null, "cas-number": "156586-92-4", "unii": null, "groups": {"group": ["investigational"]}, "general-references": {"articles": null, "textbooks": null, "links": null, "attachments": null}, "synthesis-reference": null, "indication": null, "pharmacodynamics": null, "mechanism-of-action": null, "toxicity": null, "metabolism": null, "absorption": null, "half-life": null, "protein-binding": null, "route-of-elimination": null, "volume-of-distribution": null, "clearance": null, "classification": {"description": null, "direct-parent": "Peptides", "kingdom": "Organic Compounds", "superclass": "Organic Acids", "class": "Carboxylic Acids and Derivatives", "subclass": "Amino Acids, Peptides, and Analogues"}, "salts": null, "synonyms": null, "products": null, "international-brands": null, "mixtures": null, "packagers": null, "manufacturers": null, "prices": null, "categories": null, "affected-organisms": null, "dosages": null, "atc-codes": null, "ahfs-codes": null, "pdb-entries": null, "patents": null, "food-interactions": null, "drug-interactions": null, "sequences": null, "experimental-properties": null, "external-identifiers": null, "external-links": null, "pathways": null, "reactions": null, "snp-effects": null, "snp-adverse-drug-reactions": null, "targets": null, "enzymes": null, "carriers": null, "transporters": null}, {"@type": "small molecule", "@created": "2022-12-06", "@updated": "2022-12-08", "drugbank-id": [{"@primary": true, "$": "DB17335"}], "name": "Indium-111 Pentetreotide", "description": null, "cas-number": "139096-04-1", "unii": "M312JJ6Z32", "groups": {"group": ["investigational"]}, "general-references": {"articles": null, "textbooks": null, "links": null, "attachments": null}, "synthesis-reference": null, "indication": null, "pharmacodynamics": null, "mechanism-of-action": null, "toxicity": null, "metabolism": null, "absorption": null, "half-life": null, "protein-binding": null, "route-of-elimination": null, "volume-of-distribution": null, "clearance": null, "salts": null, "synonyms": null, "products": null, "international-brands": null, "mixtures": null, "packagers": null, "manufacturers": null, "prices": null, "categories": {"category": [{"category": "Radioactive Diagnostic Agent", "mesh-id": null}]}, "affected-organisms": null, "dosages": null, "atc-codes": null, "ahfs-codes": null, "pdb-entries": null, "patents": null, "food-interactions": null, "drug-interactions": null, "calculated-properties": null, "experimental-properties": null, "external-identifiers": null, "external-links": null, "pathways": null, "reactions": null, "snp-effects": null, "snp-adverse-drug-reactions": null, "targets": null, "enzymes": null, "carriers": null, "transporters": null}, {"@type": "biotech", "@created": "2022-12-06", "@updated": "2022-12-08", "drugbank-id": [{"@primary": true, "$": "DB17336"}], "name": "IMGN779", "description": null, "cas-number": null, "unii": "YE6R3UY9IV", "groups": {"group": ["investigational"]}, "general-references": {"articles": null, "textbooks": null, "links": null, "attachments": null}, "synthesis-reference": null, "indication": null, "pharmacodynamics": null, "mechanism-of-action": null, "toxicity": null, "metabolism": null, "absorption": null, "half-life": null, "protein-binding": null, "route-of-elimination": null, "volume-of-distribution": null, "clearance": null, "classification": {"description": null, "direct-parent": "Peptides", "kingdom": "Organic Compounds", "superclass": "Organic Acids", "class": "Carboxylic Acids and Derivatives", "subclass": "Amino Acids, Peptides, and Analogues"}, "salts": null, "synonyms": null, "products": null, "international-brands": null, "mixtures": null, "packagers": null, "manufacturers": null, "prices": null, "categories": null, "affected-organisms": null, "dosages": null, "atc-codes": null, "ahfs-codes": null, "pdb-entries": null, "patents": null, "food-interactions": null, "drug-interactions": null, "sequences": null, "experimental-properties": null, "external-identifiers": null, "external-links": null, "pathways": null, "reactions": null, "snp-effects": null, "snp-adverse-drug-reactions": null, "targets": null, "enzymes": null, "carriers": null, "transporters": null}, {"@type": "biotech", "@created": "2022-12-06", "@updated": "2022-12-08", "drugbank-id": [{"@primary": true, "$": "DB17337"}], "name": "IMGN632", "description": null, "cas-number": null, "unii": null, "groups": {"group": ["investigational"]}, "general-references": {"articles": null, "textbooks": null, "links": null, "attachments": null}, "synthesis-reference": null, "indication": null, "pharmacodynamics": null, "mechanism-of-action": null, "toxicity": null, "metabolism": null, "absorption": null, "half-life": null, "protein-binding": null, "route-of-elimination": null, "volume-of-distribution": null, "clearance": null, "classification": {"description": null, "direct-parent": "Peptides", "kingdom": "Organic Compounds", "superclass": "Organic Acids", "class": "Carboxylic Acids and Derivatives", "subclass": "Amino Acids, Peptides, and Analogues"}, "salts": null, "synonyms": null, "products": null, "international-brands": null, "mixtures": null, "packagers": null, "manufacturers": null, "prices": null, "categories": null, "affected-organisms": null, "dosages": null, "atc-codes": null, "ahfs-codes": null, "pdb-entries": null, "patents": null, "food-interactions": null, "drug-interactions": null, "sequences": null, "experimental-properties": null, "external-identifiers": null, "external-links": null, "pathways": null, "reactions": null, "snp-effects": null, "snp-adverse-drug-reactions": null, "targets": null, "enzymes": null, "carriers": null, "transporters": null}, {"@type": "biotech", "@created": "2022-12-06", "@updated": "2022-12-08", "drugbank-id": [{"@primary": true, "$": "DB17338"}], "name": "MGN-4893", "description": null, "cas-number": null, "unii": null, "groups": {"group": ["investigational"]}, "general-references": {"articles": null, "textbooks": null, "links": null, "attachments": null}, "synthesis-reference": null, "indication": null, "pharmacodynamics": null, "mechanism-of-action": null, "toxicity": null, "metabolism": null, "absorption": null, "half-life": null, "protein-binding": null, "route-of-elimination": null, "volume-of-distribution": null, "clearance": null, "salts": null, "synonyms": null, "products": null, "international-brands": null, "mixtures": null, "packagers": null, "manufacturers": null, "prices": null, "categories": null, "affected-organisms": null, "dosages": null, "atc-codes": null, "ahfs-codes": null, "pdb-entries": null, "patents": null, "food-interactions": null, "drug-interactions": null, "sequences": null, "experimental-properties": null, "external-identifiers": null, "external-links": null, "pathways": null, "reactions": null, "snp-effects": null, "snp-adverse-drug-reactions": null, "targets": null, "enzymes": null, "carriers": null, "transporters": null}, {"@type": "biotech", "@created": "2022-12-06", "@updated": "2022-12-08", "drugbank-id": [{"@primary": true, "$": "DB17339"}], "name": "Maveropepimut-S", "description": "Maveropepimut-S is a T cell activating immunotherapy.", "cas-number": null, "unii": null, "groups": {"group": ["investigational"]}, "general-references": {"articles": null, "textbooks": null, "links": null, "attachments": null}, "synthesis-reference": null, "indication": null, "pharmacodynamics": null, "mechanism-of-action": null, "toxicity": null, "metabolism": null, "absorption": null, "half-life": null, "protein-binding": null, "route-of-elimination": null, "volume-of-distribution": null, "clearance": null, "classification": {"description": null, "direct-parent": "Peptides", "kingdom": "Organic Compounds", "superclass": "Organic Acids", "class": "Carboxylic Acids and Derivatives", "subclass": "Amino Acids, Peptides, and Analogues"}, "salts": null, "synonyms": {"synonym": [{"@language": "english", "@coder": "", "$": "DPX-Survivac"}, {"@language": "english", "@coder": "", "$": "Maveropepimut S"}, {"@language": "english", "@coder": "", "$": "MVP-S"}]}, "products": null, "international-brands": null, "mixtures": null, "packagers": null, "manufacturers": null, "prices": null, "categories": null, "affected-organisms": null, "dosages": null, "atc-codes": null, "ahfs-codes": null, "pdb-entries": null, "patents": null, "food-interactions": null, "drug-interactions": null, "sequences": null, "experimental-properties": null, "external-identifiers": null, "external-links": null, "pathways": null, "reactions": null, "snp-effects": null, "snp-adverse-drug-reactions": null, "targets": null, "enzymes": null, "carriers": null, "transporters": null}, {"@type": "small molecule", "@created": "2022-12-06", "@updated": "2022-12-08", "drugbank-id": [{"@primary": true, "$": "DB17340"}], "name": "ENB-003", "description": "ENB-003 is a selective and potent inhibitor of the endothelin B receptor (ETBR) being investigated for cancer.", "cas-number": null, "unii": null, "groups": {"group": ["investigational"]}, "general-references": {"articles": null, "textbooks": null, "links": null, "attachments": null}, "synthesis-reference": null, "indication": null, "pharmacodynamics": null, "mechanism-of-action": null, "toxicity": null, "metabolism": null, "absorption": null, "half-life": null, "protein-binding": null, "route-of-elimination": null, "volume-of-distribution": null, "clearance": null, "salts": null, "synonyms": {"synonym": [{"@language": "english", "@coder": "", "$": "ENB003"}]}, "products": null, "international-brands": null, "mixtures": null, "packagers": null, "manufacturers": null, "prices": null, "categories": null, "affected-organisms": null, "dosages": null, "atc-codes": null, "ahfs-codes": null, "pdb-entries": null, "patents": null, "food-interactions": null, "drug-interactions": null, "calculated-properties": null, "experimental-properties": null, "external-identifiers": null, "external-links": null, "pathways": null, "reactions": null, "snp-effects": null, "snp-adverse-drug-reactions": null, "targets": null, "enzymes": null, "carriers": null, "transporters": null}, {"@type": "small molecule", "@created": "2022-12-06", "@updated": "2022-12-08", "drugbank-id": [{"@primary": true, "$": "DB17341"}], "name": "NC-6300", "description": "NC-6300, also known as K-912, is a novel [epirubicin] drug-conjugated polymeric micelle.", "cas-number": null, "unii": "RQU6X0IM9R", "groups": {"group": ["investigational"]}, "general-references": {"articles": null, "textbooks": null, "links": null, "attachments": null}, "synthesis-reference": null, "indication": null, "pharmacodynamics": null, "mechanism-of-action": null, "toxicity": null, "metabolism": null, "absorption": null, "half-life": null, "protein-binding": null, "route-of-elimination": null, "volume-of-distribution": null, "clearance": null, "salts": null, "synonyms": null, "products": null, "international-brands": null, "mixtures": null, "packagers": null, "manufacturers": null, "prices": null, "categories": {"category": [{"category": "Amino Acids, Peptides, and Proteins", "mesh-id": "D000602"}, {"category": "Aminoglycoside Antibacterials", "mesh-id": "D000617"}, {"category": "Anthracyclines", "mesh-id": "D018943"}, {"category": "Anti-Bacterial Agents", "mesh-id": "D000900"}, {"category": "Carbohydrates", "mesh-id": "D002241"}, {"category": "Glycosides", "mesh-id": "D006027"}, {"category": "Naphthacenes", "mesh-id": "D009279"}, {"category": "Polyethylene Glycols", "mesh-id": "D011092"}]}, "affected-organisms": null, "dosages": null, "atc-codes": null, "ahfs-codes": null, "pdb-entries": null, "patents": null, "food-interactions": null, "drug-interactions": null, "calculated-properties": null, "experimental-properties": null, "external-identifiers": null, "external-links": null, "pathways": null, "reactions": null, "snp-effects": null, "snp-adverse-drug-reactions": null, "targets": null, "enzymes": null, "carriers": null, "transporters": null}, {"@type": "small molecule", "@created": "2022-12-06", "@updated": "2022-12-13", "drugbank-id": [{"@primary": true, "$": "DB17342"}], "name": "Trimethyltetradecylammonium", "description": null, "cas-number": "10182-92-0", "unii": "Y3IR7RCT6J", "average-mass": 256.497, "monoisotopic-mass": 256.299876648, "groups": {"group": ["investigational"]}, "general-references": {"articles": null, "textbooks": null, "links": null, "attachments": null}, "synthesis-reference": null, "indication": null, "pharmacodynamics": null, "mechanism-of-action": null, "toxicity": null, "metabolism": null, "absorption": null, "half-life": null, "protein-binding": null, "route-of-elimination": null, "volume-of-distribution": null, "clearance": null, "salts": {"salt": [{"drugbank-id": [{"@primary": true, "$": "DBSALT003327"}], "name": "tetradonium bromide", "unii": "8483H94W1E", "cas-number": "1119-97-7", "inchikey": null}]}, "synonyms": {"synonym": [{"@language": "english", "@coder": "", "$": "1-tetradecanaminium, n,n,n-trimethyl-"}, {"@language": "english", "@coder": "", "$": "Ammonium, trimethyltetradecyl-"}, {"@language": "english", "@coder": "", "$": "Myristyltrimethylammonium"}, {"@language": "english", "@coder": "", "$": "Tetradecyltrimethylammonium"}, {"@language": "english", "@coder": "", "$": "Tetradonium"}, {"@language": "english", "@coder": "", "$": "Tetradonium cation"}, {"@language": "english", "@coder": "", "$": "Tetradonium ion"}]}, "products": null, "international-brands": null, "mixtures": null, "packagers": null, "manufacturers": null, "prices": null, "categories": {"category": [{"category": "Amines", "mesh-id": "D000588"}, {"category": "Compounds used in a research, industrial, or household setting", "mesh-id": "D020313"}, {"category": "Detergents", "mesh-id": "D003902"}, {"category": "Household Products", "mesh-id": "D006795"}, {"category": "Quaternary Ammonium Compounds", "mesh-id": "D000644"}, {"category": "Surface-Active Agents", "mesh-id": "D013501"}]}, "affected-organisms": null, "dosages": null, "atc-codes": null, "ahfs-codes": null, "pdb-entries": null, "patents": null, "food-interactions": null, "drug-interactions": null, "calculated-properties": {"property": [{"kind": "logP", "value": "2.17", "source": "ALOGPS"}, {"kind": "logS", "value": "-7.6", "source": "ALOGPS"}, {"kind": "Water Solubility", "value": "6.68e-06 g/l", "source": "ALOGPS"}, {"kind": "logP", "value": "1.8", "source": "ChemAxon"}, {"kind": "IUPAC Name", "value": "trimethyl(tetradecyl)azanium", "source": "ChemAxon"}, {"kind": "Traditional IUPAC Name", "value": "tetradonium", "source": "ChemAxon"}, {"kind": "Molecular Weight", "value": "256.497", "source": "ChemAxon"}, {"kind": "Monoisotopic Weight", "value": "256.299876648", "source": "ChemAxon"}, {"kind": "SMILES", "value": "CCCCCCCCCCCCCC[N+](C)(C)C", "source": "ChemAxon"}, {"kind": "Molecular Formula", "value": "C17H38N", "source": "ChemAxon"}, {"kind": "InChI", "value": "InChI=1S/C17H38N/c1-5-6-7-8-9-10-11-12-13-14-15-16-17-18(2,3)4/h5-17H2,1-4H3/q+1", "source": "ChemAxon"}, {"kind": "InChIKey", "value": "GLFDLEXFOHUASB-UHFFFAOYSA-N", "source": "ChemAxon"}, {"kind": "Polar Surface Area (PSA)", "value": "0", "source": "ChemAxon"}, {"kind": "Refractivity", "value": "95.79", "source": "ChemAxon"}, {"kind": "Polarizability", "value": "36.78", "source": "ChemAxon"}, {"kind": "Rotatable Bond Count", "value": "13", "source": "ChemAxon"}, {"kind": "H Bond Acceptor Count", "value": "0", "source": "ChemAxon"}, {"kind": "H Bond Donor Count", "value": "0", "source": "ChemAxon"}, {"kind": "Physiological Charge", "value": "1", "source": "ChemAxon"}, {"kind": "Number of Rings", "value": "0", "source": "ChemAxon"}, {"kind": "Bioavailability", "value": "1", "source": "ChemAxon"}, {"kind": "Rule of Five", "value": "1", "source": "ChemAxon"}, {"kind": "Ghose Filter", "value": "1", "source": "ChemAxon"}, {"kind": "MDDR-Like Rule", "value": "0", "source": "ChemAxon"}]}, "experimental-properties": null, "external-identifiers": {"external-identifier": [{"resource": "ChemSpider", "identifier": "13613"}, {"resource": "BindingDB", "identifier": "50060597"}, {"resource": "ChEMBL", "identifier": "CHEMBL1180003"}, {"resource": "ZINC", "identifier": "ZINC000006845519"}]}, "external-links": null, "pathways": null, "reactions": null, "snp-effects": null, "snp-adverse-drug-reactions": null, "targets": null, "enzymes": null, "carriers": null, "transporters": null}, {"@type": "biotech", "@created": "2022-12-06", "@updated": "2022-12-08", "drugbank-id": [{"@primary": true, "$": "DB17343"}], "name": "ICG-136", "description": null, "cas-number": null, "unii": null, "groups": {"group": ["investigational"]}, "general-references": {"articles": null, "textbooks": null, "links": null, "attachments": null}, "synthesis-reference": null, "indication": null, "pharmacodynamics": null, "mechanism-of-action": null, "toxicity": null, "metabolism": null, "absorption": null, "half-life": null, "protein-binding": null, "route-of-elimination": null, "volume-of-distribution": null, "clearance": null, "salts": null, "synonyms": null, "products": null, "international-brands": null, "mixtures": null, "packagers": null, "manufacturers": null, "prices": null, "categories": null, "affected-organisms": null, "dosages": null, "atc-codes": null, "ahfs-codes": null, "pdb-entries": null, "patents": null, "food-interactions": null, "drug-interactions": null, "sequences": null, "experimental-properties": null, "external-identifiers": null, "external-links": null, "pathways": null, "reactions": null, "snp-effects": null, "snp-adverse-drug-reactions": null, "targets": null, "enzymes": null, "carriers": null, "transporters": null}, {"@type": "biotech", "@created": "2022-12-06", "@updated": "2022-12-08", "drugbank-id": [{"@primary": true, "$": "DB17344"}], "name": "ICG-140", "description": null, "cas-number": null, "unii": null, "groups": {"group": ["investigational"]}, "general-references": {"articles": null, "textbooks": null, "links": null, "attachments": null}, "synthesis-reference": null, "indication": null, "pharmacodynamics": null, "mechanism-of-action": null, "toxicity": null, "metabolism": null, "absorption": null, "half-life": null, "protein-binding": null, "route-of-elimination": null, "volume-of-distribution": null, "clearance": null, "salts": null, "synonyms": null, "products": null, "international-brands": null, "mixtures": null, "packagers": null, "manufacturers": null, "prices": null, "categories": null, "affected-organisms": null, "dosages": null, "atc-codes": null, "ahfs-codes": null, "pdb-entries": null, "patents": null, "food-interactions": null, "drug-interactions": null, "sequences": null, "experimental-properties": null, "external-identifiers": null, "external-links": null, "pathways": null, "reactions": null, "snp-effects": null, "snp-adverse-drug-reactions": null, "targets": null, "enzymes": null, "carriers": null, "transporters": null}, {"@type": "biotech", "@created": "2022-12-06", "@updated": "2022-12-08", "drugbank-id": [{"@primary": true, "$": "DB17345"}], "name": "MDNA-55", "description": null, "cas-number": "1236019-35-4", "unii": "FRY3MOL2QU", "groups": {"group": ["investigational"]}, "general-references": {"articles": null, "textbooks": null, "links": null, "attachments": null}, "synthesis-reference": null, "indication": null, "pharmacodynamics": null, "mechanism-of-action": null, "toxicity": null, "metabolism": null, "absorption": null, "half-life": null, "protein-binding": null, "route-of-elimination": null, "volume-of-distribution": null, "clearance": null, "classification": {"description": null, "direct-parent": "Peptides", "kingdom": "Organic Compounds", "superclass": "Organic Acids", "class": "Carboxylic Acids and Derivatives", "subclass": "Amino Acids, Peptides, and Analogues"}, "salts": null, "synonyms": {"synonym": [{"@language": "english", "@coder": "", "$": "Il-4 pseudomonas toxin fusion protein (il-4(38-37)-pe38kdel)"}, {"@language": "english", "@coder": "", "$": "Il4-pseudomonas exotoxin fusion protein mdna55"}]}, "products": null, "international-brands": null, "mixtures": null, "packagers": null, "manufacturers": null, "prices": null, "categories": {"category": [{"category": "Amino Acids, Peptides, and Proteins", "mesh-id": "D000602"}, {"category": "Biological Factors", "mesh-id": "D001685"}, {"category": "Cytokines", "mesh-id": "D016207"}, {"category": "Intercellular Signaling Peptides and Proteins", "mesh-id": "D036341"}, {"category": "Interleukins", "mesh-id": "D007378"}, {"category": "Peptides", "mesh-id": "D010455"}, {"category": "Proteins", "mesh-id": "D011506"}, {"category": "Toxins, Biological", "mesh-id": "D014118"}]}, "affected-organisms": null, "dosages": null, "atc-codes": null, "ahfs-codes": null, "pdb-entries": null, "patents": null, "food-interactions": null, "drug-interactions": null, "sequences": null, "experimental-properties": null, "external-identifiers": null, "external-links": null, "pathways": null, "reactions": null, "snp-effects": null, "snp-adverse-drug-reactions": null, "targets": null, "enzymes": null, "carriers": null, "transporters": null}, {"@type": "biotech", "@created": "2022-12-06", "@updated": "2022-12-08", "drugbank-id": [{"@primary": true, "$": "DB17346"}], "name": "LSTA1", "description": null, "cas-number": "1392278-76-0", "unii": "Z8MXU5GH4Q", "groups": {"group": ["investigational"]}, "general-references": {"articles": null, "textbooks": null, "links": null, "attachments": null}, "synthesis-reference": null, "indication": null, "pharmacodynamics": null, "mechanism-of-action": null, "toxicity": null, "metabolism": null, "absorption": null, "half-life": null, "protein-binding": null, "route-of-elimination": null, "volume-of-distribution": null, "clearance": null, "classification": {"description": null, "direct-parent": "Peptides", "kingdom": "Organic Compounds", "superclass": "Organic Acids", "class": "Carboxylic Acids and Derivatives", "subclass": "Amino Acids, Peptides, and Analogues"}, "salts": null, "synonyms": {"synonym": [{"@language": "english", "@coder": "", "$": "Internalized-arginylglycylaspartic acid cyclic peptide"}, {"@language": "english", "@coder": "", "$": "L-cysteine, l-cysteinyl-l-arginylglycyl-l-.alpha.-aspartyl-l-lysylglycyl-l-prolyl-l-.alpha.-aspartyl-, cyclic (1->9)-disulfide"}]}, "products": null, "international-brands": null, "mixtures": null, "packagers": null, "manufacturers": null, "prices": null, "categories": null, "affected-organisms": null, "dosages": null, "atc-codes": null, "ahfs-codes": null, "pdb-entries": null, "patents": null, "food-interactions": null, "drug-interactions": null, "sequences": null, "experimental-properties": null, "external-identifiers": null, "external-links": null, "pathways": null, "reactions": null, "snp-effects": null, "snp-adverse-drug-reactions": null, "targets": null, "enzymes": null, "carriers": null, "transporters": null}, {"@type": "biotech", "@created": "2022-12-06", "@updated": "2022-12-08", "drugbank-id": [{"@primary": true, "$": "DB17347"}], "name": "MORAb-066", "description": "MORAb-066 is a humanized antibody directed against tissue factor (TF). It is being investigated in pancreatic cancer.", "cas-number": null, "unii": null, "groups": {"group": ["investigational"]}, "general-references": {"articles": null, "textbooks": null, "links": null, "attachments": null}, "synthesis-reference": null, "indication": null, "pharmacodynamics": null, "mechanism-of-action": null, "toxicity": null, "metabolism": null, "absorption": null, "half-life": null, "protein-binding": null, "route-of-elimination": null, "volume-of-distribution": null, "clearance": null, "classification": {"description": null, "direct-parent": "Peptides", "kingdom": "Organic Compounds", "superclass": "Organic Acids", "class": "Carboxylic Acids and Derivatives", "subclass": "Amino Acids, Peptides, and Analogues"}, "salts": null, "synonyms": null, "products": null, "international-brands": null, "mixtures": null, "packagers": null, "manufacturers": null, "prices": null, "categories": null, "affected-organisms": null, "dosages": null, "atc-codes": null, "ahfs-codes": null, "pdb-entries": null, "patents": null, "food-interactions": null, "drug-interactions": null, "sequences": null, "experimental-properties": null, "external-identifiers": null, "external-links": null, "pathways": null, "reactions": null, "snp-effects": null, "snp-adverse-drug-reactions": null, "targets": null, "enzymes": null, "carriers": null, "transporters": null}, {"@type": "biotech", "@created": "2022-12-06", "@updated": "2022-12-08", "drugbank-id": [{"@primary": true, "$": "DB17348"}], "name": "TNT-1", "description": null, "cas-number": null, "unii": null, "groups": {"group": ["investigational"]}, "general-references": {"articles": null, "textbooks": null, "links": null, "attachments": null}, "synthesis-reference": null, "indication": null, "pharmacodynamics": null, "mechanism-of-action": null, "toxicity": null, "metabolism": null, "absorption": null, "half-life": null, "protein-binding": null, "route-of-elimination": null, "volume-of-distribution": null, "clearance": null, "classification": {"description": null, "direct-parent": "Peptides", "kingdom": "Organic Compounds", "superclass": "Organic Acids", "class": "Carboxylic Acids and Derivatives", "subclass": "Amino Acids, Peptides, and Analogues"}, "salts": null, "synonyms": null, "products": null, "international-brands": null, "mixtures": null, "packagers": null, "manufacturers": null, "prices": null, "categories": null, "affected-organisms": null, "dosages": null, "atc-codes": null, "ahfs-codes": null, "pdb-entries": null, "patents": null, "food-interactions": null, "drug-interactions": null, "sequences": null, "experimental-properties": null, "external-identifiers": null, "external-links": null, "pathways": null, "reactions": null, "snp-effects": null, "snp-adverse-drug-reactions": null, "targets": null, "enzymes": null, "carriers": null, "transporters": null}, {"@type": "biotech", "@created": "2022-12-06", "@updated": "2022-12-08", "drugbank-id": [{"@primary": true, "$": "DB17349"}], "name": "Cibisatamab", "description": null, "cas-number": "2101242-53-7", "unii": "ZAM5J1ATF2", "groups": {"group": ["investigational"]}, "general-references": {"articles": null, "textbooks": null, "links": null, "attachments": null}, "synthesis-reference": null, "indication": null, "pharmacodynamics": null, "mechanism-of-action": null, "toxicity": null, "metabolism": null, "absorption": null, "half-life": null, "protein-binding": null, "route-of-elimination": null, "volume-of-distribution": null, "clearance": null, "classification": {"description": null, "direct-parent": "Peptides", "kingdom": "Organic Compounds", "superclass": "Organic Acids", "class": "Carboxylic Acids and Derivatives", "subclass": "Amino Acids, Peptides, and Analogues"}, "salts": null, "synonyms": {"synonym": [{"@language": "english", "@coder": "", "$": "Anti-cea/cd3 bispecific antibody ro6958688"}, {"@language": "english", "@coder": "", "$": "Cea cd3 tcb"}, {"@language": "english", "@coder": "", "$": "CEA TCB"}, {"@language": "english", "@coder": "", "$": "Humanized immunoglobulin g1 (igg1) t-cell bispecific (tcb) antibody targeting carcinoembryonic antigen (cea) and cd3 epsilon chain (cd3e) on t-cells"}]}, "products": null, "international-brands": null, "mixtures": null, "packagers": null, "manufacturers": null, "prices": null, "categories": {"category": [{"category": "Amino Acids, Peptides, and Proteins", "mesh-id": "D000602"}, {"category": "Antibodies", "mesh-id": "D000906"}, {"category": "Blood Proteins", "mesh-id": "D001798"}, {"category": "Globulins", "mesh-id": "D005916"}, {"category": "Immunoglobulins", "mesh-id": "D007136"}, {"category": "Immunoproteins", "mesh-id": "D007162"}, {"category": "Proteins", "mesh-id": "D011506"}, {"category": "Serum Globulins", "mesh-id": "D012712"}]}, "affected-organisms": null, "dosages": null, "atc-codes": null, "ahfs-codes": null, "pdb-entries": null, "patents": null, "food-interactions": null, "drug-interactions": null, "sequences": null, "experimental-properties": null, "external-identifiers": null, "external-links": null, "pathways": null, "reactions": null, "snp-effects": null, "snp-adverse-drug-reactions": null, "targets": null, "enzymes": null, "carriers": null, "transporters": null}, {"@type": "biotech", "@created": "2022-12-06", "@updated": "2022-12-08", "drugbank-id": [{"@primary": true, "$": "DB17350"}], "name": "AIC100", "description": null, "cas-number": null, "unii": null, "groups": {"group": ["investigational"]}, "general-references": {"articles": null, "textbooks": null, "links": null, "attachments": null}, "synthesis-reference": null, "indication": null, "pharmacodynamics": null, "mechanism-of-action": null, "toxicity": null, "metabolism": null, "absorption": null, "half-life": null, "protein-binding": null, "route-of-elimination": null, "volume-of-distribution": null, "clearance": null, "salts": null, "synonyms": null, "products": null, "international-brands": null, "mixtures": null, "packagers": null, "manufacturers": null, "prices": null, "categories": null, "affected-organisms": null, "dosages": null, "atc-codes": null, "ahfs-codes": null, "pdb-entries": null, "patents": null, "food-interactions": null, "drug-interactions": null, "sequences": null, "experimental-properties": null, "external-identifiers": null, "external-links": null, "pathways": null, "reactions": null, "snp-effects": null, "snp-adverse-drug-reactions": null, "targets": null, "enzymes": null, "carriers": null, "transporters": null}, {"@type": "small molecule", "@created": "2022-12-06", "@updated": "2022-12-08", "drugbank-id": [{"@primary": true, "$": "DB17351"}], "name": "Cvac", "description": null, "cas-number": null, "unii": null, "groups": {"group": ["approved", "investigational"]}, "general-references": {"articles": null, "textbooks": null, "links": null, "attachments": null}, "synthesis-reference": null, "indication": null, "pharmacodynamics": null, "mechanism-of-action": null, "toxicity": null, "metabolism": null, "absorption": null, "half-life": null, "protein-binding": null, "route-of-elimination": null, "volume-of-distribution": null, "clearance": null, "salts": null, "synonyms": null, "products": null, "international-brands": null, "mixtures": null, "packagers": null, "manufacturers": null, "prices": null, "categories": null, "affected-organisms": null, "dosages": null, "atc-codes": null, "ahfs-codes": null, "pdb-entries": null, "patents": null, "food-interactions": null, "drug-interactions": null, "calculated-properties": null, "experimental-properties": null, "external-identifiers": null, "external-links": null, "pathways": null, "reactions": null, "snp-effects": null, "snp-adverse-drug-reactions": null, "targets": null, "enzymes": null, "carriers": null, "transporters": null}, {"@type": "small molecule", "@created": "2022-12-07", "@updated": "2022-12-08", "drugbank-id": [{"@primary": true, "$": "DB17352"}], "name": "WT-1 A1", "description": null, "cas-number": "852243-39-1", "unii": "V4JB309K8X", "average-mass": 1115.31, "monoisotopic-mass": 1114.515753657, "groups": {"group": ["investigational"]}, "general-references": {"articles": null, "textbooks": null, "links": null, "attachments": null}, "synthesis-reference": null, "indication": null, "pharmacodynamics": null, "mechanism-of-action": null, "toxicity": null, "metabolism": null, "absorption": null, "half-life": null, "protein-binding": null, "route-of-elimination": null, "volume-of-distribution": null, "clearance": null, "salts": null, "synonyms": {"synonym": [{"@language": "english", "@coder": "", "$": "L-leucine, l-tyrosyl-l-methionyl-l-phenylalanyl-l-prolyl-l-asparaginyl-l-alanyl-l-prolyl-l-tyrosyl-"}, {"@language": "english", "@coder": "", "$": "Tyr-met-phe-pro-asn-ala-pro-tyr-leu"}]}, "products": null, "international-brands": null, "mixtures": null, "packagers": null, "manufacturers": null, "prices": null, "categories": null, "affected-organisms": null, "dosages": null, "atc-codes": null, "ahfs-codes": null, "pdb-entries": null, "patents": null, "food-interactions": null, "drug-interactions": null, "calculated-properties": {"property": [{"kind": "logP", "value": "-0.4", "source": "ALOGPS"}, {"kind": "logS", "value": "-5", "source": "ALOGPS"}, {"kind": "Water Solubility", "value": "1.26e-02 g/l", "source": "ALOGPS"}, {"kind": "logP", "value": "-1.8", "source": "ChemAxon"}, {"kind": "IUPAC Name", "value": "(2S)-2-[(2S)-2-{[(2S)-1-[(2S)-2-[(2S)-2-{[(2S)-1-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-(4-hydroxyphenyl)propanamido]-4-(methylsulfanyl)butanamido]-3-phenylpropanoyl]pyrrolidin-2-yl]formamido}-3-carbamoylpropanamido]propanoyl]pyrrolidin-2-yl]formamido}-3-(4-hydroxyphenyl)propanamido]-4-methylpentanoic acid", "source": "ChemAxon"}, {"kind": "Traditional IUPAC Name", "value": "(2S)-2-[(2S)-2-{[(2S)-1-[(2S)-2-[(2S)-2-{[(2S)-1-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-(4-hydroxyphenyl)propanamido]-4-(methylsulfanyl)butanamido]-3-phenylpropanoyl]pyrrolidin-2-yl]formamido}-3-carbamoylpropanamido]propanoyl]pyrrolidin-2-yl]formamido}-3-(4-hydroxyphenyl)propanamido]-4-methylpentanoic acid", "source": "ChemAxon"}, {"kind": "Molecular Weight", "value": "1115.31", "source": "ChemAxon"}, {"kind": "Monoisotopic Weight", "value": "1114.515753657", "source": "ChemAxon"}, {"kind": "SMILES", "value": "CSCC[C@H](NC(=O)[C@@H](N)CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(C)C)C(O)=O", "source": "ChemAxon"}, {"kind": "Molecular Formula", "value": "C55H74N10O13S", "source": "ChemAxon"}, {"kind": "InChI", "value": "InChI=1S/C55H74N10O13S/c1-31(2)26-43(55(77)78)63-50(72)40(28-35-16-20-37(67)21-17-35)60-51(73)44-12-8-23-64(44)53(75)32(3)58-49(71)41(30-46(57)68)61-52(74)45-13-9-24-65(45)54(76)42(29-33-10-6-5-7-11-33)62-48(70)39(22-25-79-4)59-47(69)38(56)27-34-14-18-36(66)19-15-34/h5-7,10-11,14-21,31-32,38-45,66-67H,8-9,12-13,22-30,56H2,1-4H3,(H2,57,68)(H,58,71)(H,59,69)(H,60,73)(H,61,74)(H,62,70)(H,63,72)(H,77,78)/t32-,38-,39-,40-,41-,42-,43-,44-,45-/m0/s1", "source": "ChemAxon"}, {"kind": "InChIKey", "value": "IBNSYSWDJJQKSY-PJYANRIDSA-N", "source": "ChemAxon"}, {"kind": "Polar Surface Area (PSA)", "value": "362.09", "source": "ChemAxon"}, {"kind": "Refractivity", "value": "290.69", "source": "ChemAxon"}, {"kind": "Polarizability", "value": "115.81", "source": "ChemAxon"}, {"kind": "Rotatable Bond Count", "value": "28", "source": "ChemAxon"}, {"kind": "H Bond Acceptor Count", "value": "14", "source": "ChemAxon"}, {"kind": "H Bond Donor Count", "value": "11", "source": "ChemAxon"}, {"kind": "pKa (strongest acidic)", "value": "3.47", "source": "ChemAxon"}, {"kind": "pKa (strongest basic)", "value": "7.72", "source": "ChemAxon"}, {"kind": "Physiological Charge", "value": "0", "source": "ChemAxon"}, {"kind": "Number of Rings", "value": "5", "source": "ChemAxon"}, {"kind": "Bioavailability", "value": "0", "source": "ChemAxon"}, {"kind": "Rule of Five", "value": "0", "source": "ChemAxon"}, {"kind": "Ghose Filter", "value": "0", "source": "ChemAxon"}, {"kind": "MDDR-Like Rule", "value": "1", "source": "ChemAxon"}]}, "experimental-properties": null, "external-identifiers": {"external-identifier": [{"resource": "ChemSpider", "identifier": "9655063"}]}, "external-links": null, "pathways": null, "reactions": null, "snp-effects": null, "snp-adverse-drug-reactions": null, "targets": null, "enzymes": null, "carriers": null, "transporters": null}, {"@type": "biotech", "@created": "2022-12-07", "@updated": "2022-12-08", "drugbank-id": [{"@primary": true, "$": "DB17353"}], "name": "WT-1 122 long", "description": null, "cas-number": "952720-86-4", "unii": "8ER98W0K2C", "groups": {"group": ["investigational"]}, "general-references": {"articles": null, "textbooks": null, "links": null, "attachments": null}, "synthesis-reference": null, "indication": null, "pharmacodynamics": null, "mechanism-of-action": null, "toxicity": null, "metabolism": null, "absorption": null, "half-life": null, "protein-binding": null, "route-of-elimination": null, "volume-of-distribution": null, "clearance": null, "classification": {"description": null, "direct-parent": "Peptides", "kingdom": "Organic Compounds", "superclass": "Organic Acids", "class": "Carboxylic Acids and Derivatives", "subclass": "Amino Acids, Peptides, and Analogues"}, "salts": null, "synonyms": {"synonym": [{"@language": "english", "@coder": "", "$": "Ser-gly-gln-ala-tyr-met-phe-pro-asn-ala-pro-tyr-leu-pro-ser-cys-leu-glu-ser"}]}, "products": null, "international-brands": null, "mixtures": null, "packagers": null, "manufacturers": null, "prices": null, "categories": null, "affected-organisms": null, "dosages": null, "atc-codes": null, "ahfs-codes": null, "pdb-entries": null, "patents": null, "food-interactions": null, "drug-interactions": null, "sequences": null, "experimental-properties": null, "external-identifiers": {"external-identifier": [{"resource": "ChemSpider", "identifier": "64854236"}]}, "external-links": null, "pathways": null, "reactions": null, "snp-effects": null, "snp-adverse-drug-reactions": null, "targets": null, "enzymes": null, "carriers": null, "transporters": null}, {"@type": "biotech", "@created": "2022-12-07", "@updated": "2022-12-08", "drugbank-id": [{"@primary": true, "$": "DB17354"}], "name": "WT-1 427 long", "description": null, "cas-number": "935395-33-8", "unii": "WYT2ZC05X2", "groups": {"group": ["investigational"]}, "general-references": {"articles": null, "textbooks": null, "links": null, "attachments": null}, "synthesis-reference": null, "indication": null, "pharmacodynamics": null, "mechanism-of-action": null, "toxicity": null, "metabolism": null, "absorption": null, "half-life": null, "protein-binding": null, "route-of-elimination": null, "volume-of-distribution": null, "clearance": null, "classification": {"description": null, "direct-parent": "Peptides", "kingdom": "Organic Compounds", "superclass": "Organic Acids", "class": "Carboxylic Acids and Derivatives", "subclass": "Amino Acids, Peptides, and Analogues"}, "salts": null, "synonyms": {"synonym": [{"@language": "english", "@coder": "", "$": "Arg-ser-asp-glu-leu-val-arg-his-his-asn-met-his-gln-arg-asn-met-thr-lys-leu"}]}, "products": null, "international-brands": null, "mixtures": null, "packagers": null, "manufacturers": null, "prices": null, "categories": null, "affected-organisms": null, "dosages": null, "atc-codes": null, "ahfs-codes": null, "pdb-entries": null, "patents": null, "food-interactions": null, "drug-interactions": null, "sequences": null, "experimental-properties": null, "external-identifiers": {"external-identifier": [{"resource": "ChemSpider", "identifier": "64854724"}]}, "external-links": null, "pathways": null, "reactions": null, "snp-effects": null, "snp-adverse-drug-reactions": null, "targets": null, "enzymes": null, "carriers": null, "transporters": null}, {"@type": "biotech", "@created": "2022-12-07", "@updated": "2022-12-08", "drugbank-id": [{"@primary": true, "$": "DB17355"}], "name": "WT-1 331 long", "description": null, "cas-number": "935395-34-9", "unii": "4OLC0A0F4I", "groups": {"group": ["investigational"]}, "general-references": {"articles": null, "textbooks": null, "links": null, "attachments": null}, "synthesis-reference": null, "indication": null, "pharmacodynamics": null, "mechanism-of-action": null, "toxicity": null, "metabolism": null, "absorption": null, "half-life": null, "protein-binding": null, "route-of-elimination": null, "volume-of-distribution": null, "clearance": null, "classification": {"description": null, "direct-parent": "Peptides", "kingdom": "Organic Compounds", "superclass": "Organic Acids", "class": "Carboxylic Acids and Derivatives", "subclass": "Amino Acids, Peptides, and Analogues"}, "salts": null, "synonyms": {"synonym": [{"@language": "english", "@coder": "", "$": "Pro-gly-cys-asn-lys-arg-tyr-phe-lys-leu-ser-his-leu-gln-met-his-ser-arg-lys-his-thr-gly"}]}, "products": null, "international-brands": null, "mixtures": null, "packagers": null, "manufacturers": null, "prices": null, "categories": null, "affected-organisms": null, "dosages": null, "atc-codes": null, "ahfs-codes": null, "pdb-entries": null, "patents": null, "food-interactions": null, "drug-interactions": null, "sequences": null, "experimental-properties": null, "external-identifiers": null, "external-links": null, "pathways": null, "reactions": null, "snp-effects": null, "snp-adverse-drug-reactions": null, "targets": null, "enzymes": null, "carriers": null, "transporters": null}, {"@type": "biotech", "@created": "2022-12-07", "@updated": "2022-12-08", "drugbank-id": [{"@primary": true, "$": "DB17356"}], "name": "OBI-999", "description": null, "cas-number": null, "unii": null, "groups": {"group": ["investigational"]}, "general-references": {"articles": null, "textbooks": null, "links": null, "attachments": null}, "synthesis-reference": null, "indication": null, "pharmacodynamics": null, "mechanism-of-action": null, "toxicity": null, "metabolism": null, "absorption": null, "half-life": null, "protein-binding": null, "route-of-elimination": null, "volume-of-distribution": null, "clearance": null, "classification": {"description": null, "direct-parent": "Peptides", "kingdom": "Organic Compounds", "superclass": "Organic Acids", "class": "Carboxylic Acids and Derivatives", "subclass": "Amino Acids, Peptides, and Analogues"}, "salts": null, "synonyms": null, "products": null, "international-brands": null, "mixtures": null, "packagers": null, "manufacturers": null, "prices": null, "categories": null, "affected-organisms": null, "dosages": null, "atc-codes": null, "ahfs-codes": null, "pdb-entries": null, "patents": null, "food-interactions": null, "drug-interactions": null, "sequences": null, "experimental-properties": null, "external-identifiers": null, "external-links": null, "pathways": null, "reactions": null, "snp-effects": null, "snp-adverse-drug-reactions": null, "targets": null, "enzymes": null, "carriers": null, "transporters": null}, {"@type": "biotech", "@created": "2022-12-07", "@updated": "2022-12-08", "drugbank-id": [{"@primary": true, "$": "DB17357"}], "name": "AMG 424", "description": "AMG 424 is a novel, humanized, anti-CD3/CD38 bispecific monoclonal antibody being investigated for multiple myeloma.", "cas-number": null, "unii": null, "groups": {"group": ["investigational"]}, "general-references": {"articles": null, "textbooks": null, "links": null, "attachments": null}, "synthesis-reference": null, "indication": null, "pharmacodynamics": null, "mechanism-of-action": null, "toxicity": null, "metabolism": null, "absorption": null, "half-life": null, "protein-binding": null, "route-of-elimination": null, "volume-of-distribution": null, "clearance": null, "classification": {"description": null, "direct-parent": "Peptides", "kingdom": "Organic Compounds", "superclass": "Organic Acids", "class": "Carboxylic Acids and Derivatives", "subclass": "Amino Acids, Peptides, and Analogues"}, "salts": null, "synonyms": {"synonym": [{"@language": "english", "@coder": "", "$": "AMG-424"}, {"@language": "english", "@coder": "", "$": "Humanized Bi-Specific Xmab(R) T Cell Recruiting Antibody Construct Directed Against Cd3 And Cd38"}]}, "products": null, "international-brands": null, "mixtures": null, "packagers": null, "manufacturers": null, "prices": null, "categories": null, "affected-organisms": null, "dosages": null, "atc-codes": null, "ahfs-codes": null, "pdb-entries": null, "patents": null, "food-interactions": null, "drug-interactions": null, "sequences": null, "experimental-properties": null, "external-identifiers": null, "external-links": null, "pathways": null, "reactions": null, "snp-effects": null, "snp-adverse-drug-reactions": null, "targets": null, "enzymes": null, "carriers": null, "transporters": null}, {"@type": "biotech", "@created": "2022-12-07", "@updated": "2022-12-08", "drugbank-id": [{"@primary": true, "$": "DB17358"}], "name": "STM-434", "description": null, "cas-number": "2055761-25-4", "unii": "7G4D2B5AC8", "groups": {"group": ["investigational"]}, "general-references": {"articles": null, "textbooks": null, "links": null, "attachments": null}, "synthesis-reference": null, "indication": null, "pharmacodynamics": null, "mechanism-of-action": null, "toxicity": null, "metabolism": null, "absorption": null, "half-life": null, "protein-binding": null, "route-of-elimination": null, "volume-of-distribution": null, "clearance": null, "classification": {"description": null, "direct-parent": "Peptides", "kingdom": "Organic Compounds", "superclass": "Organic Acids", "class": "Carboxylic Acids and Derivatives", "subclass": "Amino Acids, Peptides, and Analogues"}, "salts": null, "synonyms": {"synonym": [{"@language": "english", "@coder": "", "$": "Soluble receptor fused to part of an antibody that is designed to block the growth factor activin a"}]}, "products": null, "international-brands": null, "mixtures": null, "packagers": null, "manufacturers": null, "prices": null, "categories": null, "affected-organisms": null, "dosages": null, "atc-codes": null, "ahfs-codes": null, "pdb-entries": null, "patents": null, "food-interactions": null, "drug-interactions": null, "sequences": null, "experimental-properties": null, "external-identifiers": null, "external-links": null, "pathways": null, "reactions": null, "snp-effects": null, "snp-adverse-drug-reactions": null, "targets": null, "enzymes": null, "carriers": null, "transporters": null}, {"@type": "biotech", "@created": "2022-12-07", "@updated": "2022-12-08", "drugbank-id": [{"@primary": true, "$": "DB17359"}], "name": "Ocaratuzumab", "description": "Ocaratuzumab is a humanized monoclonal antibody directed against CD20. It is being investigated for cancers and autoimmune disorders.", "cas-number": "1169956-08-4", "unii": "NTY9893GD0", "groups": {"group": ["investigational"]}, "general-references": {"articles": null, "textbooks": null, "links": null, "attachments": null}, "synthesis-reference": null, "indication": null, "pharmacodynamics": null, "mechanism-of-action": null, "toxicity": null, "metabolism": null, "absorption": null, "half-life": null, "protein-binding": null, "route-of-elimination": null, "volume-of-distribution": null, "clearance": null, "classification": {"description": null, "direct-parent": "Peptides", "kingdom": "Organic Compounds", "superclass": "Organic Acids", "class": "Carboxylic Acids and Derivatives", "subclass": "Amino Acids, Peptides, and Analogues"}, "salts": null, "synonyms": {"synonym": [{"@language": "english", "@coder": "", "$": "Immunoglobulin G1, anti-(human B-lymphocyte antigen CD20 (B-lymphocyte surface antigen B1, Bp35, leukocyte surface antigen Leu-16, membrane-spanning 4-domains subfamily A member 1))"}]}, "products": null, "international-brands": null, "mixtures": null, "packagers": null, "manufacturers": null, "prices": null, "categories": {"category": [{"category": "Amino Acids, Peptides, and Proteins", "mesh-id": "D000602"}, {"category": "Antibodies", "mesh-id": "D000906"}, {"category": "Antibodies, Monoclonal", "mesh-id": "D000911"}, {"category": "Blood Proteins", "mesh-id": "D001798"}, {"category": "Globulins", "mesh-id": "D005916"}, {"category": "Immunoglobulins", "mesh-id": "D007136"}, {"category": "Immunoproteins", "mesh-id": "D007162"}, {"category": "Proteins", "mesh-id": "D011506"}, {"category": "Serum Globulins", "mesh-id": "D012712"}]}, "affected-organisms": null, "dosages": null, "atc-codes": null, "ahfs-codes": null, "pdb-entries": null, "patents": null, "food-interactions": null, "drug-interactions": null, "sequences": null, "experimental-properties": null, "external-identifiers": {"external-identifier": [{"resource": "Wikipedia", "identifier": "Ocaratuzumab"}]}, "external-links": null, "pathways": null, "reactions": null, "snp-effects": null, "snp-adverse-drug-reactions": null, "targets": null, "enzymes": null, "carriers": null, "transporters": null}, {"@type": "biotech", "@created": "2022-12-07", "@updated": "2022-12-08", "drugbank-id": [{"@primary": true, "$": "DB17360"}], "name": "TALL-104", "description": null, "cas-number": null, "unii": null, "groups": {"group": ["investigational"]}, "general-references": {"articles": null, "textbooks": null, "links": null, "attachments": null}, "synthesis-reference": null, "indication": null, "pharmacodynamics": null, "mechanism-of-action": null, "toxicity": null, "metabolism": null, "absorption": null, "half-life": null, "protein-binding": null, "route-of-elimination": null, "volume-of-distribution": null, "clearance": null, "salts": null, "synonyms": null, "products": null, "international-brands": null, "mixtures": null, "packagers": null, "manufacturers": null, "prices": null, "categories": null, "affected-organisms": null, "dosages": null, "atc-codes": null, "ahfs-codes": null, "pdb-entries": null, "patents": null, "food-interactions": null, "drug-interactions": null, "sequences": null, "experimental-properties": null, "external-identifiers": null, "external-links": null, "pathways": null, "reactions": null, "snp-effects": null, "snp-adverse-drug-reactions": null, "targets": null, "enzymes": null, "carriers": null, "transporters": null}, {"@type": "biotech", "@created": "2022-12-07", "@updated": "2022-12-08", "drugbank-id": [{"@primary": true, "$": "DB17361"}], "name": "Autologous DNP-conjugated tumour vaccine", "description": "Autologous DNP-conjugated tumour vaccine, or melanoma vaccine, is an investigational autologous cell vaccine technology for melanoma.[A254806]", "cas-number": null, "unii": null, "groups": {"group": ["investigational"]}, "general-references": {"articles": {"article": [{"ref-id": "A254806", "pubmed-id": "12534322", "citation": "Authors unspecified: Melanoma Vaccine--AVAX Technologies: DNP-VACC, M-Vax. BioDrugs. 2003;17(1):69-72. doi: 10.2165/00063030-200317010-00007."}]}, "textbooks": null, "links": null, "attachments": null}, "synthesis-reference": null, "indication": null, "pharmacodynamics": null, "mechanism-of-action": null, "toxicity": null, "metabolism": null, "absorption": null, "half-life": null, "protein-binding": null, "route-of-elimination": null, "volume-of-distribution": null, "clearance": null, "salts": null, "synonyms": {"synonym": [{"@language": "english", "@coder": "", "$": "DNP-VACC"}, {"@language": "english", "@coder": "", "$": "M Vax"}, {"@language": "english", "@coder": "", "$": "M-Vax"}, {"@language": "english", "@coder": "", "$": "MVax"}]}, "products": null, "international-brands": null, "mixtures": null, "packagers": null, "manufacturers": null, "prices": null, "categories": null, "affected-organisms": null, "dosages": null, "atc-codes": null, "ahfs-codes": null, "pdb-entries": null, "patents": null, "food-interactions": null, "drug-interactions": null, "sequences": null, "experimental-properties": null, "external-identifiers": null, "external-links": null, "pathways": null, "reactions": null, "snp-effects": null, "snp-adverse-drug-reactions": null, "targets": null, "enzymes": null, "carriers": null, "transporters": null}, {"@type": "biotech", "@created": "2022-12-07", "@updated": "2022-12-08", "drugbank-id": [{"@primary": true, "$": "DB17362"}], "name": "Obecabtagene autoleucel", "description": "Obecabtagene autoleucel is an investigational autologous CD19 CAR T cell therapy.", "cas-number": null, "unii": "760HJB0YRD", "groups": {"group": ["investigational"]}, "general-references": {"articles": null, "textbooks": null, "links": null, "attachments": null}, "synthesis-reference": null, "indication": null, "pharmacodynamics": null, "mechanism-of-action": null, "toxicity": null, "metabolism": null, "absorption": null, "half-life": null, "protein-binding": null, "route-of-elimination": null, "volume-of-distribution": null, "clearance": null, "salts": null, "synonyms": {"synonym": [{"@language": "english", "@coder": "", "$": "Obe-cel"}]}, "products": null, "international-brands": null, "mixtures": null, "packagers": null, "manufacturers": null, "prices": null, "categories": null, "affected-organisms": null, "dosages": null, "atc-codes": null, "ahfs-codes": null, "pdb-entries": null, "patents": null, "food-interactions": null, "drug-interactions": null, "sequences": null, "experimental-properties": null, "external-identifiers": null, "external-links": null, "pathways": null, "reactions": null, "snp-effects": null, "snp-adverse-drug-reactions": null, "targets": null, "enzymes": null, "carriers": null, "transporters": null}, {"@type": "biotech", "@created": "2022-12-07", "@updated": "2022-12-08", "drugbank-id": [{"@primary": true, "$": "DB17363"}], "name": "AMG-119", "description": "AMG-119 are CAR-T cells targeting delta-like ligand 3 (DLL3).[A254811]", "cas-number": null, "unii": null, "groups": {"group": ["investigational"]}, "general-references": {"articles": {"article": [{"ref-id": "A254811", "pubmed-id": "33737119", "citation": "Remon J, Aldea M, Besse B, Planchard D, Reck M, Giaccone G, Soria JC: Small cell lung cancer: a slightly less orphan disease after immunotherapy. Ann Oncol. 2021 Jun;32(6):698-709. doi: 10.1016/j.annonc.2021.02.025. Epub 2021 Mar 15."}]}, "textbooks": null, "links": null, "attachments": null}, "synthesis-reference": null, "indication": null, "pharmacodynamics": null, "mechanism-of-action": null, "toxicity": null, "metabolism": null, "absorption": null, "half-life": null, "protein-binding": null, "route-of-elimination": null, "volume-of-distribution": null, "clearance": null, "salts": null, "synonyms": null, "products": null, "international-brands": null, "mixtures": null, "packagers": null, "manufacturers": null, "prices": null, "categories": null, "affected-organisms": null, "dosages": null, "atc-codes": null, "ahfs-codes": null, "pdb-entries": null, "patents": null, "food-interactions": null, "drug-interactions": null, "sequences": null, "experimental-properties": null, "external-identifiers": null, "external-links": null, "pathways": null, "reactions": null, "snp-effects": null, "snp-adverse-drug-reactions": null, "targets": null, "enzymes": null, "carriers": null, "transporters": null}, {"@type": "biotech", "@created": "2022-12-07", "@updated": "2022-12-08", "drugbank-id": [{"@primary": true, "$": "DB17364"}], "name": "AUTO3", "description": "AUTO3 is bicistronic chimeric antigen receptor T-cell therapy investigated for acute lymphoblastic leukemia (ALL). It is an investigational chimeric antigen receptor (CAR) T cell treatment targeting CD19 and CD22.", "cas-number": null, "unii": null, "groups": {"group": ["investigational"]}, "general-references": {"articles": null, "textbooks": null, "links": null, "attachments": null}, "synthesis-reference": null, "indication": null, "pharmacodynamics": null, "mechanism-of-action": null, "toxicity": null, "metabolism": null, "absorption": null, "half-life": null, "protein-binding": null, "route-of-elimination": null, "volume-of-distribution": null, "clearance": null, "salts": null, "synonyms": {"synonym": [{"@language": "english", "@coder": "", "$": "AUTO 3"}]}, "products": null, "international-brands": null, "mixtures": null, "packagers": null, "manufacturers": null, "prices": null, "categories": null, "affected-organisms": null, "dosages": null, "atc-codes": null, "ahfs-codes": null, "pdb-entries": null, "patents": null, "food-interactions": null, "drug-interactions": null, "sequences": null, "experimental-properties": null, "external-identifiers": null, "external-links": null, "pathways": null, "reactions": null, "snp-effects": null, "snp-adverse-drug-reactions": null, "targets": null, "enzymes": null, "carriers": null, "transporters": null}, {"@type": "biotech", "@created": "2022-12-07", "@updated": "2022-12-08", "drugbank-id": [{"@primary": true, "$": "DB17365"}], "name": "SynKIR-110", "description": "SynKIR-110 are autologous T cells genetically engineered to express an anti-mesothelin killer immunoglobulin-like receptor-chimeric antigen receptor (KIR-CAR).", "cas-number": null, "unii": null, "groups": {"group": ["investigational"]}, "general-references": {"articles": null, "textbooks": null, "links": null, "attachments": null}, "synthesis-reference": null, "indication": null, "pharmacodynamics": null, "mechanism-of-action": null, "toxicity": null, "metabolism": null, "absorption": null, "half-life": null, "protein-binding": null, "route-of-elimination": null, "volume-of-distribution": null, "clearance": null, "salts": null, "synonyms": {"synonym": [{"@language": "english", "@coder": "", "$": "SynKIR-meso"}, {"@language": "english", "@coder": "", "$": "SynKIR-meso CAR-T cells"}]}, "products": null, "international-brands": null, "mixtures": null, "packagers": null, "manufacturers": null, "prices": null, "categories": null, "affected-organisms": null, "dosages": null, "atc-codes": null, "ahfs-codes": null, "pdb-entries": null, "patents": null, "food-interactions": null, "drug-interactions": null, "sequences": null, "experimental-properties": null, "external-identifiers": null, "external-links": null, "pathways": null, "reactions": null, "snp-effects": null, "snp-adverse-drug-reactions": null, "targets": null, "enzymes": null, "carriers": null, "transporters": null}, {"@type": "biotech", "@created": "2022-12-07", "@updated": "2022-12-08", "drugbank-id": [{"@primary": true, "$": "DB17366"}], "name": "MB-102 CD123 CAR", "description": "MB-102 are autologous T cells genetically modified to express CD123-specific, hinge-optimized CD28-costimulatory chimeric receptor and a truncated human epidermal growth factor receptor.", "cas-number": null, "unii": null, "groups": {"group": ["investigational"]}, "general-references": {"articles": null, "textbooks": null, "links": null, "attachments": null}, "synthesis-reference": null, "indication": null, "pharmacodynamics": null, "mechanism-of-action": null, "toxicity": null, "metabolism": null, "absorption": null, "half-life": null, "protein-binding": null, "route-of-elimination": null, "volume-of-distribution": null, "clearance": null, "salts": null, "synonyms": null, "products": null, "international-brands": null, "mixtures": null, "packagers": null, "manufacturers": null, "prices": null, "categories": null, "affected-organisms": null, "dosages": null, "atc-codes": null, "ahfs-codes": null, "pdb-entries": null, "patents": null, "food-interactions": null, "drug-interactions": null, "sequences": null, "experimental-properties": null, "external-identifiers": null, "external-links": null, "pathways": null, "reactions": null, "snp-effects": null, "snp-adverse-drug-reactions": null, "targets": null, "enzymes": null, "carriers": null, "transporters": null}, {"@type": "biotech", "@created": "2022-12-07", "@updated": "2022-12-08", "drugbank-id": [{"@primary": true, "$": "DB17367"}], "name": "Gavocabtagene autoleucel", "description": "Gavocabtagene autoleucel is a novel cell therapy consisting of autologous genetically engineered T cells expressing a single-domain antibody that recognizes human Mesothelin, fused to the CD3-epsilon subunit which, upon expression, is incorporated into the endogenous T cell receptor (TCR) complex.[L44271]", "cas-number": null, "unii": "NP6CFH3G8H", "groups": {"group": ["investigational"]}, "general-references": {"articles": null, "textbooks": null, "links": {"link": [{"ref-id": "L44271", "title": "Clinicaltrials.gov: Phase 1/2 Trial of Gavo-cel (TC-210) in Patients With Advanced Mesothelin-Expressing Cancer", "url": "https://clinicaltrials.gov/ct2/show/NCT03907852"}]}, "attachments": null}, "synthesis-reference": null, "indication": null, "pharmacodynamics": null, "mechanism-of-action": null, "toxicity": null, "metabolism": null, "absorption": null, "half-life": null, "protein-binding": null, "route-of-elimination": null, "volume-of-distribution": null, "clearance": null, "salts": null, "synonyms": {"synonym": [{"@language": "english", "@coder": "", "$": "Gavo-cel"}]}, "products": null, "international-brands": null, "mixtures": null, "packagers": null, "manufacturers": null, "prices": null, "categories": null, "affected-organisms": null, "dosages": null, "atc-codes": null, "ahfs-codes": null, "pdb-entries": null, "patents": null, "food-interactions": null, "drug-interactions": null, "sequences": null, "experimental-properties": null, "external-identifiers": null, "external-links": null, "pathways": null, "reactions": null, "snp-effects": null, "snp-adverse-drug-reactions": null, "targets": null, "enzymes": null, "carriers": null, "transporters": null}, {"@type": "biotech", "@created": "2022-12-07", "@updated": "2022-12-08", "drugbank-id": [{"@primary": true, "$": "DB17368"}], "name": "LioCyx-M004", "description": "LioCyx-M004 are autologous T cells transduced with a retroviral vector encoding a hepatitis B virus antigen-specific T cell receptor.", "cas-number": null, "unii": null, "groups": {"group": ["investigational"]}, "general-references": {"articles": null, "textbooks": null, "links": null, "attachments": null}, "synthesis-reference": null, "indication": null, "pharmacodynamics": null, "mechanism-of-action": null, "toxicity": null, "metabolism": null, "absorption": null, "half-life": null, "protein-binding": null, "route-of-elimination": null, "volume-of-distribution": null, "clearance": null, "salts": null, "synonyms": {"synonym": [{"@language": "english", "@coder": "", "$": "mRNA HBV/TCR T-cells"}]}, "products": null, "international-brands": null, "mixtures": null, "packagers": null, "manufacturers": null, "prices": null, "categories": null, "affected-organisms": null, "dosages": null, "atc-codes": null, "ahfs-codes": null, "pdb-entries": null, "patents": null, "food-interactions": null, "drug-interactions": null, "sequences": null, "experimental-properties": null, "external-identifiers": null, "external-links": null, "pathways": null, "reactions": null, "snp-effects": null, "snp-adverse-drug-reactions": null, "targets": null, "enzymes": null, "carriers": null, "transporters": null}, {"@type": "biotech", "@created": "2022-12-07", "@updated": "2022-12-08", "drugbank-id": [{"@primary": true, "$": "DB17369"}], "name": "RR001", "description": "RR001 is an investigational gene therapy consisting of autologous human adipose perivascular stromal cells genetically modified to secrete soluble tumour necrosis factor-related apoptosis-inducing ligand (AD-PC sTRAIL).[L44276]", "cas-number": null, "unii": null, "groups": {"group": ["investigational"]}, "general-references": {"articles": null, "textbooks": null, "links": {"link": [{"ref-id": "L44276", "title": "Rigenerand SRL: Anti-Cancer Gene Therapies", "url": "https://rigenerand-biotech.com/drug-development/"}]}, "attachments": null}, "synthesis-reference": null, "indication": null, "pharmacodynamics": null, "mechanism-of-action": null, "toxicity": null, "metabolism": null, "absorption": null, "half-life": null, "protein-binding": null, "route-of-elimination": null, "volume-of-distribution": null, "clearance": null, "salts": null, "synonyms": null, "products": null, "international-brands": null, "mixtures": null, "packagers": null, "manufacturers": null, "prices": null, "categories": null, "affected-organisms": null, "dosages": null, "atc-codes": null, "ahfs-codes": null, "pdb-entries": null, "patents": null, "food-interactions": null, "drug-interactions": null, "sequences": null, "experimental-properties": null, "external-identifiers": null, "external-links": null, "pathways": null, "reactions": null, "snp-effects": null, "snp-adverse-drug-reactions": null, "targets": null, "enzymes": null, "carriers": null, "transporters": null}, {"@type": "biotech", "@created": "2022-12-07", "@updated": "2022-12-08", "drugbank-id": [{"@primary": true, "$": "DB17370"}], "name": "TBX-3400", "description": "TBX-3400 is an investigational cell-based immunotherapy consisting of autologous peripheral blood mononuclear cells (PBMCs) treated ex vivo with TBX-4000, which is a recombinant TAT-MYC fusion protein.[L44281,L44286]", "cas-number": null, "unii": null, "groups": {"group": ["investigational"]}, "general-references": {"articles": null, "textbooks": null, "links": {"link": [{"ref-id": "L44281", "title": "Cancer.gov: autologous TBX-4000-treated peripheral blood mononuclear cells TBX-3400", "url": "https://www.cancer.gov/publications/dictionaries/cancer-drug/def/autologous-tbx-4000-treated-peripheral-blood-mononuclear-cells-tbx-3400"}, {"ref-id": "L44286", "title": "BioSpace: Taiga Treats First Cancer Patient in TBX-3400-003 Clinical Trial in Israel", "url": "https://www.biospace.com/article/releases/taiga-treats-first-cancer-patient-in-tbx-3400-003-clinical-trial-in-israel/"}]}, "attachments": null}, "synthesis-reference": null, "indication": null, "pharmacodynamics": null, "mechanism-of-action": null, "toxicity": null, "metabolism": null, "absorption": null, "half-life": null, "protein-binding": null, "route-of-elimination": null, "volume-of-distribution": null, "clearance": null, "salts": null, "synonyms": {"synonym": [{"@language": "english", "@coder": "", "$": "TBX 3400"}]}, "products": null, "international-brands": null, "mixtures": null, "packagers": null, "manufacturers": null, "prices": null, "categories": null, "affected-organisms": null, "dosages": null, "atc-codes": null, "ahfs-codes": null, "pdb-entries": null, "patents": null, "food-interactions": null, "drug-interactions": null, "sequences": null, "experimental-properties": null, "external-identifiers": null, "external-links": null, "pathways": null, "reactions": null, "snp-effects": null, "snp-adverse-drug-reactions": null, "targets": null, "enzymes": null, "carriers": null, "transporters": null}, {"@type": "biotech", "@created": "2022-12-07", "@updated": "2022-12-08", "drugbank-id": [{"@primary": true, "$": "DB17371"}], "name": "P-BCMA-101", "description": "P-BCMA-101 is an autologous CAR-T therapy developed using Poseida\u2019s piggyBac platform technology.", "cas-number": null, "unii": null, "groups": {"group": ["investigational"]}, "general-references": {"articles": null, "textbooks": null, "links": null, "attachments": null}, "synthesis-reference": null, "indication": null, "pharmacodynamics": null, "mechanism-of-action": null, "toxicity": null, "metabolism": null, "absorption": null, "half-life": null, "protein-binding": null, "route-of-elimination": null, "volume-of-distribution": null, "clearance": null, "salts": null, "synonyms": null, "products": null, "international-brands": null, "mixtures": null, "packagers": null, "manufacturers": null, "prices": null, "categories": null, "affected-organisms": null, "dosages": null, "atc-codes": null, "ahfs-codes": null, "pdb-entries": null, "patents": null, "food-interactions": null, "drug-interactions": null, "sequences": null, "experimental-properties": null, "external-identifiers": null, "external-links": null, "pathways": null, "reactions": null, "snp-effects": null, "snp-adverse-drug-reactions": null, "targets": null, "enzymes": null, "carriers": null, "transporters": null}, {"@type": "biotech", "@created": "2022-12-07", "@updated": "2022-12-08", "drugbank-id": [{"@primary": true, "$": "DB17372"}], "name": "Human Recombinant Bone Morphogenetic Protein 4", "description": null, "cas-number": null, "unii": "08RQ4CQ601", "groups": {"group": ["investigational"]}, "general-references": {"articles": null, "textbooks": null, "links": null, "attachments": null}, "synthesis-reference": null, "indication": null, "pharmacodynamics": null, "mechanism-of-action": null, "toxicity": null, "metabolism": null, "absorption": null, "half-life": null, "protein-binding": null, "route-of-elimination": null, "volume-of-distribution": null, "clearance": null, "classification": {"description": null, "direct-parent": "Peptides", "kingdom": "Organic Compounds", "superclass": "Organic Acids", "class": "Carboxylic Acids and Derivatives", "subclass": "Amino Acids, Peptides, and Analogues"}, "salts": null, "synonyms": {"synonym": [{"@language": "english", "@coder": "", "$": "HRBMP4"}, {"@language": "english", "@coder": "", "$": "R-HBMP4"}, {"@language": "english", "@coder": "", "$": "RECOMBINANT HUMAN BONE MORPHOGENETIC PROTEIN 4"}]}, "products": null, "international-brands": null, "mixtures": null, "packagers": null, "manufacturers": null, "prices": null, "categories": null, "affected-organisms": null, "dosages": null, "atc-codes": null, "ahfs-codes": null, "pdb-entries": null, "patents": null, "food-interactions": null, "drug-interactions": null, "sequences": null, "experimental-properties": null, "external-identifiers": null, "external-links": null, "pathways": null, "reactions": null, "snp-effects": null, "snp-adverse-drug-reactions": null, "targets": null, "enzymes": null, "carriers": null, "transporters": null}, {"@type": "biotech", "@created": "2022-12-07", "@updated": "2022-12-08", "drugbank-id": [{"@primary": true, "$": "DB17373"}], "name": "BB 21217", "description": "BB 21217 is an anti-BCMA CAR T cell therapy that uses the same CAR molecule as [idecabtagene vicleucel] (bb2121), but adds the PI3K inhibitor bb007 during ex vivo culture to enrich the drug product (DP) for memory-like T cells.[L44291]", "cas-number": null, "unii": null, "groups": {"group": ["investigational"]}, "general-references": {"articles": null, "textbooks": null, "links": {"link": [{"ref-id": "L44291", "title": "ASH: Updated Results from the Phase I CRB-402 Study of Anti-Bcma CAR-T Cell Therapy bb21217 in Patients with Relapsed and Refractory Multiple Myeloma: Correlation of Expansion and Duration of Response with T Cell Phenotypes", "url": "https://ash.confex.com/ash/2020/webprogram/Paper140410.html"}]}, "attachments": null}, "synthesis-reference": null, "indication": null, "pharmacodynamics": null, "mechanism-of-action": null, "toxicity": null, "metabolism": null, "absorption": null, "half-life": null, "protein-binding": null, "route-of-elimination": null, "volume-of-distribution": null, "clearance": null, "salts": null, "synonyms": null, "products": null, "international-brands": null, "mixtures": null, "packagers": null, "manufacturers": null, "prices": null, "categories": null, "affected-organisms": null, "dosages": null, "atc-codes": null, "ahfs-codes": null, "pdb-entries": null, "patents": null, "food-interactions": null, "drug-interactions": null, "sequences": null, "experimental-properties": null, "external-identifiers": null, "external-links": null, "pathways": null, "reactions": null, "snp-effects": null, "snp-adverse-drug-reactions": null, "targets": null, "enzymes": null, "carriers": null, "transporters": null}, {"@type": "small molecule", "@created": "2022-12-07", "@updated": "2022-12-08", "drugbank-id": [{"@primary": true, "$": "DB17374"}], "name": "Tabituximab Barzuxetan", "description": null, "cas-number": "1612758-88-9", "unii": "3K3IOQ7Q1K", "groups": {"group": ["investigational"]}, "general-references": {"articles": null, "textbooks": null, "links": null, "attachments": null}, "synthesis-reference": null, "indication": null, "pharmacodynamics": null, "mechanism-of-action": null, "toxicity": null, "metabolism": null, "absorption": null, "half-life": null, "protein-binding": null, "route-of-elimination": null, "volume-of-distribution": null, "clearance": null, "salts": null, "synonyms": null, "products": null, "international-brands": null, "mixtures": null, "packagers": null, "manufacturers": null, "prices": null, "categories": null, "affected-organisms": null, "dosages": null, "atc-codes": null, "ahfs-codes": null, "pdb-entries": null, "patents": null, "food-interactions": null, "drug-interactions": null, "calculated-properties": null, "experimental-properties": null, "external-identifiers": null, "external-links": null, "pathways": null, "reactions": null, "snp-effects": null, "snp-adverse-drug-reactions": null, "targets": null, "enzymes": null, "carriers": null, "transporters": null}, {"@type": "biotech", "@created": "2022-12-07", "@updated": "2022-12-08", "drugbank-id": [{"@primary": true, "$": "DB17375"}], "name": "Ferritarg P", "description": null, "cas-number": null, "unii": null, "groups": {"group": ["investigational"]}, "general-references": {"articles": null, "textbooks": null, "links": null, "attachments": null}, "synthesis-reference": null, "indication": null, "pharmacodynamics": null, "mechanism-of-action": null, "toxicity": null, "metabolism": null, "absorption": null, "half-life": null, "protein-binding": null, "route-of-elimination": null, "volume-of-distribution": null, "clearance": null, "classification": {"description": null, "direct-parent": "Peptides", "kingdom": "Organic Compounds", "superclass": "Organic Acids", "class": "Carboxylic Acids and Derivatives", "subclass": "Amino Acids, Peptides, and Analogues"}, "salts": null, "synonyms": {"synonym": [{"@language": "english", "@coder": "", "$": "Yttrium (90Y) Antiferritin Polyclonal Antibodies"}]}, "products": null, "international-brands": null, "mixtures": null, "packagers": null, "manufacturers": null, "prices": null, "categories": null, "affected-organisms": null, "dosages": null, "atc-codes": null, "ahfs-codes": null, "pdb-entries": null, "patents": null, "food-interactions": null, "drug-interactions": null, "sequences": null, "experimental-properties": null, "external-identifiers": null, "external-links": null, "pathways": null, "reactions": null, "snp-effects": null, "snp-adverse-drug-reactions": null, "targets": null, "enzymes": null, "carriers": null, "transporters": null}, {"@type": "biotech", "@created": "2022-12-07", "@updated": "2022-12-08", "drugbank-id": [{"@primary": true, "$": "DB17376"}], "name": "Zanolimumab", "description": "Zanolimumab is a fully human monoclonal antibody directed against CD4.", "cas-number": "652153-01-0", "unii": "HG3L8885M0", "groups": {"group": ["investigational"]}, "general-references": {"articles": null, "textbooks": null, "links": null, "attachments": null}, "synthesis-reference": null, "indication": null, "pharmacodynamics": null, "mechanism-of-action": null, "toxicity": null, "metabolism": null, "absorption": null, "half-life": null, "protein-binding": null, "route-of-elimination": null, "volume-of-distribution": null, "clearance": null, "classification": {"description": null, "direct-parent": "Peptides", "kingdom": "Organic Compounds", "superclass": "Organic Acids", "class": "Carboxylic Acids and Derivatives", "subclass": "Amino Acids, Peptides, and Analogues"}, "salts": null, "synonyms": {"synonym": [{"@language": "english", "@coder": "", "$": "Humax-cd4"}]}, "products": null, "international-brands": null, "mixtures": null, "packagers": null, "manufacturers": null, "prices": null, "categories": {"category": [{"category": "Amino Acids, Peptides, and Proteins", "mesh-id": "D000602"}, {"category": "Antibodies", "mesh-id": "D000906"}, {"category": "Antibodies, Monoclonal", "mesh-id": "D000911"}, {"category": "Antineoplastic Agents", "mesh-id": "D000970"}, {"category": "Antineoplastic Agents, Immunological", "mesh-id": "D000074322"}, {"category": "Blood Proteins", "mesh-id": "D001798"}, {"category": "Globulins", "mesh-id": "D005916"}, {"category": "Immunoglobulins", "mesh-id": "D007136"}, {"category": "Immunoproteins", "mesh-id": "D007162"}, {"category": "Proteins", "mesh-id": "D011506"}, {"category": "Serum Globulins", "mesh-id": "D012712"}]}, "affected-organisms": null, "dosages": null, "atc-codes": null, "ahfs-codes": null, "pdb-entries": null, "patents": null, "food-interactions": null, "drug-interactions": null, "sequences": null, "experimental-properties": null, "external-identifiers": {"external-identifier": [{"resource": "Wikipedia", "identifier": "Zanolimumab"}]}, "external-links": null, "pathways": null, "reactions": null, "snp-effects": null, "snp-adverse-drug-reactions": null, "targets": null, "enzymes": null, "carriers": null, "transporters": null}, {"@type": "biotech", "@created": "2022-12-07", "@updated": "2022-12-08", "drugbank-id": [{"@primary": true, "$": "DB17377"}], "name": "Bersanlimab", "description": "Bersanlimab is an investigational monoclonal antibody directed against intercellular adhesion molecule 1 (ICAM-1).", "cas-number": "1987854-08-9", "unii": "MP3N1L4OR6", "groups": {"group": ["investigational"]}, "general-references": {"articles": null, "textbooks": null, "links": null, "attachments": null}, "synthesis-reference": null, "indication": null, "pharmacodynamics": null, "mechanism-of-action": null, "toxicity": null, "metabolism": null, "absorption": null, "half-life": null, "protein-binding": null, "route-of-elimination": null, "volume-of-distribution": null, "clearance": null, "classification": {"description": null, "direct-parent": "Peptides", "kingdom": "Organic Compounds", "superclass": "Organic Acids", "class": "Carboxylic Acids and Derivatives", "subclass": "Amino Acids, Peptides, and Analogues"}, "salts": null, "synonyms": {"synonym": [{"@language": "english", "@coder": "", "$": "Anti-icam-1 monoclonal antibody bi-505"}, {"@language": "english", "@coder": "", "$": "Immunoglobulin g1-lambda, anti-(homo sapiens icam1(intercellular adhesion molecule 1, icam-1, cd54)), human monoclonal antibody"}, {"@language": "english", "@coder": "", "$": "Immunoglobulin g1, anti-(human intercellular adhesion molecule icam-1) (human monoclonal bi-505 .gamma.1-chain), disulfide with monoclonal bi-505 light-chain, dimer"}]}, "products": null, "international-brands": null, "mixtures": null, "packagers": null, "manufacturers": null, "prices": null, "categories": null, "affected-organisms": null, "dosages": null, "atc-codes": null, "ahfs-codes": null, "pdb-entries": null, "patents": null, "food-interactions": null, "drug-interactions": null, "sequences": null, "experimental-properties": null, "external-identifiers": null, "external-links": null, "pathways": null, "reactions": null, "snp-effects": null, "snp-adverse-drug-reactions": null, "targets": null, "enzymes": null, "carriers": null, "transporters": null}, {"@type": "biotech", "@created": "2022-12-07", "@updated": "2022-12-08", "drugbank-id": [{"@primary": true, "$": "DB17378"}], "name": "MVR-T3011", "description": "MVR-T3011 is a genetically modified oncolytic Herpes Simplex Virus (HSV-1) with 2 exogenous genes encoding the active heterodimer human interleukin 12 (IL-12) and the Fab fragment of an anti-human PD-1 antibody.", "cas-number": null, "unii": null, "groups": {"group": ["investigational"]}, "general-references": {"articles": null, "textbooks": null, "links": null, "attachments": null}, "synthesis-reference": null, "indication": null, "pharmacodynamics": null, "mechanism-of-action": null, "toxicity": null, "metabolism": null, "absorption": null, "half-life": null, "protein-binding": null, "route-of-elimination": null, "volume-of-distribution": null, "clearance": null, "salts": null, "synonyms": {"synonym": [{"@language": "english", "@coder": "", "$": "T3011"}]}, "products": null, "international-brands": null, "mixtures": null, "packagers": null, "manufacturers": null, "prices": null, "categories": null, "affected-organisms": null, "dosages": null, "atc-codes": null, "ahfs-codes": null, "pdb-entries": null, "patents": null, "food-interactions": null, "drug-interactions": null, "sequences": null, "experimental-properties": null, "external-identifiers": null, "external-links": null, "pathways": null, "reactions": null, "snp-effects": null, "snp-adverse-drug-reactions": null, "targets": null, "enzymes": null, "carriers": null, "transporters": null}, {"@type": "small molecule", "@created": "2022-12-07", "@updated": "2023-01-03", "drugbank-id": [{"@primary": true, "$": "DB17379"}], "name": "(-)-Gossypol", "description": "(-)-Gossypol or (R)-Gossypol, is the R-isomer of [Gossypol].", "cas-number": "90141-22-3", "unii": "8DY2X8LXW4", "average-mass": 518.5544, "monoisotopic-mass": 518.194067936, "groups": {"group": ["investigational"]}, "general-references": {"articles": null, "textbooks": null, "links": null, "attachments": null}, "synthesis-reference": null, "indication": null, "pharmacodynamics": null, "mechanism-of-action": null, "toxicity": null, "metabolism": null, "absorption": null, "half-life": null, "protein-binding": null, "route-of-elimination": null, "volume-of-distribution": null, "clearance": null, "classification": {"description": "This compound belongs to the class of organic compounds known as sesquiterpenoids. These are terpenes with three consecutive isoprene units.", "direct-parent": "Sesquiterpenoids", "kingdom": "Organic compounds", "superclass": "Lipids and lipid-like molecules", "class": "Prenol lipids", "subclass": "Sesquiterpenoids", "alternative-parent": ["1-hydroxy-4-unsubstituted benzenoids", "Aryl-aldehydes", "Hydrocarbon derivatives", "Naphthols and derivatives", "Organic oxides", "Polyols", "Vinylogous acids"], "substituent": ["1-hydroxy-4-unsubstituted benzenoid", "1-naphthol", "2-naphthol", "Aldehyde", "Aromatic homopolycyclic compound", "Aryl-aldehyde", "Benzenoid", "Cadinane sesquiterpenoid", "Hydrocarbon derivative", "Naphthalene", "Organic oxide", "Organic oxygen compound", "Organooxygen compound", "Polyol", "Sesquiterpenoid", "Vinylogous acid"]}, "salts": null, "synonyms": {"synonym": [{"@language": "english", "@coder": "", "$": "(r)-2,2'-bis(8-formyl-1,6,7-trihydroxy-5-isopropyl-3-methylnaphthalene)"}, {"@language": "english", "@coder": "", "$": "(r)-gossypol"}, {"@language": "english", "@coder": "", "$": "Gossypol r-form"}, {"@language": "english", "@coder": "", "$": "Gossypol, (r)-"}, {"@language": "english", "@coder": "", "$": "Gossypol, r-"}, {"@language": "english", "@coder": "", "$": "R-(-)-gossypol"}]}, "products": null, "international-brands": null, "mixtures": null, "packagers": null, "manufacturers": null, "prices": null, "categories": null, "affected-organisms": null, "dosages": null, "atc-codes": null, "ahfs-codes": null, "pdb-entries": null, "patents": null, "food-interactions": null, "drug-interactions": null, "calculated-properties": {"property": [{"kind": "logP", "value": "4.49", "source": "ALOGPS"}, {"kind": "logS", "value": "-5.1", "source": "ALOGPS"}, {"kind": "Water Solubility", "value": "3.85e-03 g/l", "source": "ALOGPS"}, {"kind": "logP", "value": "8.02", "source": "ChemAxon"}, {"kind": "IUPAC Name", "value": "1,1',6,6',7,7'-hexahydroxy-3,3'-dimethyl-5,5'-bis(propan-2-yl)-[2,2'-binaphthalene]-8,8'-dicarbaldehyde", "source": "ChemAxon"}, {"kind": "Traditional IUPAC Name", "value": "(-)-gossypol", "source": "ChemAxon"}, {"kind": "Molecular Weight", "value": "518.5544", "source": "ChemAxon"}, {"kind": "Monoisotopic Weight", "value": "518.194067936", "source": "ChemAxon"}, {"kind": "SMILES", "value": "CC(C)C1=C(O)C(O)=C(C=O)C2=C(O)C(=C(C)C=C12)C1=C(O)C2=C(C=C1C)C(C(C)C)=C(O)C(O)=C2C=O", "source": "ChemAxon"}, {"kind": "Molecular Formula", "value": "C30H30O8", "source": "ChemAxon"}, {"kind": "InChI", "value": "InChI=1S/C30H30O8/c1-11(2)19-15-7-13(5)21(27(35)23(15)17(9-31)25(33)29(19)37)22-14(6)8-16-20(12(3)4)30(38)26(34)18(10-32)24(16)28(22)36/h7-12,33-38H,1-6H3", "source": "ChemAxon"}, {"kind": "InChIKey", "value": "QBKSWRVVCFFDOT-UHFFFAOYSA-N", "source": "ChemAxon"}, {"kind": "Polar Surface Area (PSA)", "value": "155.52", "source": "ChemAxon"}, {"kind": "Refractivity", "value": "147.61", "source": "ChemAxon"}, {"kind": "Polarizability", "value": "55.98", "source": "ChemAxon"}, {"kind": "Rotatable Bond Count", "value": "4", "source": "ChemAxon"}, {"kind": "H Bond Acceptor Count", "value": "8", "source": "ChemAxon"}, {"kind": "H Bond Donor Count", "value": "6", "source": "ChemAxon"}, {"kind": "pKa (strongest acidic)", "value": "7.8", "source": "ChemAxon"}, {"kind": "pKa (strongest basic)", "value": "-6.1", "source": "ChemAxon"}, {"kind": "Physiological Charge", "value": "-1", "source": "ChemAxon"}, {"kind": "Number of Rings", "value": "4", "source": "ChemAxon"}, {"kind": "Bioavailability", "value": "0", "source": "ChemAxon"}, {"kind": "Rule of Five", "value": "0", "source": "ChemAxon"}, {"kind": "Ghose Filter", "value": "0", "source": "ChemAxon"}, {"kind": "MDDR-Like Rule", "value": "0", "source": "ChemAxon"}]}, "experimental-properties": null, "external-identifiers": {"external-identifier": [{"resource": "BindingDB", "identifier": "46555"}]}, "external-links": null, "pathways": null, "reactions": null, "snp-effects": null, "snp-adverse-drug-reactions": null, "targets": null, "enzymes": null, "carriers": null, "transporters": null}, {"@type": "biotech", "@created": "2022-12-07", "@updated": "2022-12-08", "drugbank-id": [{"@primary": true, "$": "DB17380"}], "name": "Saposin C", "description": "Saposin C is a lysosomal protein. Recombinant, non-glycosylated Saposin C is an active ingredient of BXQ-350, which is a novel, investigational anti-neoplastic therapy. BXQ-350 consists of Saposin C and the phospholipid dioleoylphosphatidyl-serine (DOPS), a phospholipid located on cell membranes.", "cas-number": null, "unii": "2N62LTC861", "groups": {"group": ["investigational"]}, "general-references": {"articles": null, "textbooks": null, "links": null, "attachments": null}, "synthesis-reference": null, "indication": null, "pharmacodynamics": null, "mechanism-of-action": null, "toxicity": null, "metabolism": null, "absorption": null, "half-life": null, "protein-binding": null, "route-of-elimination": null, "volume-of-distribution": null, "clearance": null, "classification": {"description": null, "direct-parent": "Peptides", "kingdom": "Organic Compounds", "superclass": "Organic Acids", "class": "Carboxylic Acids and Derivatives", "subclass": "Amino Acids, Peptides, and Analogues"}, "salts": null, "synonyms": {"synonym": [{"@language": "english", "@coder": "", "$": "BXQ-350"}, {"@language": "english", "@coder": "", "$": "SAPOSIN C (NON-GLYCOSYLATED)"}, {"@language": "english", "@coder": "", "$": "SAPOSIN C RECOMBINANT"}]}, "products": null, "international-brands": null, "mixtures": null, "packagers": null, "manufacturers": null, "prices": null, "categories": {"category": [{"category": "Coenzymes", "mesh-id": "D003067"}, {"category": "Enzymes and Coenzymes", "mesh-id": "D045762"}, {"category": "Sphingolipid Activator Proteins", "mesh-id": "D049128"}]}, "affected-organisms": null, "dosages": null, "atc-codes": null, "ahfs-codes": null, "pdb-entries": null, "patents": null, "food-interactions": null, "drug-interactions": null, "sequences": null, "experimental-properties": null, "external-identifiers": null, "external-links": null, "pathways": null, "reactions": null, "snp-effects": null, "snp-adverse-drug-reactions": null, "targets": null, "enzymes": null, "carriers": null, "transporters": null}, {"@type": "biotech", "@created": "2022-12-19", "@updated": "2022-12-23", "drugbank-id": [{"@primary": true, "$": "DB17381"}], "name": "Nadofaragene firadenovec", "description": "Nadofaragene firadenovec (nadofaragene firadenovec-vncg) is a recombinant non-replicating adenovirus serotype 5 vector containing a transgene encoding human interferon alfa-2b (IFN\u03b12b).[L44381] It was approved by the FDA on December 2022 for the treatment of high-risk Bacillus Calmette-Gu\u00e9rin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma _in situ_ (CIS) with or without papillary tumors. It is the first gene therapy approved by the FDA for the treatment of bladder cancer.[L44381,L44431]\r\n\r\nBCG-unresponsive NMIBC has a high recurrence and is notably difficult to treat. Most patients with this condition undergo radical cystectomy since other non-surgical treatments are far less effective. The use of nadofaragene firadenovec provides a therapeutic alternative to patients seeking non-surgical alternatives for the treatment of BCG-unresponsive NMIBC.[A255111] Nadofaragene firadenovec is formulated with an excipient (Syn-3) that facilitates gene transfer across the urothelium and promotes the transduction of IFN\u03b12b. The localized expression of this gene induces anti-tumor effects.[A255106,L44381] Nadofaragene firadenovec also has a manageable adverse event profile. Compared to [pembrolizumab], a smaller proportion of patients experienced grade 3-4 adverse events (4% vs 12.7%).[A255111]", "cas-number": "1823059-12-6", "unii": "0OOS09O1FH", "state": "liquid", "groups": {"group": ["approved", "investigational"]}, "general-references": {"articles": {"article": [{"ref-id": "A255106", "pubmed-id": "33253641", "citation": "Boorjian SA, Alemozaffar M, Konety BR, Shore ND, Gomella LG, Kamat AM, Bivalacqua TJ, Montgomery JS, Lerner SP, Busby JE, Poch M, Crispen PL, Steinberg GD, Schuckman AK, Downs TM, Svatek RS, Mashni J Jr, Lane BR, Guzzo TJ, Bratslavsky G, Karsh LI, Woods ME, Brown G, Canter D, Luchey A, Lotan Y, Krupski T, Inman BA, Williams MB, Cookson MS, Keegan KA, Andriole GL Jr, Sankin AI, Boyd A, O'Donnell MA, Sawutz D, Philipson R, Coll R, Narayan VM, Treasure FP, Yla-Herttuala S, Parker NR, Dinney CPN: Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial. Lancet Oncol. 2021 Jan;22(1):107-117. doi: 10.1016/S1470-2045(20)30540-4. Epub 2020 Nov 27."}, {"ref-id": "A255111", "pubmed-id": "33253640", "citation": "Kulkarni GS: Nadofaragene firadenovec: a new gold standard for BCG-unresponsive bladder cancer? Lancet Oncol. 2021 Jan;22(1):8-9. doi: 10.1016/S1470-2045(20)30586-6. Epub 2020 Nov 27."}, {"ref-id": "A255116", "pubmed-id": "35847448", "citation": "Mokkapati S, Narayan VM, Manyam GC, Lim AH, Duplisea JJ, Kokorovic A, Miest TS, Mitra AP, Plote D, Anand SS, Metcalfe MJ, Dunner K Jr, Johnson BA, Czerniak BA, Nieminen T, Heikura T, Yla-Herttuala S, Parker NR, Schluns KS, McConkey DJ, Dinney CP: Lentiviral interferon: A novel method for gene therapy in bladder cancer. Mol Ther Oncolytics. 2022 Jun 10;26:141-157. doi: 10.1016/j.omto.2022.06.005. eCollection 2022 Sep 15."}, {"ref-id": "A255121", "pubmed-id": "35158964", "citation": "Deininger S, Torzsok P, Mitterberger M, Pallauf M, Oswald D, Deininger C, Lusuardi L: From Interferon to Checkpoint Inhibition Therapy-A Systematic Review of New Immune-Modulating Agents in Bacillus Calmette-Guerin (BCG) Refractory Non-Muscle-Invasive Bladder Cancer (NMIBC). Cancers (Basel). 2022 Jan 29;14(3):694. doi: 10.3390/cancers14030694."}]}, "textbooks": null, "links": {"link": [{"ref-id": "L44381", "title": "FDA Approved Drug Products: ADSTILADRIN (nadofaragene firadenovec-vncg) suspension for intravesical use", "url": "https://www.ferringusa.com/wp-content/uploads/sites/12/2022/12/ADSTILADRIN_pi.pdf"}, {"ref-id": "L44431", "title": "Ferring Pharmaceuticals: Ferring Receives Approval from U.S. FDA for Adstiladrin for High-Risk, BCG-Unresponsive Non-Muscle Invasive Bladder Cancer", "url": "https://www.ferring.com/ferring-receives-approval-from-u-s-fda-for-adstiladrin-for-high-risk-bcg-unresponsive-non-muscle-invasive-bladder-cancer/"}]}, "attachments": null}, "synthesis-reference": null, "indication": "Nadofaragene firadenovec is indicated for the treatment of adult patients with high-risk Bacillus CalmetteGu\u00e9rin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma _in situ_ (CIS) with or without papillary tumors.[L44381]", "pharmacodynamics": "The safety, tolerability, and maximum tolerated dose (MTD) of nadofaragene firadenovec were evaluated in a phase 1 first-in-human study that enrolled patients (n=17) with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC). Patients were given five different dose levels in a dose volume of 75 ml: 3 x 10<sup>9</sup> vp/mL, 1 x 10<sup>10</sup> vp/mL, 3 x 10<sup>10</sup> vp/mL, 1 x 10<sup>11</sup> vp/mL, and 3 x 10<sup>11</sup> vp/mL; and human interferon alfa-2b (IFN\u03b12b) protein was used as a pharmacodynamic marker. Except for two patients given the lowest nadofaragene firadenovec dose, IFN\u03b12b protein was detected in the urine of all patients. IFN\u03b12b protein was detected up to 10 days after nadofaragene firadenovec administration, suggesting that IFN\u03b12b is expressed in the bladder. Following nadofaragene firadenovec administration, measurable concentrations of IFN\u03b12b protein were detected in urine up to day 12 post-dose, and this was more common in patients at the high dose level.[L44381]", "mechanism-of-action": "Non-muscle invasive bladder cancer (NMIBC) that is unresponsive to Bacillus Calmette-Gu\u00e9rin (BCG) therapy is a type of cancer that is highly difficult to treat. Patients with BCG-unresponsive NMIBC usually undergo radical cystectomy; however, a surgical procedure may not be possible in all patients. For these patients, gene therapies such as nadofaragene firadenovec can be used as an alternative.[A255111,A255116] Nadofaragene firadenovec is a non-replicating adenoviral vector-based gene therapy carrying a copy of a human interferon-alfa 2b (IFN\u03b12b) gene combined with Syn-3, a polyamide surfactant that facilitates gene transfer across the urothelium and enhances viral transduction.[A255106,A255121,L44381] The local expression of IFN\u03b12b in the urothelium has pleiotropic anti-tumor effects. Preclinical studies showed that IFN\u03b1 induced apoptosis in human BCG-unresponsive bladder cancer (BLCA) cells via the induction of autocrine tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) production.[A255116,L44381]", "toxicity": "Toxicity information regarding nadofaragene firadenovec is not readily available. Patients experiencing an overdose are at an increased risk of severe adverse effects such as disseminated adenovirus infection.[L44381] Symptomatic and supportive measures are recommended. The carcinogenic, mutagenic and fertility effects of nadofaragene firadenovec have not been evaluated.[L44381] Cynomolgus monkeys given 2.5 x 10<sup>11</sup> or 1.25 x 10<sub>13</sub> viral particles of nadofaragene firadenovec 90 days apart (1 x 10<sup>11</sup> or 5x10<sup>11 </sup>viral particles/mL) experienced inflammation, urothelial hyperplasia, cytoplasmic vacuolation, and focal/multifocal ulceration in the urinary bladder and irritation in the ureter and urethra at necropsy 7 days after the first and second doses. These findings were resolved following the 57-day recovery period after the second administration. At this point, a limited number of monkeys had minimal fibrosis in the lamina propria of the bladder.[L44381]", "metabolism": "As a gene therapy medicinal product, nadofaragene firadenovec is expected to be metabolized by nucleases throughout the body.", "absorption": "The biodistribution of nadofaragene firadenovec was evaluated in two clinical studies. One of the patients given a second dose of nadofaragene firadenovec at 3 x 10<sup>11</sup> vp/mL (2.25 x 10<sup>13</sup> vp) had measurable vector DNA in blood. The rest of the patients did not have measurable vector DNA in blood one hour after nadofaragene firadenovec administration. In a phase 1 study, one out of 4 patients given 3 x 10<sup>11</sup> vp/mL (2.25 x 10<sup>13</sup> vp) of nadofaragene firadenovec had detectable levels of vector DNA at Day 14. In a phase 2 study, 16 out of 19 patients had detectable levels of vector DNA at Day 12.[L44381]", "half-life": null, "protein-binding": null, "route-of-elimination": "Nadofaragene firadenovec can be detected in urine. The frequency of detection of urine samples positive for vector-derived DNA and persistence of vector-derived DNA is correlated with the dose level.[L44381]", "volume-of-distribution": null, "clearance": null, "salts": null, "synonyms": {"synonym": [{"@language": "english", "@coder": "", "$": "Instiladrin"}, {"@language": "english", "@coder": "inn/usan", "$": "Nadofaragene firadenovec"}, {"@language": "english", "@coder": "", "$": "Nadofaragene firadenovec-vncg"}, {"@language": "english", "@coder": "", "$": "RAD-IFN"}, {"@language": "english", "@coder": "", "$": "RAD-IFN-2B"}, {"@language": "english", "@coder": "", "$": "Replication-deficient adenovirus type 5 (ad5) vector encoding the human interferon alpha 2 (ifna2, interferon alpha-2b) gene under the control of the cytomegalovirus (cmv) immediate-early enhancer/promoter"}, {"@language": "english", "@coder": "", "$": "SCH-209702/SCH-721015"}]}, "products": null, "international-brands": {"international-brand": [{"name": "Adstiladrin", "company": "Ferring Pharmaceuticals"}]}, "mixtures": null, "packagers": null, "manufacturers": null, "prices": null, "categories": {"category": [{"category": "Adeno-associated Viral Vector Therapies", "mesh-id": null}, {"category": "Antineoplastic Agents", "mesh-id": "D000970"}, {"category": "Cellular and Gene Therapy", "mesh-id": null}, {"category": "Genetic Therapy", "mesh-id": "D015316"}, {"category": "Recombinant Proteins", "mesh-id": "D011994"}]}, "affected-organisms": {"affected-organism": ["Humans and other mammals"]}, "dosages": null, "atc-codes": null, "ahfs-codes": null, "pdb-entries": null, "patents": null, "food-interactions": null, "drug-interactions": null, "sequences": null, "experimental-properties": null, "external-identifiers": {"external-identifier": [{"resource": "Wikipedia", "identifier": "Nadofaragene_firadenovec"}]}, "external-links": null, "pathways": null, "reactions": null, "snp-effects": null, "snp-adverse-drug-reactions": null, "targets": null, "enzymes": null, "carriers": null, "transporters": null}, {"@type": "small molecule", "@created": "2022-12-22", "@updated": "2022-12-23", "drugbank-id": [{"@primary": true, "$": "DB17382"}], "name": "AUM-601", "description": "AUM-601 is a highly selective pan-TRK(tropomyosin receptor kinase). It is currently being investigated in clinical trials for the treatment of cancer.", "cas-number": null, "unii": null, "groups": {"group": ["investigational"]}, "general-references": {"articles": null, "textbooks": null, "links": null, "attachments": null}, "synthesis-reference": null, "indication": null, "pharmacodynamics": null, "mechanism-of-action": null, "toxicity": null, "metabolism": null, "absorption": null, "half-life": null, "protein-binding": null, "route-of-elimination": null, "volume-of-distribution": null, "clearance": null, "salts": null, "synonyms": {"synonym": [{"@language": "english", "@coder": "", "$": "(R,E)-3-(5-(2-(2,5-difluorophenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidin-3-yl)-1-(piperazin-1-yl)prop-2-en-1-on hemi-oxalate"}, {"@language": "english", "@coder": "", "$": "AUM 601"}, {"@language": "english", "@coder": "", "$": "AUM601"}, {"@language": "english", "@coder": "", "$": "CHC 2014"}, {"@language": "english", "@coder": "", "$": "HL 5101"}, {"@language": "english", "@coder": "", "$": "NOV 1601"}]}, "products": null, "international-brands": null, "mixtures": null, "packagers": null, "manufacturers": null, "prices": null, "categories": null, "affected-organisms": null, "dosages": null, "atc-codes": null, "ahfs-codes": null, "pdb-entries": null, "patents": null, "food-interactions": null, "drug-interactions": null, "calculated-properties": null, "experimental-properties": null, "external-identifiers": null, "external-links": null, "pathways": null, "reactions": null, "snp-effects": null, "snp-adverse-drug-reactions": null, "targets": null, "enzymes": null, "carriers": null, "transporters": null}, {"@type": "small molecule", "@created": "2022-12-22", "@updated": "2022-12-23", "drugbank-id": [{"@primary": true, "$": "DB17383"}], "name": "FN-1501", "description": null, "cas-number": "1429515-59-2", "unii": "6MC966B505", "average-mass": 431.504, "monoisotopic-mass": 431.218206461, "groups": {"group": ["investigational"]}, "general-references": {"articles": null, "textbooks": null, "links": null, "attachments": null}, "synthesis-reference": null, "indication": null, "pharmacodynamics": null, "mechanism-of-action": null, "toxicity": null, "metabolism": null, "absorption": null, "half-life": null, "protein-binding": null, "route-of-elimination": null, "volume-of-distribution": null, "clearance": null, "salts": null, "synonyms": {"synonym": [{"@language": "english", "@coder": "", "$": "4-((7h-pyrrolo (2,3-d)pyrimidin-4-yl)amino)-n-(4-((4-methylpiperazin-1-yl)methyl)phenyl)-1h-pyrazole-3-carboxamide"}]}, "products": null, "international-brands": null, "mixtures": null, "packagers": null, "manufacturers": null, "prices": null, "categories": null, "affected-organisms": null, "dosages": null, "atc-codes": null, "ahfs-codes": null, "pdb-entries": null, "patents": null, "food-interactions": null, "drug-interactions": null, "calculated-properties": {"property": [{"kind": "Molecular Weight", "value": "431.504", "source": "ChemAxon"}, {"kind": "Monoisotopic Weight", "value": "431.218206461", "source": "ChemAxon"}, {"kind": "SMILES", "value": "CN1CCN(CC2=CC=C(NC(=O)C3=NNC=C3NC3=C4C=CNC4=NC=N3)C=C2)CC1", "source": "ChemAxon"}, {"kind": "Molecular Formula", "value": "C22H25N9O", "source": "ChemAxon"}, {"kind": "InChI", "value": "InChI=1S/C22H25N9O/c1-30-8-10-31(11-9-30)13-15-2-4-16(5-3-15)27-22(32)19-18(12-26-29-19)28-21-17-6-7-23-20(17)24-14-25-21/h2-7,12,14H,8-11,13H2,1H3,(H,26,29)(H,27,32)(H2,23,24,25,28)", "source": "ChemAxon"}, {"kind": "InChIKey", "value": "VXLAKHWYGRKCGI-UHFFFAOYSA-N", "source": "ChemAxon"}]}, "experimental-properties": null, "external-identifiers": {"external-identifier": [{"resource": "ChemSpider", "identifier": "67886359"}, {"resource": "BindingDB", "identifier": "50270304"}, {"resource": "ChEMBL", "identifier": "CHEMBL4077071"}]}, "external-links": null, "pathways": null, "reactions": null, "snp-effects": null, "snp-adverse-drug-reactions": null, "targets": null, "enzymes": null, "carriers": null, "transporters": null}, {"@type": "small molecule", "@created": "2022-12-22", "@updated": "2022-12-23", "drugbank-id": [{"@primary": true, "$": "DB17384"}], "name": "Tinengotinib", "description": null, "cas-number": "2230490-29-4", "unii": "WZ9TJ0L9Y8", "average-mass": 394.86, "monoisotopic-mass": 394.130887, "groups": {"group": ["investigational"]}, "general-references": {"articles": null, "textbooks": null, "links": null, "attachments": null}, "synthesis-reference": null, "indication": null, "pharmacodynamics": null, "mechanism-of-action": null, "toxicity": null, "metabolism": null, "absorption": null, "half-life": null, "protein-binding": null, "route-of-elimination": null, "volume-of-distribution": null, "clearance": null, "salts": null, "synonyms": {"synonym": [{"@language": "english", "@coder": "", "$": "4-(5-(2-Chlorophenyl)-3-Methyl-2,10-Dihydropyrazolo[4,3-B] Pyrido[4,3-E][1,4]Diazepin-8-Yl) Morpholine"}, {"@language": "english", "@coder": "", "$": "5-(2-chlorophenyl)-3-methyl-8-(morpholin-4-yl)-1,10-dihydropyrazolo[4,3-b]pyrido[4,3-e][1,4]diazepine"}, {"@language": "english", "@coder": "", "$": "Pyrazolo(4,3-b)pyrido(4,3-e)(1,4)diazepine, 5-(2-chlorophenyl)-1,2-dihydro-3-methyl-8-(4-morpholinyl)-"}]}, "products": null, "international-brands": null, "mixtures": null, "packagers": null, "manufacturers": null, "prices": null, "categories": null, "affected-organisms": null, "dosages": null, "atc-codes": null, "ahfs-codes": null, "pdb-entries": null, "patents": null, "food-interactions": null, "drug-interactions": null, "calculated-properties": {"property": [{"kind": "Molecular Weight", "value": "394.86", "source": "ChemAxon"}, {"kind": "Monoisotopic Weight", "value": "394.130887", "source": "ChemAxon"}, {"kind": "SMILES", "value": "CC1=C2N=C(C3=CC=CC=C3Cl)C3=C(NC2=NN1)C=C(N=C3)N1CCOCC1", "source": "ChemAxon"}, {"kind": "Molecular Formula", "value": "C20H19ClN6O", "source": "ChemAxon"}, {"kind": "InChI", "value": "InChI=1S/C20H19ClN6O/c1-12-18-20(26-25-12)23-16-10-17(27-6-8-28-9-7-27)22-11-14(16)19(24-18)13-4-2-3-5-15(13)21/h2-5,10-11H,6-9H2,1H3,(H2,23,25,26)", "source": "ChemAxon"}, {"kind": "InChIKey", "value": "DQFCVOOFMXEPOC-UHFFFAOYSA-N", "source": "ChemAxon"}]}, "experimental-properties": null, "external-identifiers": {"external-identifier": [{"resource": "ChemSpider", "identifier": "115008005"}]}, "external-links": null, "pathways": null, "reactions": null, "snp-effects": null, "snp-adverse-drug-reactions": null, "targets": null, "enzymes": null, "carriers": null, "transporters": null}, {"@type": "small molecule", "@created": "2022-12-23", "@updated": "2022-12-31", "drugbank-id": [{"@primary": true, "$": "DB17385"}], "name": "Lipotecan", "description": null, "cas-number": "1432468-79-5", "unii": "D47234N30N", "average-mass": 850.71, "monoisotopic-mass": 850.183062298, "groups": {"group": ["investigational"]}, "general-references": {"articles": null, "textbooks": null, "links": null, "attachments": null}, "synthesis-reference": null, "indication": null, "pharmacodynamics": null, "mechanism-of-action": null, "toxicity": null, "metabolism": null, "absorption": null, "half-life": null, "protein-binding": null, "route-of-elimination": null, "volume-of-distribution": null, "clearance": null, "salts": {"salt": [{"drugbank-id": [{"@primary": true, "$": "DBSALT003329"}], "name": "Lipotecan hydrochloride", "unii": null, "cas-number": null, "inchikey": null}]}, "synonyms": {"synonym": [{"@language": "english", "@coder": "", "$": "Lipothecan free base"}, {"@language": "english", "@coder": "", "$": "Propanoic acid, 2-(((2,4,5,7-tetranitro-9h-fluoren-9-ylidene)amino)oxy)-, (4s)-10-((dimethylamino)methyl)-4-ethyl-3,4,12,14-tetrahydro-9-hydroxy-3,14-dioxo-1h-pyrano(3',4':6,7)indolizino(1,2-b)quinolin-4-yl ester"}]}, "products": null, "international-brands": null, "mixtures": null, "packagers": null, "manufacturers": null, "prices": null, "categories": {"category": [{"category": "Alkaloids", "mesh-id": "D000470"}]}, "affected-organisms": null, "dosages": null, "atc-codes": null, "ahfs-codes": null, "pdb-entries": null, "patents": null, "food-interactions": null, "drug-interactions": null, "calculated-properties": {"property": [{"kind": "Molecular Weight", "value": "850.71", "source": "ChemAxon"}, {"kind": "Monoisotopic Weight", "value": "850.183062298", "source": "ChemAxon"}, {"kind": "SMILES", "value": "CC[C@@]1(OC(=O)C(C)ON=C2C3=C(C4=C2C=C(C=C4[N+]([O-])=O)[N+]([O-])=O)C(=CC(=C3)[N+]([O-])=O)[N+]([O-])=O)C(=O)OCC2=C1C=C1N(CC3=C1N=C1C=CC(O)=C(CN(C)C)C1=C3)C2=O", "source": "ChemAxon"}, {"kind": "Molecular Formula", "value": "C39H30N8O15", "source": "ChemAxon"}, {"kind": "InChI", "value": "InChI=1S/C39H30N8O15/c1-5-39(26-13-30-34-18(14-43(30)36(49)25(26)16-60-38(39)51)8-21-24(15-42(3)4)31(48)7-6-27(21)40-34)61-37(50)17(2)62-41-35-22-9-19(44(52)53)11-28(46(56)57)32(22)33-23(35)10-20(45(54)55)12-29(33)47(58)59/h6-13,17,48H,5,14-16H2,1-4H3/t17?,39-/m0/s1", "source": "ChemAxon"}, {"kind": "InChIKey", "value": "JCCCLGDYMMTBPM-HXDHBHDHSA-N", "source": "ChemAxon"}]}, "experimental-properties": null, "external-identifiers": {"external-identifier": [{"resource": "ChemSpider", "identifier": "64854346"}, {"resource": "ChEMBL", "identifier": "CHEMBL4594352"}]}, "external-links": null, "pathways": null, "reactions": null, "snp-effects": null, "snp-adverse-drug-reactions": null, "targets": null, "enzymes": null, "carriers": null, "transporters": null}, {"@type": "small molecule", "@created": "2023-01-03", "@updated": "2023-01-03", "drugbank-id": [{"@primary": true, "$": "DB17386"}], "name": "Xenon Xe-129", "description": null, "cas-number": "13965-99-6", "unii": "9C7571UDT5", "average-mass": 128.9048, "monoisotopic-mass": 128.90478086, "groups": {"group": ["approved"]}, "general-references": {"articles": null, "textbooks": null, "links": null, "attachments": null}, "synthesis-reference": null, "indication": null, "pharmacodynamics": null, "mechanism-of-action": null, "toxicity": null, "metabolism": null, "absorption": null, "half-life": null, "protein-binding": null, "route-of-elimination": null, "volume-of-distribution": null, "clearance": null, "salts": null, "synonyms": {"synonym": [{"@language": "english", "@coder": "", "$": "Xenon xe-129m"}, {"@language": "english", "@coder": "", "$": "Xenon-129m"}, {"@language": "english", "@coder": "", "$": "Xenon, isotope of mass 129"}, {"@language": "english", "@coder": "", "$": "Xenon, isotope of mass 129m(8.88 d)"}, {"@language": "english", "@coder": "", "$": "Xenon, xe-129m"}]}, "products": null, "international-brands": null, "mixtures": null, "packagers": null, "manufacturers": null, "prices": null, "categories": null, "affected-organisms": null, "dosages": null, "atc-codes": null, "ahfs-codes": null, "pdb-entries": null, "patents": null, "food-interactions": null, "drug-interactions": null, "calculated-properties": {"property": [{"kind": "Molecular Weight", "value": "128.9048", "source": "ChemAxon"}, {"kind": "Monoisotopic Weight", "value": "128.90478086", "source": "ChemAxon"}, {"kind": "SMILES", "value": "[129Xe]", "source": "ChemAxon"}, {"kind": "Molecular Formula", "value": "Xe", "source": "ChemAxon"}, {"kind": "InChI", "value": "InChI=1S/Xe/i1-2", "source": "ChemAxon"}, {"kind": "InChIKey", "value": "FHNFHKCVQCLJFQ-YPZZEJLDSA-N", "source": "ChemAxon"}]}, "experimental-properties": null, "external-identifiers": null, "external-links": null, "pathways": null, "reactions": null, "snp-effects": null, "snp-adverse-drug-reactions": null, "targets": null, "enzymes": null, "carriers": null, "transporters": null}]